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Abstract 
Undeniable phenotypic similarities exist between patients suffering from Cushing’s 
syndrome (caused by excess circulating glucocorticoids (GCs)) and patients suffering from 
idiopathic obesity. Obese patients display normal circulating GC levels, but exhibit raised 
intracellular GC levels in several tissues. Intracellular GC levels are predominantly 
modulated by the enzyme 11β-hydroxysteroid dehydrogenase 1 (11βHSD1), which catalyses 
the conversion of inactive-GC (in rodents this is 11-dehydrocorticosterone) to active-GC (in 
rodents this is corticosterone). 
 
Glucocorticoids play a physiological role in the regulation of energy homeostasis, which is 
thought to be mediated via the hypothalamus; however the exact effects of GCs and their 
sites of action are unclear, partially due to the difficulty of manipulating GC levels in discrete 
hypothalamic nuclei. To overcome this, recombinant adeno-associated virus (rAAV) to 
overexpress 11βHSD1 (rAAV-11βHSD1) was stereotaxically injected into the arcuate 
nucleus (ARC) and the paraventricular nucleus (PVN) of male Wistar rats, to investigate the 
effects of a sustained increase in GC levels in these nuclei. 
 
Injection of rAAV-11βHSD1 successfully increased expression of 11βHSD1 mRNA in the 
hypothalamus, and significantly increased corticosterone levels in the target nuclei. In all 
experiments, circulating levels of corticosterone were unchanged, suggesting that HPA axis 
activity was unaffected by raised hypothalamic corticosterone levels. 
 
Animals injected with rAAV-11βHSD1 intra-ARC displayed a significant increase in 
cumulative food intake, bodyweight and white adipose tissue (WAT) compared to controls. 
Additionally, intra-ARC microinjection of rAAV-11βHSD1 reduced whole-body glucose 
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tolerance and insulin sensitivity at the beginning and mid-point of the study period.  
Together, these results suggest that hypothalamic GCs play a physiological role in appetite 
regulation and glucose homeostasis, and that these effects are mediated via the ARC. 
Interestingly, effects on food intake and bodyweight were ameliorated when the experiment 
was repeated with animals fed a high-fat diet.  
 
Animals injected with rAAV-11βHSD1 intra-PVN displayed a significant increase in 
bodyweight gain compared to controls. This increase was not associated with altered food 
intake, suggesting that hypothalamic GCs play a physiological role in the regulation of 
energy expenditure, an effect mediated via the PVN.  
 
These experiments provide novel information about the role of hypothalamic GCs in energy 
homeostasis. They suggest that endogenous GCs exert nucleus-specific effects and act via 
alternate mechanisms in the hypothalamus to physiologically regulate food intake, glucose 
homeostasis, and energy expenditure.  
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1 Introduction 
1.1 Prevalence of obesity 
Obesity is defined as an individual having a body mass index (BMI; bodyweight in kilograms 
divided by the square of height in metres) greater than 30 kg/m2. In 2005, more than 
400 million adults worldwide were classified as obese; this number is predicted to rise to 
700 million by 2015 (W.H.O., 2006). Obesity is associated with multiple complications, 
including cardiovascular disease, type 2 diabetes mellitus (T2DM) and cancer (Conway and 
Rene, 2004), consequently obesity increases risk of morbidity and mortality. Thus, rising 
levels of obesity are a major public health issue. 
 
A high-calorie diet and sedentary lifestyle are thought to be responsible for the rising levels 
of obesity (James, 2008). Indeed, in the short term, an effective treatment for obesity is to 
reduce calorie intake with dietary modification, and increase physical activity with exercise; 
however, when this fails, more drastic interventions are required. Bariatric surgery is a 
proven treatment for obesity (Cummings et al., 2004), but it is extreme, costly and not 
suitable for all patients. Hence a great deal of research is currently focused on the 
development of a pharmacological solution. Unfortunately, to date, successful treatment 
remains largely unrealised. To develop effective pharmacological therapies for the treatment 
of obesity, it is first necessary to understand the physiological systems regulating energy 
homeostasis. 
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1.2 The hypothalamus 
Many of the complex autonomic mechanisms that maintain the internal environment are 
mediated via the hypothalamus (Swanson and Mogenson, 1981). The hypothalamus is 
considered an integratory relay between afferent and efferent homeostatic signals. 
Information from both the internal and external environment is relayed directly to the 
hypothalamus. The hypothalamus regulates circadian rhythms, body temperature and 
multiple hormone axes as well as appetitive, sexual and affective behaviours (Kruk, 1991, 
Williams et al., 2001).  
 
The hypothalamus is located at the anterior end of the diencephalon, below the hypothalamic 
sulcus and circumscribing the third ventricle (Sayers et al., 1958). It contains multiple, 
discrete nuclei which are involved in a variety of functions and have extensive connections 
amongst themselves, and to other regions of the nervous system (Swanson and Mogenson, 
1981, Risold et al., 1997). Within the hypothalamus, the arcuate nucleus (ARC), the 
paraventricular nucleus (PVN), the ventromedial nucleus (VMN), the lateral hypothalamic 
area (LHA) and the dorsomedial nucleus (DMN) are critical in the regulation of energy 
homeostasis.  
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1.3 Hypothalamic regulation of energy homeostasis 
The hypothalamus integrates both long- and short-term signals of energy status and 
coordinates physiological responses to maintain energy homeostasis (Morton et al., 2006). 
Studies introducing lesions into discrete nuclei of the medial hypothalamus provided some of 
the earliest evidence for a role in the regulation of appetite (Hetherington and Ranson, 1940). 
Lesions within, or surgical ablation of, the ARC, PVN, VMN or DMN, results in hyperphagia 
in rats. Conversely, disruption of the lateral hypothalamus (LHA) suppresses voluntary 
feeding in rodents, and eventually leads to starvation and death (Anand and Brobeck, 1951). 
These studies suggested that a distinct feeding centre (the LHA) and satiety centre (the VMN) 
exist within the hypothalamus. More refined experimental approaches have revised this 
overly simplistic ‘dual-centre model’, and it is now thought that discrete neuronal pathways 
are involved in appetite regulation. These pathways are integrated into a complex neural 
network, with orexigenic and anorexigenic neurotransmitters released from specific neurons 
to regulate food intake and energy expenditure. Signals originating from specialised 
endocrine cells in the periphery, such as the gastrointestinal system and adipose tissue are 
also received and integrated by diverse neuronal circuits in the hypothalamus, brain stem and 
other brain regions (Elmquist et al., 1999).  
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Figure 1.01 Diagrammatic representation of the relative positioning of hypothalamic 
nuclei in the rat. Abbreviations: AHA, anterior hypothalamic area; ARC, arcuate nucleus; 
AV3V, anteroventral area of third ventricle; CI, capsula interna; DP, dorsal parvocellular 
subnucleus of paraventricular nucleus; DMH, dorsomedial nucleus; F, fornix; LHA, lateral 
hypothalamic area; LM, lateral magnocellular subnucleus of paraventricular nucleus; LPOA, 
lateral preoptic area; ME, median eminence; MP, medial parvocellular subnucleus of 
paraventricular nucleus; MPO, medial preoptic area; OT, optic tract; SCh, suprachiasmatic 
nucleus; SON, supraoptic nucleus; SI, substantia inomminata; ST, subthalamic nucleus; 
VMH, ventromedial nucleus; VP, ventral parvocellular subnucleus of paraventricular 
nucleus. Taken from (Berthoud, 2002). 
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1.3.1 The arcuate nucleus  
The ARC is located at the base of the hypothalamus on either side of the third cerebral 
ventricle (Figure 1.01). The ARC lies directly above the median eminence (ME). The ME is a 
circumventricular organ (CVO); that is, an area of the central nervous system (CNS) where 
neural cells have an open connection with blood capillaries. In most areas of the CNS, cells 
are protected from direct exposure to factors in the circulation by a complex structure of 
endothelial cells that make up the blood-brain barrier (BBB). A CVO permits peptides 
secreted by neural tissue to enter circulation, and permits neural cells to sense specific 
circulating hormones. In particular, the ME permits the passage of peripheral hormones to 
reach hypothalamic targets without making the BBB leaky (Rodriguez et al., 2010). The 
positioning of the ARC adjacent to the ME is therefore ideal to respond to changes in 
hormone concentration; hence, the ARC is thought to be the primary site at which circulating 
hormone levels are monitored by the hypothalamus (Cone et al., 2001). 
 
Within the ARC there are two well characterised neuronal populations which have opposing 
effects on food intake. The first population co-express the neuropeptides agouti-related 
protein (AgRP) and neuropeptide-Y (NPY), whilst the second co-express the anorexigenic 
neuropeptides cocaine-and amphetamine-regulated transcript (CART) and α-melanocyte 
stimulating hormone (α-MSH), which is derived from pro-opiomelanocortin (POMC) (Jobst 
et al., 2004). Activation of NPY/AgRP neurons increases food intake, whereas activation of 
POMC/CART neurons suppresses food intake. Both neuronal populations project to the 
PVN, although the ARC also communicates with other nuclei such as the VMN, LHA, and 
DMN (Elmquist et al., 1998). ARC neurons also project to other areas of the brain involved 
in food intake, including the brainstem, ventral tegmental area (VTA) and the nucleus 
accumbens (NAc) (Haskell-Luevano et al., 1999, Jacobowitz and O'Donohue, 1978, Joseph 
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and Michael, 1988). Additionally, other peptides involved in food intake, including β-
endorphin (Finley et al., 1981), galanin (Skofitsch and Jacobowitz, 1985), γ-aminobutyric 
acid (GABA) (Cowley et al., 2001) and glutamate (Boulland et al., 2004) are expressed in the 
ARC.  
 
Recent work suggests that AgRP and POMC neurons in the ARC are not necessarily first 
order signalling neurons for peripheral factors regulating energy homeostasis. A recent study 
by Vong et al. suggests that leptin, an anorexigenic hormone secreted into circulation by 
adipose tissue, predominantly signals via presynaptic GABAergic, and to a lesser extent, 
glutamatergic neurons in the ARC (Vong et al., 2011). Thus, leptin signalling may alter 
GABAergic output and reduce inhibitory tone on postsynaptic POMC neurons, thereby 
reducing food intake. Thus, GABAergic and glutamatergic neurons may act as first order 
signalling neurons in the ARC and may play a more important role in the regulation of food 
intake than previously thought.  
 
Neurons in the ARC are glucose sensing (Muroya et al., 2005, Wang et al., 2004) and are also 
responsive to peripheral signals of long-term energy stores, such as leptin and insulin 
(Hakansson et al., 1996, Obici et al., 2002a). Furthermore, these neurons express the receptor 
for the orexigenic gut-peptide ghrelin (Willesen et al., 1999). Taken together, these findings 
suggest that the ARC assimilates signalling from the periphery to regulate food intake via 
hypothalamic neural circuits (Figure 1.02).  
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Figure 1.02 Diagrammatic representation of hypothalamic integration of appetite 
signalling. Activation of NPY/AgRP neurons promotes food intake and reduces energy 
expenditure, whereas activation of POMC/CART neurons reduces food intake and increases 
energy expenditure. Insulin (released from the pancreas) and leptin (released from adipose 
tissue) inhibit NPY/AgRP neurons and stimulate POMC/CART neurons, thereby reducing 
food intake. Ghrelin (released from the stomach) activates NPY/AgRP neurons and thereby 
increases food intake. Abbreviations: Ghsr, growth hormone secretagogue receptor; Lepr, 
leptin receptor; Mc3r/Mc4r, melanocortin 3/4 receptor; Y1r, neuropeptide Y1 receptor. Taken 
from (Barsh and Schwartz, 2002). 
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1.3.2 The paraventricular nucleus  
The PVN is located on both sides of the top of the third cerebral ventricle (Figure 1.01). It 
contains two distinct regions which are made up of magnocellular and parvocellular 
neurosecretory neurons (Alonso and Assenmacher, 1981). Magnocellular neurons express 
oxytocin (OXY) and arginine vasopressin (AVP) (Swanson and Sawchenko, 1983) and these 
axons project to the neural lobe of the posterior pituitary, where OXY and AVP are released 
into circulation. Parvocellular neurons extend to the ME and other CNS regions, and express 
a variety of neuropeptides, including corticotropin releasing hormone (CRH), thyrotropin 
releasing hormone (TRH) and somatostatin (Merchenthaler et al., 1984, Fliers et al., 1994, 
Alonso et al., 1992). 
 
The PVN receives signalling from the ARC via NPY/AgRP and POMC/CART neurons. 
Microinjection of almost all known orexigenic peptides into the PVN, including NPY 
(Stanley and Leibowitz, 1984) and AgRP (Kim et al., 2000) potently increases food intake, 
whilst injection of the anorexigenic peptide cholecystokinin (CCK) reduces food intake 
(Blevins et al., 2000). Thus, the PVN is thought to be heavily implicated in the regulation of 
food intake.  
 
1.3.3 The ventromedial nucleus 
The VMN is located superior to the ARC (Figure 1.01) and is composed of two distinct cell 
populations; the dorsomedial and ventrolateral subdivisions. The VMN receives inputs from 
various hypothalamic nuclei involved in appetite regulation, including the PVN, the DMN 
and the LHA, and has projections to the DMN and LHA.  
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In rodents, lesioning of the VMN results in hyperphagia and obesity (Albert et al., 1971). 
Additionally, microinjection of the orexigenic peptides NPY (Stanley et al., 1985) and 
galanin (Schick et al., 1993) increases food intake, whilst microinjection of leptin reduces 
food intake (Satoh et al., 1997). This work suggests that the VMN is involved in the 
regulation of food intake. 
 
1.3.4 The lateral hypothalamic area  
The LHA is situated laterally to the VMN (Figure 1.01). Lesions to this area result in 
temporary aphagia and dramatic loss of body weight (Anand and Brobeck, 1951). 
Conversely, electrical stimulation of the LHA increases food intake and bodyweight gain 
(Steinbaum and Miller, 1965). 
 
The LHA contains the orexigenic neuropeptides melanin-concentrating hormone (MCH), 
orexin A and orexin B (Bittencourt et al., 1992, Sakurai et al., 1998) and injection of any of 
these peptides into the LHA increases food intake (Sakurai et al., 1998). The LHA contains 
orexin neurons, which innervate almost all regions of the brain and are thought to be involved 
in the regulation of arousal, but may also have an independent effect on food intake (Horvath 
et al., 1999). Therefore the LHA is likely to play an important role in the regulation of energy 
homeostasis. 
  
1.3.5 The dorsomedial nucleus 
The DMN is positioned immediately dorsal to the VMN, on either side of the third ventricle. 
Destruction of the DMN results in hypophagia, indicating the important role that it plays in 
the regulation of appetite (Bellinger and Bernardis, 2002).  
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1.3.6 Hypothalamic neuropeptide circuits regulating energy homeostasis 
The hypothalamic circuits which control food intake and energy expenditure are complex and 
involve a number of important neuropeptides, some of which are detailed below. 
 
1.3.6.1.1 Neuropeptide-Y  
NPY is a potent orexigenic neurotransmitter (Schwartz et al., 2000) that is heavily implicated 
in the regulation of bodyweight via its effects on food intake and energy expenditure 
(Tomaszuk et al., 1996). Intracerebroventricular (ICV) administration of NPY increases food 
intake (Clark et al., 1984), an effect that is enhanced when NPY is injected directly into the 
PVN (Stanley and Leibowitz, 1984), as daily injections of NPY into the PVN result in 
hyperphagia and increased bodyweight (Stanley et al., 1986). Additionally, hypothalamic 
levels of NPY mRNA and protein increase after fasting and normalise after feeding, 
indicating the important role of this neuropeptide in the regulation of food intake (Brady et 
al., 1990). There are five known mammalian NPY receptors, designated Y1R through Y5R. 
Receptors Y1 and Y5 are expressed in the hypothalamus and are thought to be the main 
receptors by which NPY regulates food intake (Duhault et al., 2000, Marsh et al., 1998). 
 
NPY expressing neurons in the hypothalamus are located predominantly in the ARC, but 
these neurons also project to other hypothalamic nuclei involved in energy expenditure, 
including the PVN, the DMN and the lateral hypothalamus (Bai et al., 1985). The NPY-ergic 
pathway from ARC to PVN is thought to be involved in mediating fasting induced alterations 
in hypothalamic-pituitary-adrenal (HPA) axis activity as ICV infusion of NPY results in 
increased plasma levels of corticosterone (Clark et al., 1984). The orexigenic effects of NPY 
are abolished after adrenalectomy (ADX), the removal of the adrenal glands, but return after 
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co-administration of NPY and dexamethasone (Zakrzewska et al., 1999b), a synthetic 
glucocorticoid (GC), suggesting that GCs play a permissive role with respect to NPY. 
 
1.3.6.1.2 The melanocortin system 
The central melanocortin system consists of several biologically active peptides derived from 
the post-translational processing of POMC, including α-, β-, and γ-MSH, β-endorphin and 
adrenocorticotropic hormone (ACTH) (Gramsch et al., 1980, Liotta et al., 1984, Emeson and 
Eipper, 1986). These are produced in a variety of tissues, including the ARC, brainstem, and 
pituitary gland. The central melanocortin system is a critical player in the regulation of 
bodyweight and metabolism. Indeed, POMC expression levels in the ARC reflect energy 
status, with POMC levels reduced in fasted animals; an effect that is reversed after re-
feeding. 
 
Melanocortins bind to at least five G-protein coupled receptors, designated MC1R through 
MC5R (Cone et al., 1996). MC3R and MC4R are expressed in the CNS and are the receptors 
via which melanocortins are thought to exert effects on energy homeostasis. Mice that lack 
MC3R have increased fat mass and reduced lean mass (Chen et al., 2000) whilst mice lacking 
MC4R become hyperphagic and obese (Huszar et al., 1997). This suggests that tonic 
signalling at MC4R limits food intake and body fat mass (Schwartz et al., 2000). α-MSH is 
an agonist of MC3R and MC4R (Gramsch et al., 1980, Liotta et al., 1984, Gee et al., 1983) 
and ICV administration of α-MSH in rats reduces food intake and increases energy 
expenditure (Rossi et al., 1998).  
 
AgRP is a potent orexigenic neuropeptide that is co-localised with NPY in ARC neurons 
(Broberger et al., 1998, Hahn et al., 1998). AgRP is a competitive antagonist of α-MSH 
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binding at MC3R and MC4R, hence the orexigenic effect of AgRP is due to it preventing the 
anorectic effects of α-MSH binding at these receptors (Rossi et al., 1998, Hagan et al., 2000). 
ICV administration of AgRP induces hyperphagia (Hagan et al., 2000, Rossi et al., 1998). 
More recent work suggests that AgRP can also modulate food intake independent of MC3R 
and MC4R competitive antagonism by acting as an inverse agonist at the MC4R (Haskell-
Luevano and Monck, 2001, Tolle and Low, 2008), however the physiological relevance of 
this is unresolved. 
 
1.3.6.1.3 Cocaine and amphetamine-regulated transcript 
CART is co-expressed in POMC-containing neurons in the ARC (Elias et al., 2001, Vrang et 
al., 1999a, Koylu et al., 1998, Kristensen et al., 1998). Fasting reduces CART mRNA levels 
in the ARC, and ICV administration of CART reduces food intake in both rats and mice (Aja 
et al., 2001, Thim et al., 1998, Lambert et al., 1998, Vrang et al., 1999b). However, 
microinjection of CART into discrete hypothalamic nuclei in rats can also increase food 
intake (Abbott et al., 2001), implying there may be more than one population of CART-
expressing neurons that influence food intake. Thus, CART appears to have a complex role in 
feeding behaviour.  
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1.3.7 Peripheral signalling regulating energy homeostasis  
Some peripheral tissues secrete signals into circulation that act on the CNS where they are 
integrated with hypothalamic neural circuits to produce a coordinated regulation of energy 
homeostasis. For example, peptides secreted from the gastrointestinal tract, such as 
peptide YY (PYY), pancreatic polypeptide (PP), glucagon-like peptide-1 (GLP-1) and CCK 
signal via the hypothalamus and brainstem to reduce food intake. Additionally ghrelin, which 
is a potent orexigenic hormone synthesised and secreted into circulation by the stomach, is 
thought to signal via the ARC (Wren et al., 2001). 
 
Leptin and insulin are peripheral signals that reflect long-term energy storage. Leptin is an 
adipocyte derived hormone, secreted into circulation in proportion to adiposity (Considine et 
al., 1996). Both ICV and peripheral administration of leptin reduce food intake in lean 
animals (Halaas et al., 1995, Schwartz et al., 1996), however this effect is lost in obese 
animals due to leptin resistance (Cusin et al., 1996, Halaas et al., 1997). Leptin binds to the 
receptor Ob-Rb, and signals via midbrain, brainstem and hypothalamic neurons. Within the 
ARC, the leptin receptor is expressed in NPY/AgRP and POMC/CART neurons (Baskin et 
al., 1999, Wilson et al., 1999, Cheung et al., 1997, Kristensen et al., 1998). Leptin inhibits 
NPY/AgRP neuronal activity, whilst it increases POMC/CART neuronal activity, thereby 
influencing the regulation of food intake and energy homeostasis. 
 
Insulin is a peptide secreted from the pancreas and, like leptin, circulates in levels 
proportional to adiposity (Polonsky et al., 1988). In the periphery insulin is anabolic, whilst it 
has opposing actions in the CNS. Indeed, ICV administration of insulin reduces food intake 
(Woods et al., 1979). Insulin binds to the insulin receptor, which is widely expressed 
throughout the CNS, with high levels expressed in NPY/AgRP and POMC/CART neurons of 
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the ARC (Baskin et al., 1987). Additionally, ICV insulin administration is associated with the 
activation of POMC/CART neurons and inhibition of NPY neuronal firing (Sipols et al., 
1995), suggesting that insulin mediates effects on food intake, at least partly, via the ARC. 
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1.3.8 Hypothalamic-pituitary axis 
The pituitary gland and hypothalamus form a unit that controls several endocrine glands and 
a wide range of physiological functions. The pituitary has two subdivisions, the 
adenohypophysis and the neurohypophysis. The neurohypophysis contains axon terminals 
arising from magnocellular secretory neurons located in the PVN and supraoptic nucleus of 
the hypothalamus (Swanson and Sawchenko, 1983). The adenohypophysis is formed from a 
variety of endocrine cell types and secretion from these is regulated in part by hypothalamic 
neurons whose axons terminate in the ME. The ME is composed of an extensive array of 
blood vessels and nerve endings. Its blood supply arises from the superior hypophyseal artery 
which sends off many small branches that form capillary loops. Neuropeptides and other 
molecules which regulate pituitary secretion are released into the ME and are transported via 
the hypophyseal-portal circulation to the anterior pituitary where they mediate their effects. 
 
 
 
 
 
 
 
 
 
 
 
40 
 
1.3.9 Hypothalamic-pituitary adrenal axis 
Stressors initiate a physiological response designed to maintain energy homeostasis (Selye, 
1998). The HPA axis is the final common pathway in the mediation of the stress response. 
The PVN plays a pivotal role in the regulation of the HPA axis as it contains a subpopulation 
of hypophysiotropic neurons which are the primary source of the ACTH secretagogues, CRH 
and AVP. These act synergistically to stimulate ACTH secretion from pituitary corticotrophs 
(Whitnall, 1993). ACTH acts via the melanocortin 2 (MC2) receptor to stimulate GC 
synthesis and secretion from the adrenal gland (Ramachandran, 1984) (Figure 1.03). The 
PVN receives direct and indirect afferents from multiple sources including the brainstem and 
limbic forebrain structures, which modulate the activity of CRH neurons (Herman et al., 
2003). While the majority of CRH neurons extend from the PVN to the ME, others project to 
regions of the CNS involved in the coordination of behavioural, autonomic and endocrine 
responses to stress (Bale and Vale, 2004).  
 
The adrenal gland contains two endocrine regions; the adrenal medulla and adrenal cortex. 
The adrenal medulla secretes catecholamines, such as adrenaline, into circulation, whilst the 
adrenal cortex synthesises and secretes steroid hormones such as GCs. The adrenal cortex is 
comprised of three subdivisions; the zona glomerulosa, zona fasciculate, and the zona 
reticularis (Mitani et al., 1999). GCs are secreted from the zona fasciculata under the control 
of ACTH, whereas mineralocorticoids (MCs), such as aldosterone, are secreted from the zona 
glomerulosa under the control of angiotensin II. The zona reticularis secretes adrenal 
androgens which exert minor effects on reproductive function.  
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Figure 1.03 Diagrammatic representation of the hypothalamic-pituitary-adrenal axis in 
the rodent. Stress, or circadian-mediated signalling at the hypothalamus, initiates the release 
of CRH from the PVN. Subsequently, this induces ACTH synthesis and secretion into 
circulation from the pituitary gland. ACTH binds to receptors on the adrenal glands, thereby 
promoting secretion of active GC into circulation; in the rodent this is corticosterone, in 
humans this is cortisol. Circulating corticosterone is detected by the hippocampus, which 
signals to the hypothalamus, down-regulating the HPA axis via negative feedback 
mechanisms. Diagram adapted from University of Utah website: 
http://learn.genetics.utah.edu/content/epigenetics/rats/ 
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1.3.10 Glucocorticoids  
GCs have a diverse array of physiological roles and influence the activity of almost every cell 
in the human body (Munck and Naray-Fejes-Toth, 1992). GCs are essential for homeostasis 
and enable an organism to prepare for, and respond to, physical and emotional stressors 
(Sapolsky et al., 2000). GCs are catabolic and promote the breakdown of carbohydrate and 
protein. Within the CNS, GCs act on both neurons and glial cells, where they contribute to 
neuronal plasticity and are implicated in neurodegeneration (Jauregui-Huerta et al., 2010). 
Other central effects include alterations in mood, behaviour, and neuroendocrine function 
(Fink, 2000).  
 
In humans, the principal active circulating GC is cortisol (in rodents, the active equivalent is 
corticosterone), whilst the principal inactive GC is cortisone (in rodents, the inactive 
equivalent is 11-dehydrocorticosterone). Cortisol, and its rodent counterpart corticosterone, 
are synthesised from cholesterol in the zona fasciculata of the adrenal cortex. GC release into 
circulation by the adrenals is pulsatile and pulse amplitude varies according to a distinct 
circadian pattern. Serum GC concentrations show a 3-5 fold change over 24 hours, being 
maximal just before awakening, followed by a rapid decrease over the next few hours and 
gradual declining thereafter, eventually reaching a nadir early in the sleep phase (Kurina et 
al., 2005). GCs are also released into circulation in response to physical and emotional stress. 
The acute effects of GC in response to stress contribute to adaptive responses, for example, 
by increasing substrate availability for mitochondrial activity.  
 
GCs activate two types of intracellular receptors; the GC receptor (GR) and the 
mineralocorticoid receptor (MR). Within the CNS, the GR has a widespread expression 
throughout the brain, whilst the MR is restricted to limbic structures (de Kloet et al., 1998). 
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After binding to a ligand, receptors translocate to the nucleus where they modulate gene 
transcription via transactivation or transrepression. Transactivation is the dimerization of 
ligand-bound receptors to form homodimers (Liu and DeFranco, 2000) that bind to specific 
palindromic sequences in the cis-regulatory region of target genes, termed glucocorticoid 
response elements (GREs). Gene transcription is usually enhanced (via positive GREs), but 
can also be repressed (via negative GREs). GC induced negative feedback of the HPA axis is 
partly mediated via direct inhibition of CRH gene transcription at a negative GRE in the CRH 
promoter (Malkoski and Dorin, 1999). Additionally, ACTH expression is downregulated by 
GCs via a negative GRE in the POMC gene, the precursor molecule for ACTH (Drouin et al., 
1989). Transrepression is the inhibition of gene expression by monomeric ligand-bound 
receptors binding to transcription factors to prevent their association with DNA or by 
competing with transcription factors for nuclear co-activators.  
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1.3.11 Glucocorticoids and energy homeostasis 
GCs have been proposed as major regulators of energy homeostasis (Hirschberg, 1998). It 
has long been known that GCs pharmacologically stimulate food intake and reduce energy 
expenditure (Cohn et al., 1955, Tataranni et al., 1996). Chronic elevation of circulating 
cortisol (hypercorticolism), as seen in Cushing’s syndrome or after prolonged administration 
of exogenous steroids, increases food intake and reduces energy expenditure, resulting in a 
phenotype similar to that of the metabolic syndrome. Other symptoms of hypercorticolism 
include a significant redistribution of fat (leading to centripetal obesity), hypertension, 
protein wasting, raised cholesterol, insulin resistance, hyperglycaemia, immunodeficiency 
and sometimes impaired cognitive function (Cushing, 1913). This positive energy balance is 
further bolstered by reductions in anorectic CRH content in the PVN, increased output of 
anabolic insulin and reduced expression of uncoupling protein-1 (UCP-1) (Fraser et al., 1999, 
Viengchareun et al., 2002, MacKenzie et al., 2008). Additionally, in adipose tissue, cortisol 
promotes differentiation of pre-adipocytes into mature adipocytes and an increase in 
lipoprotein lipase activity, thereby promoting an increase in adipose tissue and weight gain 
(Tataranni et al., 1996). Conversely, insufficient cortisol secretion (hypocorticolism) results 
in an opposing phenotype, seen in patients suffering from Addison’s disease (degeneration of 
the adrenal cortex), adrenogenital syndrome (a disorder of GC synthesis) or pituitary disease. 
Patients display hypophagia and weight loss, hypoglycaemia, hypotension and vulnerability 
to stress. In both cases of hyper- and hypocorticolism, symptoms can be reversed by 
treatment to normalise circulating cortisol levels (Nussey and Whitehead, 2001).  
 
These observations are supported by a large amount of experimental data in rodents. In both 
rats and mice, peripheral administration of exogenous corticosterone increases food intake 
and bodyweight in normal weight animals (Cusin et al., 2001, Green, 1992). Additionally, the 
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diurnal rhythm of corticosterone secretion corresponds with animal feeding patterns (Akana 
et al., 1999). ADX prevents endogenous GC production and reduces food intake and 
bodyweight gain in both rats and mice (Freedman et al., 1986). Administration of 
corticosterone back to physiological levels reverses these effects and normalises caloric 
intake (Freedman et al., 1986), an effect not seen following replacement with MCs, the other 
main product secreted by the adrenal cortex. 
 
ADX prevents the onset of obesity in most animal models, including hypothalamic damage, 
ob/ob mice, db/db mice, and Zucker rats (Freedman et al., 1986, Walker and Romsos, 1992, 
Shimomura et al., 1987, Makimura et al., 2000, Sainsbury et al., 1997a, Debons, 1982). In all 
of these models, the effects are reversed by the administration of physiological concentrations 
of GCs. Similar results are obtained after ADX in rats with diet induced obesity (DIO) 
(Mantha and Deshaies, 2000). Thus, GCs appear to promote positive energy balance in both 
normal and pathological conditions. However, ADX animals are sick and eventually require 
supplementation of GCs in order to survive; hence data in these animals with regard to food 
intake and bodyweight should be interpreted with caution. 
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1.3.12 Glucocorticoid pre-receptor metabolism 
Despite the obvious link between GCs and metabolism, it is not thought that alterations in 
circulating GCs are part of the aetiology of idiopathic obesity in humans. In fact, plasma 
cortisol levels are found to be normal or even low in obese individuals (Seckl and Walker, 
2004) and overall HPA axis function is relatively normal. Instead, it is thought that obesity 
may alter local GC availability at receptors (Holmes and Seckl, 2006). This is determined, in 
part, by circulating GC levels, but is primarily controlled by pre-receptor GC metabolism by 
the isoenzymes 11β-hydroxysteroid dehydrogenase 1 and 2 (11βHSD1 and 11βHSD2) (Seckl 
and Walker, 2001). By controlling substrate availability, 11βHSD enzymes act as gatekeepers 
for intracellular GR and MR, thus mediating tissue specific GR activation, independent of 
circulating plasma GC levels (Rask et al., 2001). 11βHSD1 and 11βHSD2 are coded for by 
separate genes and have distinct tissue distribution. 11βHSD1 is expressed in many 
metabolically active tissues, notably liver, adipose, bone and discrete brain regions (Moisan, 
1990, Holmes et al., 2003).  
 
 
 
 
 
 
Figure 1.04 Diagram detailing the interconversion of cortisone and cortisol by the 
isoenzymes 11beta-hydroxysteroid dehydrogenase 1 and 2. 11βHSD1 is a bidirectional 
NADPH dependent reductase (that converts inactive cortisone to active cortisol) and 
dehydrogenase enzyme (that converts cortisol to cortisone). 11βHSD2 is a NAD+ dependent 
dehydrogenase enzyme.  
 
 
11βHSD1 
11βHSD2 
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11βHSD1 is a high capacity enzyme with a low affinity for GCs. It utilises reduced 
nicotinamide adenine dinucleotide phosphate (NADPH) as a cofactor and catalyses 
dehydrogenation (cortisol and corticosterone to cortisone and 11-dehydrocorticosterone, 
respectively) (Figure 1.04). Oxo-reductase behaviour is more prominent in vivo, but 
11βHSD1 acts as a dehydrogenase in cellular homogenates or when purified. Reductase 
activity is preserved in vivo due a supply of NADPH from hexose-6-phosphate 
dehydrogenase (H6PDH) in the lumen of the endoplasmic reticulum (ER) (Figure 1.05), 
which is thought to modulate 11βHSD1 activity (Agarwal, 2003). 11βHSD1 causes a local 
amplification of GC availability at the GR (Seckl and Walker, 2001). 11βHSD1 is thought to 
be the sole 11β-reductase in the body, as infusion of 11-dehydrocorticosterone in ADX 
transgenic mice with a knockout of 11βHSD1 did not result in GC activity, nor did the 
animals have circulating corticosterone (Kotelevtsev et al., 1997). 
 
11βHSD2 has a much higher affinity for GCs than 11βHSD1 and in vivo functions almost 
exclusively as a dehydrogenase; responsible for converting active GCs to the functionally 
inert 11-keto form (cortisone or 11dehydrocorticosterone) utilising NAD+ as a cofactor 
(Figure 1.04). 11βHSD2 is mainly expressed in MC target tissues, where its role is to prevent 
inappropriate activation of low affinity MRs in aldosterone sensitive tissues by active GCs, 
which are also able to bind to this receptor. As such, 11βHSD2 activity is essential for 
maintaining the functional specificity of the MR for aldosterone. However, 11βHSD2 does 
not necessarily colocalise with MR expression, thus 11βHSD2 is thought to be responsible 
for other physiological roles. For instance, 11βHSD2 is thought to be heavily implicated in 
foetal development, as high levels of 11βHSD2 expression are observed in the placenta. The 
high affinity of 11βHSD2 for GCs is thought to serve as a GC barrier; reducing GC transfer 
from the mother to the foetus.  
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Figure 1.05 Schematic of 11beta-hydroxysteroid dehydrogenase 1 situated in the lumen 
of the endoplasmic reticulum utilising reduced nicotinamide adenine dinucleotide 
phosphate to function as a reductase. Hexose-6-phosphate dehydrogenase (H6PDH) 
generates NADPH by the conversion of glucose-6-phosphate (G6P), transported via the ER-
luminal glucose-6-phosphate translocase (G6PT) to 6-phosphogluconolactone (6PGL) within 
the endoplasmic reticulum. The supply of NADPH drives 11βHSD1 to function as a 
reductase, converting inactive GC to active GC. 
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1.4 Glucose homeostasis 
Glucose is the primary fuel for the vast majority of life on Earth. In multicellular organisms, 
maintenance of circulating glucose levels within a narrow range is vital. In humans and 
animals, blood glucose levels are generally maintained around 4 - 5 mmol/l (termed 
euglycemia), but levels fluctuate throughout the day; being lowest in the morning (before the 
first meal), and rising postprandially. If circulating glucose levels fall too low (generally 
when blood glucose levels fall below 3 mmol/l) a potentially fatal condition termed 
hypoglycaemia occurs. Whereas if blood glucose levels go too high, the result is 
hyperglycaemia, a condition which can lead to many long-term health problems; seen in 
patients suffering from diabetes mellitus. To counteract both hypo- and hyperglycaemia, 
animals have evolved cellular, autonomic, endocrine, and behavioural measures, to maintain 
euglycemia. A central component of these measures is the ability of sensory elements at 
various locations throughout the body (including the pancreas, gut and brain) to detect 
changes in blood glucose concentration and use this information to produce an appropriate 
response to counteract changes in glucose level. Regulation of this response is mediated by 
the secretion of glucoregulatory hormones and by neural mechanisms. There are two types of 
mutually antagonistic glucoregulatory hormones; catabolic hormones (e.g. glucagon) which 
increase blood glucose, and anabolic hormones (e.g. insulin) which decrease blood glucose. 
The hormones glucagon and insulin, secreted from glucose-sensing pancreatic islet cells, act 
to raise and lower blood glucose respectively (Goke et al., 1995). Maintenance of glucose 
homeostasis also requires a coordinated response from a network of glucose sensors located 
in the periphery and the brain. Glucose sensing neurons are distributed throughout the brain 
in areas associated with homeostatic control mechanisms (Levin et al., 1999). The best 
characterised populations of glucose sensing neurons are located in the hindbrain and 
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hypothalamus. Important glucose sensing elements are also found in the hepatic portal vein, 
gut, carotid body, and oral cavity.  
 
Glucose sensitive nuclei within the hypothalamus and hindbrain sense and respond to 
changes in circulating glucose concentration to coordinate autonomic, neuroendocrine and 
behavioural responses to prevent glucoprivation; known as the counterregulatory response 
(CRR) to hypoglycaemia. The CRR to hypoglycaemia is activated when blood glucose levels 
fall below 4.0 mmol/l (Cryer, 1999), and utilises two pathways. The first is the innervation of 
peripheral organs involved in glucose homeostasis via the sympathetic nervous system (SNS) 
(Pocai et al., 2005). The second pathway, the HPA axis, is activated during prolonged 
hypoglycaemic episodes (De Feo et al., 1989). Stimulation of the SNS via the hindbrain and 
hypothalamus mediates direct CRR effects upon peripheral organs such as the liver, pancreas 
and adrenal glands. Sympathetic stimulation of these organs either increases net glucose 
production directly, or stimulates the release of CRR hormones, such as glucagon, adrenaline, 
nor-adrenaline, cortisol and growth hormone (GH), which increase glucose production and 
decrease glucose utilisation in other peripheral tissues. 
 
Glucagon, the primary CRR hormone, is produced in the α-cells of the pancreatic islets of 
Langerhans. The secretion of glucagon is tightly regulated and intimately tied to blood 
glucose levels. Lowering levels of blood glucose stimulates the pancreatic α-cells to secrete 
glucagon into the circulation. Glucagon binds to the glucagon receptor, expressed in the liver, 
promoting glycogenolysis; the breakdown of glycogen. Glycogen is the storage molecule of 
glucose, a starch-like polymer chain made up of glucose monomers. Glycogenolysis cleaves 
glycogen into glucose monomers which are then released into the bloodstream, thereby 
increasing blood glucose concentration. When glycogen stores are depleted, glucagon 
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stimulates the liver to synthesise additional glucose by gluconeogenesis; the generation of 
glucose molecules from non-carbohydrate substances. Glucagon also inhibits glycolysis (the 
breakdown of glucose) in the liver, causing glycolytic intermediates to be shuttled into 
gluconeogenesis, the production of glucose. Glucagon secretion is promoted via the action of 
voltage-dependent Na+ and Ca2+ channels, which maintain action potentials during times of 
low glucose. Depolarisation increases Ca2+ influx and subsequent glucagon secretion. As 
glucose levels rise, secretion of glucagon is inhibited through the elevation of cytosolic ATP, 
leading to the blockade of ATP-sensitive K+ (KATP) channels, and termination of the Na+ and 
Ca2+ induced action potentials, thereby inhibiting Ca2+ influx. During episodes of severe 
hypoglycaemia, the SNS response is augmented by further release of CRR hormones via the 
HPA axis. Hypothalamic glucose sensing nuclei act on the PVN to stimulate the release of 
GH and CRH from the anterior pituitary. These hormones exert a longer-lasting effect on 
peripheral gluconeogenesis than glucagon.  
 
Conversely, a rise in blood glucose concentration promotes glucose uptake and metabolism 
within pancreatic β-cells, thereby increasing ATP production at the cell membrane. This 
induces a closure of KATP channels, depolarising the entire cell and stimulating exocytosis of 
insulin granules into circulation (German, 1993). Insulin also promotes glucose uptake from 
circulation in liver and muscle tissue, storing it as glycogen. Insulin prevents the metabolism 
of fat as an energy source by inhibiting the release of glucagon. Insulin acts on the insulin 
receptor, which is distributed throughout the body. Upon insulin binding, the insulin receptor 
initiates the translocation of vesicle-bound glucose transporter type 4 (GLUT4) to the cell 
membrane, consequently increasing uptake and storage of glucose from circulation into the 
cell (Watson and Pessin, 2006). Binding of insulin to the insulin receptor also exerts a 
prolonged effect on glucose homeostasis by altering the expression of genes involved in the 
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production and storage of glucose in target cells. For example, increased insulin signalling 
upregulates the expression of genes that promote glycogen synthesis, whilst downregulating 
genes which promote glycogenolysis and gluconeogenesis (Watson and Pessin, 2006). 
 
Peripheral glucose sensing 
Glucose sensitive L- and K-cells in the gastro-intestinal tract play a key role in the regulation 
of glucose homeostasis, preparing the body to deal with a postprandial rise in blood glucose. 
Orally administered glucose elicits a much greater insulin response than the equivalent dose 
of glucose administered via the intravenous route (Marty et al., 2007). The difference in 
insulin release and glucose tolerance between the two routes is known as the incretin effect 
and refers to the glucoregulatory hormones GLP-1 and glucose dependent insulinotropic 
peptide (GIP), released from glucose sensing L- and K-cells respectively (Creutzfeldt, 1979, 
Drucker, 1998).  
 
GLP-1 also targets the hepato portal glucose sensor, located in the hepato portal vein. The 
hepato portal glucose sensor enables the body to detect a rise in postprandial blood glucose 
concentration, and to translate this change into decreased signalling via vagal afferents that 
project to glucoregulatory areas of the brain. Thus, glucose infusion into the hepatic portal 
vein induces satiety (Russek, 1963, Russek, 1970) and increases hepatic glucose uptake 
(Gardemann et al., 1986), assisting clearance of glucose from the blood. Infusion of GLP-1 
into the hepatic portal vein results in an increase in hepatic glucose disposal and also 
augments insulin release from the pancreas (Nishizawa et al., 2003) via a neural mechanism. 
Thus, the hepato portal vein is a key glucose-sensitive site, enabling interaction between 
glucoregulatory systems located in the gut, CNS and pancreas. The hepato portal glucose 
sensor encodes information about blood glucose concentration just before it enters the liver 
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from the gut which is then conveyed to the hindbrain by way of the vagal nerve and spinal 
cord. These widely distributed glucose sensors therefore collectively constitute important 
entry points into the brain for information about circulating glucose. The brain then 
assimilates this information with other neural processes to influence the behavioural, 
autonomic, and neuroendocrine motor functions that regulate metabolism. 
 
Central glucose sensing 
In the brain, glucose sensing neurons are distributed in areas associated with homeostatic 
control mechanisms (Levin, 2001). Glucose sensitive neurons located in the hypothalamus 
and hindbrain are thought to be important for the regulation of glucose and energy 
homeostasis (Levin et al., 1999, Marty et al., 2007). Glucose sensing neurons can be broadly 
divided into two groups according to their response to changes in extracellular glucose. 
Glucose-excited neurons increase their firing rate in response to increased glucose, whereas 
glucose-inhibited neurons decrease their firing rate in response to increased blood glucose 
(Anand et al., 1964, Kang et al., 2004, Oomura et al., 1964). Glucose sensitive neurons are 
located in several hypothalamic nuclei, including the VMN and the ARC (Lynch et al., 2000). 
These nuclei share reciprocal projections with each other, and also with the glucose sensitive 
regions of the hindbrain, thus forming a network of glucose sensitive nuclei that are able to 
regulate glucose homeostasis.  
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1.5 Aim of thesis 
There is strong pharmacological evidence that GCs play a major physiological role in the 
regulation of energy homeostasis. Indeed, patients suffering from Cushing’s syndrome 
(which is caused by excess circulating GCs) exhibit symptoms such as increased food intake, 
reduced energy expenditure, hypertension, raised cholesterol, insulin resistance, and 
hyperglycaemia, resulting in a phenotype similar to that of the metabolic syndrome. 
Interestingly, circulating GC levels are not elevated in obese patients, and HPA axis function 
is relatively normal. However patients suffering from idiopathic obesity exhibit raised 
intracellular GC levels in central adipose tissue. 11βHSD1 is the enzyme responsible for 
catalysing the conversion of the inactive GC cortisone (11-dehydrocorticosterone in rodents) 
to active the GC cortisol (corticosterone in rodents). Hence, increased intracellular 11βHSD1 
expression, and hence raised intracellular GC levels, are thought to be implicated in the 
development of obesity.  
 
A wealth of research suggests that GCs play a major role in the hypothalamic regulation of 
energy homeostasis, yet their physiological effects and site of action remain unclear. In this 
thesis I will utilise recombinant adeno-associated virus (rAAV) to overexpress 11βHSD1 and 
subsequently increase intracellular GC levels in discrete hypothalamic nuclei and investigate 
the role of hypothalamic GCs in food intake, energy expenditure, and glucose homeostasis. 
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Chapter 2 
Genetic Modification 
Materials and Methods 
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2 Introduction 
2.1 Genetic modification  
Previous studies investigating the central role of GCs have largely relied on the 
pharmacological administration of GCs (or synthetic GCs such as dexamethasone) directly 
into the brain. This is usually performed via intracerebroventricular (ICV) administration or 
by direct injection into a specific hypothalamic nucleus (Debons et al., 1986, Zakrzewska et 
al., 1999b); however there are technical problems associated with both of these techniques. 
Administration via ICV injection is not specific to one brain region, and repeated injections 
can only be tolerated for short periods. Direct injection into a hypothalamic nucleus allows 
for anatomical localisation, but can only be sustained for short periods due to destruction of 
the brain tissue at the injection site. Studies requiring repeated or prolonged administration of 
GC require extensive handling of experimental animals, thus resulting in behavioural 
disruption. To avoid the problems associated with exogenous GC administration, an organism 
can be genetically modified (GM) and studied under conditions that require much less human 
contact with the experimental animal. Manipulation of an organism’s genome, using genetic 
engineering techniques, results in a genetically modified organism (GMO). Genetic 
modification can be performed in vitro or in vivo and as such can be performed in single 
celled or multi-cellular organisms. A GMO permits the alteration of a biological parameter in 
a specific area of the organism (e.g. the CNS) or throughout the entire body. A genome can 
be manipulated such that genes are overexpressed, which typically creates ‘gain-of-function’ 
mutations, or via gene targeting, which creates ‘loss-of-function’ mutations.  
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2.1.1 Gene delivery vectors 
To express a gene of interest in a target cell, it must first be transported across the cell 
membrane, which usually requires a vector. Vector choice varies according to a number of 
factors, including the target organ, tissue and cell type as well as the size of the gene to be 
delivered and the duration of gene expression required. Desirable features of vectors include 
easy production techniques, ability to transfer large DNA fragments, potential to target 
specific tissues (including those containing non-dividing cells) and lack of an immune 
response.  
 
The two main categories of vector are viral or non-viral. Non-viral vectors are considered to 
be safer than viral vectors as they are not targeted by the immune system. They also have the 
potential to carry large amounts of DNA. However, the efficiency of cell transfection using 
non-viral vectors is lower than that achieved using viral vectors (Gardlik et al., 2005).  
 
2.1.2 Non-viral vectors  
One of the earliest methods used to transfect cells was calcium phosphate transfection 
(Graham and van der Eb, 1973). However, a number of other non-viral agents now exist, 
including liposomes, cationic polymers and other mechanical methods such as the 
electroporation of cells. In some cases naked vector DNA, injected directly into certain 
tissues, can produce relatively high expression levels (Wolff and Budker, 2005). Non-viral 
delivery in rapidly dividing cells in vitro can achieve a relatively high rate of transfection, 
thus non-viral vectors are usually used for gene transfer in vitro, whilst viral vectors are 
utilised in vivo. 
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2.1.3 Viral vectors  
Viral particles can be modified to encapsulate a transgene of interest, in place of the viral 
genome, resulting in viral vectors. Viruses are useful vectors for gene delivery as they have 
evolved specialised mechanisms to transport DNA into cells. Viral gene transfer exploits the 
viral characteristics of gaining entry to specific cell types. The introduced transgene is 
expressed and the host’s cellular machinery is used for the synthesis of the protein encoded 
by the transgene, thus making viral vectors ideal to express recombinant genetic material in a 
target cell (Figure 2.01). 
 
A number of viruses have been adapted for use as vectors; including retrovirus, lentivirus, 
herpes simplex virus (HSV), adenovirus and adeno-associated virus (AAV). Viral vectors 
based on pathogenic viruses are modified to limit their ability to replicate in order to improve 
safety. Successful application of gene transfer requires the correct selection of viral vector i.e. 
a vector with the ability to deliver the transgene to the target tissue, without substantial 
toxicity, for the desired time period of expression. Each viral vector is characterised by 
properties that affect its suitability for specific gene transfer applications. The viral vector 
selected for the work described in these studies was AAV. 
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Figure 2.01 Diagrammatic representation of viral vector mediated expression of 
recombinant genetic material. The vector particle containing the modified genome enters 
the cell, allowing the genome to enter the nucleus, resulting in the transcription and 
translation of the modified gene.  
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2.1.3.1.1 Adeno-associated virus 
AAV is a small (25 nm), non-enveloped DNA virus, with each viral particle containing a 
single plus- or minus-strand of the single stranded genome (packaged into AAV capsids with 
equal frequency). AAV is placed in the genus dependovirus, meaning that it is replication 
defective, requiring additional functions, supplied by a helper virus (either adenovirus or 
herpes simplex virus). Without the presence of a helper virus, AAV cannot synthesise capsid 
proteins or be packaged into viral particles. AAV also possesses no lytic capability and relies 
on the helper virus to liberate newly formed viral particles. In the absence of a helper virus, 
wildtype (WT) AAV will infect the target cell and integrate site specifically into chromosome 
19, where it remains latent (Figure 2.02).  
 
In the presence of a helper virus the lytic stage ensues; AAV undergoes productive infection, 
characterised by genome replication, viral gene expression and virion production. The 
adenoviral genes that provide helper functions regarding AAV gene expression include E2a, 
E4 and VA RNA. 
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Figure 2.02 Diagrammatic representation of the AAV life cycle. In the absence of a helper 
virus, AAV infects and integrates into host chromosome 19, where it remains latent until 
rescue by a helper virus. In the presence of a helper virus (in this case adenovirus co-
infection) AAV undergoes productive infection, resulting in packaging and release of both 
AAV and adenovirus. Diagram adapted from (Daya and Berns, 2008). 
 
Twelve human serotypes of AAV (AAV serotype 1 [AAV-1] to AAV-12) and more than one 
hundred serotypes from non-human primates have been discovered to date, each of which has 
a tropism for a specific cell type (Palomeque et al., 2007). The best studied of these is AAV-
2, which displays a tropism for neurons and has been shown to transduce adult neurons in 
vivo for over one year (Klein et al., 2002). It is estimated that 80-90% of the population are 
sero-positive for AAV-2, but because AAV is non-pathogenic, infection is not associated 
with any symptoms or disease. 
 
The AAV-2 genome is approximately 4.7 kilobases (kb) long and contains two open reading 
frames (ORFs) flanked by two 145 basepair (bp) inverted terminal repeats (ITRs) (Figure 
2.03). The 5’ ORF contains the Rep gene, which produces the four proteins Rep 78, Rep 68, 
Rep 52 and Rep 40. The larger proteins (Rep 78 and 68) are produced from transcripts using 
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the p5 promoter and are important regulatory proteins. The smaller proteins (Rep 52 and 40) 
are produced from transcripts under the p19 promoter and are involved in the accumulation of 
single-stranded viral DNA used for packaging within AAV capsids. In the absence of a 
helper virus, it is these Rep proteins which suppress AAV gene expression (Trempe and 
Carter, 1988). The 3’ ORF contains the Cap gene, which produces the three viral capsid 
proteins VP1, VP2 and VP3 using the p40 promoter (Figure 2.03). The AAV-2 capsid 
comprises sixty viral capsid proteins arranged into an icosahedral structure (Figure 2.04).  
 
  
Figure 2.03 Map of wildtype AAV-2 genome. Rep and Cap genes are flanked by ITRs. The 
Rep and Cap transcripts are produced from their respective promotors (p5, p19 and p40). 
Diagram taken from (Daya and Berns, 2008). 
 
ITRs are important cis acting sequences, necessary for AAV DNA replication. Each ITR 
consists of 145 nucleotides, the first 125 of which constitute a palindromic sequence. This 
sequence folds back on itself to form a T-shaped hairpin structure (Figure 2.05), which is 
essential for incorporation of the virus into the host genome. The ITR is the origin of 
replication and serves as primer for second-strand synthesis by DNA polymerase. These 
double stranded intermediates are processed; resulting in single-stranded DNA used for viral 
packaging and double stranded DNA used for transcription. Rep binding elements (RBEs) 
RBE and RBE’ and a terminal resolution site (TRS) are located in the ITRs (Figure 2.05) and 
are critical to the genome replication process as they are used by Rep proteins to process the 
double stranded intermediates. The ITRs are also essential for AAV genome packaging and 
negative regulation of transcription. 
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Figure 2.04 AAV-2 icosahedral structure. Coloured according to distance from the viral 
centre. Diagram taken from (Xie et al., 2002). 
 
The primary attachment receptor for AAV-2 is heparan sulfate proteoglycan (HSPG) and 
target cells cannot be infected with AAV if they do not express this receptor (Summerford 
and Samulski, 1998). Internalisation of the virus is enhanced by interactions with one or more 
of six known co-receptors, including αvβ5 integrins (Wickham et al., 1993), fibroblast 
growth factor receptor 1 (Qing et al., 1999), hepatocyte growth factor receptor (Kashiwakura 
et al., 2005), αvβ1 integrin (Asokan et al., 2006), and laminin receptor (Akache et al., 2006). 
The cellular events that control AAV trafficking post entry are not completely defined. 
Current theories suggest AAV is endocytosed into clathrin coated vesicles (Duan et al., 
1999), but it is unclear how AAV escapes these endosomes to allow release of the virus into 
the cell. Additionally, it is not known how AAV enters the nucleus after escaping the 
endosome. Once inside the nucleus, AAV integrates at the AAV1 locus on chromosome 19 
(Kotin et al., 1990). AAV has been shown to transduce cells both through episomal transgene 
expression and by random chromosomal integration (Rutledge and Russell, 1997). 
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Figure 2.05 Diagrammatic representation of AAV-2 ITR secondary structure showing 
the RBE, RBE’ and TRS. Diagram taken from (Daya and Berns, 2008). 
65 
 
2.1.3.2 Recombinant adeno-associated virus 
The non-pathogenic nature of AAV and the relative ease with which its genome can be 
manipulated have led to the development of recombinant AAV (rAAV) as a vehicle for gene 
transfer. rAAV differs from AAV, in that the Rep and Cap genes have been removed. This 
ensures that rAAV cannot form viral particles, even if it infects a cell where another virus is 
present. The exception to this is during the production of rAAV, when a plasmid containing 
Rep and Cap is used to produce viral particles ready for use. The only AAV genome 
sequences contained within rAAV are the ITRs, whilst the expression cassette is modified to 
include the transgene(s) of choice, with a packaging capacity of around 4.5kb (Figure 2.06). 
Since the rAAV vector genome lacks viral coding sequences, the vector itself is not 
associated with toxicity or any inflammatory response (except for the generation of 
neutralising antibodies which may limit re-administration). However, because of the removal 
of the viral genome, rAAV does not have the ability to target the specific region of 
chromosome 19. 
 
The vector plasmid, pTRCGW, also contains genes that are essential for transgene expression 
(Figure 2.06). The early CMV promoter is a constitutively active promoter which is found in 
a wide variety of mammalian cells and is essential for driving transgene expression. The 
woodchuck post-transcriptional regulatory element (WPRE) has been shown to improve the 
transcription of mRNA in vivo, whilst also acting as a marker of expression, as it is not 
endogenously expressed. The polyadenylation signal stabilises the mRNA transcripts and the 
ampicillin resistance gene is required to select for transformed bacteria containing the vector 
plasmid during rAAV production.  
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Figure 2.06 Structure of rAAV plasmid pTRCGW with transgene insert. ITRs flank the 
expression cassette which contains the cDNA insert and CMV promoter. Outside of the 
expression cassette the gene for ampicillin resistance in included to aid selection of rAAV 
positive bacterial colonies. 
 
Recombinant AAV technology permits high and stable transgene expression to be induced at 
any point during an animal’s lifespan, thereby circumventing developmental compensation. 
Also, rAAV can infect non-dividing cells, meaning it is suitable for use in the CNS and has 
been successfully used to manipulate gene expression within the hypothalamus; both to 
promote (Tiesjema et al., 2009) and knockdown (Gardiner et al., 2005) expression a gene of 
interest. Recombinant AAV-2 has been chosen for use in this work because of its tropism for 
neurons and lack of tropism for glia (Bartlett et al., 1998), however, rAAV-2 is relatively 
non-specific in which neurons it infects. Following injection of rAAV, virus particles may 
spread a short distance due to the rAAV vehicle dispersing within tissue. In addition, within a 
hypothalamic nucleus there may be neuronal types with different functions co-localised in 
one area (e.g. in the ARC there are NPY/AgRP and POMC/CART neurons); rAAV would 
infect all neurons indiscriminately.  
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When a cell is infected with rAAV, the viral genome is conveyed to the nucleus and 
converted to a double-stranded form. After rAAV administration there is a slow rise in gene 
expression, reaching a steady state level after three weeks. This is due, perhaps in part, to a 
requirement for generation of dsDNA genomes, by either vector ssDNA annealing, or second 
strand-synthesis, followed by vector genome linking to form concatemers. 
 
A variety of methods can be used to produce rAAV for gene transfer, but the method used in 
these experiments follows the ‘two-plasmid system’ (Grimm et al., 1998). This system 
requires a packaging plasmid (in this case pTRCGW containing the transgene of interest) and 
a helper plasmid. The helper plasmid used is pDG, which contains the Rep and Cap genes, as 
well as some other adenoviral genes. The adenovirus genes allow the virus to propagate 
without the need for the extra addition of adenovirus as a helper virus (Figure 2.07).  
 
 
Figure 2.07 Structure of helper-plasmid pDG. Contains AAV and adenovirus genes 
required for amplification and packaging of rAAV. Right terminal repeat (RTR), MMTV-
Rep-Cap – promoter region encoding Rep and Cap proteins, expression is driven by mouse 
mammary tumour virus (MMTV) and long terminal repeat (LTR), VA, E2A and E4 – 
adenovirus helper genes required for replication.  
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2.2 Materials 
Unless stated otherwise all chemicals were purchased from VWR, Poole, Dorset, UK and all 
enzymes from New England Biolabs, Hitchin, Herts, UK. 
 
2.3 Methods 
2.3.1 Total RNA extraction – Tri reagent method 
Materials 
Tri-reagent (Helena Biosciences, Tyne and Wear, UK) 
1-Bromo-chloro-propane  
Isopropanol  
Absolute ethanol  
Glass distilled water (GDW) 
 
Method 
Total RNA was extracted from tissues using Tri-reagent according to the manufacturer’s 
protocol. Tissue (up to 100 mg) was ground under liquid nitrogen with a mortar and pestle 
before being homogenised in 1 ml Tri-reagent, transferred to 1.5 ml eppendorf tubes and 
incubated for 5 minutes at room temperature. One hundred microlitres of bromo-chloro-
propane was added per millilitre of Tri-reagent, mixed vigorously for 15 seconds, and 
incubated for a further 5 minutes at room temperature. RNA was separated by centrifugation 
for 15 minutes at 12,000xg and 4˚C (centrifuge 5417 C/R, Eppendorf, Hamburg, Germany) 
with the brake off. The upper aqueous phase was transferred to a clean eppendorf tube, 
precipitated using 500 μl of room temperature isopropanol for 10 minutes at room 
temperature, and subjected to centrifugation for 10 minutes at 12,000xg and 4˚C. The 
supernatant was discarded and the resulting pellet washed with one volume (1 ml) of 75 % 
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(v/v) ethanol in GDW and subjected to centrifugation for a further 10 minutes at 12,000xg 
and 4˚C. The pellet was then air dried, and dissolved in 400 μl of autoclaved GDW. RNA 
concentration was determined spectrophotometrically. RNA was diluted 1:100 in GDW and 
1 ml transferred into a quartz cuvette. Absorbance was read at 260 and 280 nm on a UV 1101 
spectrophotometer (WPA, Cambridgeshire, UK). The concentration was calculated using the 
following formula: concentration (µg/ml) = (A260 x dilution factor) x 40. Following 
quantification, RNA samples were ethanol precipitated using 0.1 volumes of sodium acetate 
(pH 5.2) and 2.5 volumes of ice cold absolute ethanol. Samples were incubated at -20°C for a 
minimum of 1 hour and the RNA recovered by centrifugation for 20 minutes at 12,000xg and 
room temperature (F45-12-11 microfuge, Eppendorf, Hamburg, Germany). The supernatant 
was discarded and the pellet air dried under vacuum for 5 minutes. RNA was dissolved in the 
appropriate volume of GDW to give a 5 mg/ml solution.  
 
2.3.2 Formaldehyde gel to check viability of RNA 
Materials 
Agarose, type II-A medium EEO 
Formaldehyde  
20x MOPS, pH 7.0 (appendix I) 
0.4 M 3-(N-Morpholin) propanesulphonic acid (MOPS) 
0.1 M sodium acetate 
0.02 M EDTA 
0.04 % formaldehyde 
10 mg/ml Ethidium bromide  
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DENAT  
70 % (v/v) Formamide (appendix I) 
3.5 % (v/v) Formaldehyde 
1.5x MOPS  
Gel loading buffer (appendix I) 
25 % (v/v) glycerol 
0.1% orange G 
25 mM EDTA 
100x TE, pH 7.5 (appendix I) 
1 M Tris base 
0.1 M EDTA 
2 M Sodium acetate, pH 5.2  
GDW 
 
Method 
RNA secondary structure was denatured before confirming the integrity of the samples using 
a formaldehyde gel. A 1 % agarose denaturing gel was prepared in 1x MOPS buffer with 7.5 
% (v/v) formaldehyde. One microlitre of RNA solution was added to 12 μl of DENAT. 
Samples were incubated at 65°C for 5 minutes and 3 μl of gel loading buffer added. The 
samples were loaded onto the gel and electrophoresed in 1x MOPS buffer with 7.5 % 
formaldehyde (v/v) at 15 V/cm until the samples had run 10 cm. The gel was stained in 
1x TE containing 0.01 mg/ml ethidium bromide on a shaking platform for 30 minutes and 
destained overnight in 1x TE to allow visualisation of the 18S and 28S ribosomal bands 
under UV light (300 nm). The presence of intact ribosomal bands indicated the RNA had not 
degraded. 
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2.3.3 Northern blot analysis 
Northern blot was used to analyse the size and quantity of RNA in tissues. This has 
advantages over other methods of analysing RNA, such as dot blot and in situ hybridisation, 
in that the message is analysed by size and is quantifiable. The method is an adaptation of the 
method introduced for analysis of DNA, Southern blotting (Southern, 1975). RNA is size 
fractioned on a denaturing agarose gel by electrophoresis, transferred by capillary action to a 
nylon filter and covalently linked to the filter by baking. The RNA is denatured to remove 
secondary structure, ensuring the rate of migration of the RNA is proportional to its total 
length. 
 
2.3.3.1.1 Electrophoresis and immobilisation of nucleic acids (Lehrach et al., 
1977) 
Method 
A denaturing agarose gel was made by dissolving 1 g agarose in GDW; 20x MOPS was 
added to a final concentration of 1x and formaldehyde added to 3 % (v/v). Once set, the gel 
was transferred to an electrophoresis tank containing a running buffer of 1x MOPS, and 3 % 
formaldehyde (v/v). Before loading, 50 µg of total RNA was denatured by addition of 10 μl 
denaturing buffer and incubation at 60˚C for 5 minutes. After denaturation, 3 μl loading 
buffer was added and the samples loaded onto the gel. The gel was electrophoresed at a 
constant voltage of 10 V/cm. After electrophoresis, the marker track was cut off and stained 
(section 2.3.2). RNA in the remainder of the gel was transferred to Hybond-N membrane 
(Amersham Pharmacia Biotech) by capillary action overnight. The gel was inverted and 
placed onto a stack constructed as in Figure 2.08. After transfer, the filter was baked for 
2 hours at 80°C. 
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Figure 2.08 Diagram of apparatus used for capillary transfer of RNA from agarose gel 
onto Hybond-N membrane prior to northern blot analysis. 
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2.3.3.2 Hybridisation of 32P labelled probe to northern filters 
Probes for northern analysis were prepared from pBluescript containing the appropriate insert 
(section 2.3.5.1). To prepare fragments for labelling, pBluscript was cleaved by restriction 
endonuclease digestion (section 2.3.5.1), purified by agarose gel electrophoresis purification 
(section 2.3.4.3), denatured and radiolabelled using DNA polymerase I with random 
oligonucleotides as primers (section 2.3.3.2.1). Pre-hybridisation of the membrane was 
performed prior to the binding of radiolabelled probe, thus blocking irreversible non-specific 
binding of probe to the membrane. Following hybridisation, a number of increasingly 
stringent washes were performed to remove non-specifically bound probe. 
 
2.3.3.2.1 Random primer labelling of DNA fragments 
DNA fragments generated by restriction endonuclease digestion and purified by agarose gel 
electrophoresis purification were denatured and radiolabelled using DNA polymerase I with 
random oligonucleotides as primers (Feinberg and Vogelstein, 1983). 
 
Materials 
20 ng/µl DNA fragment 
5x ABC Buffer: (appendix I) 
12.5 mM Magnesium chloride 
125 mM Tris-HCl, pH 8.0 
23 μM 2-mercaptoethanol 
50 μM dATP (Amersham Pharmacia Biotech, UK) 
50 μM dGTP (Amersham Pharmacia Biotech) 
50 μM dTTP (Amersham Pharmacia Biotech) 
1M N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid (HEPES), pH 6.6 
74 
 
34 μg/ml Random deoxynucleotide hexamers (Amersham Pharmacia Biotech) 
10 mg/ml BSA, fraction V  
[α-32P]-dCTP: 10 Ci/ml, 3000 Ci/mmol (Amersham Pharmacia Biotech) 
DNA polymerase I, Klenow fragment 9 U/μl (Amersham Pharmacia Biotech) 
Sephadex G50 (Amersham Pharmacia Biotech) (appendix I) 
1x TE (appendix I) 
 
Method 
Twenty nanograms of DNA in a total volume of 15 μl of GDW were boiled for 5 minutes. 
After boiling, the solution was made up to a total volume of 25 μl containing 1x ABC buffer, 
2 mg/ml BSA, 10 μCi dCTP and 1 U Klenow fragment. The reaction was incubated at 37˚C 
for 1 hour. Incorporation of radionucleotide into the oligonucleotide was measured using a 
mini Sephadex G50 column. The column was prepared by plugging a glass Pasteur pipette 
with glass wool and adding Sephadex G50. The labelling reaction volume was made up to 
200 μl with 1x TE and loaded onto the column. The column was eluted with 1x TE and 
200 μl fractions collected. The fractions were counted and the percentage incorporation 
calculated. The two fractions with the greatest radiolabel incorporation were pooled and half 
added to the hybridisation mix. 
 
2.3.3.2.2 Hybridisation of filters 
Materials 
Radiolabelled DNA probe 
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Pre-hybridisation/hybridisation buffer:  
0.25 M Sodium phosphate buffer 
5 % (w/v) SDS 
0.5 % (w/v) Dried milk powder 
2.5 mM EDTA 
25 μM ATA (appendix I) 
Amasino wash buffer: (appendix I) 
0.25 M Sodium phosphate buffer, pH 7.2 
1 mM EDTA 
2 % (w/v) SDS 
Universal wash buffer:  
0.2x SSPE 
0.2 % (w/v) SDS 
 
Method 
The baked nylon filter was pre-hybridised in 20 ml of pre-hybridisation buffer in a heat 
sealed polythene bag for a minimum of 2 hours at 60°C. Prior to hybridisation of the nylon 
filter, the radiolabelled probe was denatured by boiling for 5 minutes and added to 20 ml of 
fresh hybridisation buffer. The pre-hybridisation mix was then removed and replaced with the 
hybridisation mix and the bag re-sealed. The filter was left to hybridise with radio-labelled 
probe overnight at 60˚C. Non-specifically bound probe was removed from the filter by 
washing in decreasing concentrations of sodium chloride. Three 20 minute washes at 60˚C 
were carried out in 50 ml of amasino wash buffer followed by a further three 20 minute 
washes at 60˚C in 50 ml of universal wash buffer. The filter was then sealed in a clean 
polythene bag and exposed overnight to a phosphorimager screen (Molecular Dynamics, 
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Sunnyvale, CA, U.S.A.). Radiolabelled areas were visualised and quantified by image 
densitometry using a Storm imaging system and ImageQuant software (Molecular 
Dynamics).  
 
2.3.3.2.3 Filter stripping 
Following hybridisation with a radiolabelled probe, northern filters can be stripped of 
radioactivity and re-used with minimal loss of RNA. Most northern filters can be stripped and 
re-probed five or six times depending on the abundance of the transcript of interest. 
 
Materials 
100x TE (appendix I) 
20 % SDS (w/v) (appendix I) 
 
Method 
The filter was stripped by incubation in 200 ml of 1x TE/0.5 % SDS for 30 minutes in a water 
bath at 80˚C. The filter was then exposed overnight to a phosphorimager plate to ensure that 
all radioactive probe had been removed. 
 
2.3.3.2.4 Oligo dT correction  
To correct for variation in gel loading and RNA transfer when performing northern analysis, 
total mRNA on filters was quantified by oligo dT probing (Sambrook, 2000). Radiolabelled 
oligo dT probe hybridises with the poly A tail of the mRNA species. 
 
Materials 
20 ng oligo dT template 
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5x reaction buffer: 
500 mM Cacodylate, pH 6.8 
5 mM Cobalt (II) chloride 
0.5 mM Dithiothreitol (DTT) 
0.5 mg/ml Bovine serum albumin (BSA) 
Terminal deoxytransferase, 20 U/μl (Promega UK Ltd, Southampton, Hampshire, UK) 
[α-32P]-dATP: 10 Ci/ml, 3000 Ci/mmol (GE Healthcare, UK) 
20x SSPE (appendix I) 
Sephadex G50 (appendix I) 
1x TE (appendix I) 
20 % SDS (w/v) (appendix I) 
Nonidet solution 
Dried milk powder 
GDW 
 
Method 
Twenty nanograms of oligo dT template were added to 1x reaction buffer that contained 
70 µCi of dATP and 20 U of terminal transferase, in a final volume of 20 μl with GDW. The 
reaction was incubated for 1 hour at 37˚C. Incorporation of nucleotide was measured using a 
mini Sephadex G50 column (section 2.3.3.2.1). The filter was pre-hybridised in 20 ml of pre-
hybridisation buffer (5x SSPE, 0.2 % (w/w) milk powder, 0.2 % (v/v) nonidet) for a 
minimum of 2 hours at room temperature in a polythene bag on a shaking platform. 
Hybridisation solution was prepared by adding one tenth of the labelled probe to 10 ml of the 
pre-hybridisation buffer. Pre-hybridisation solution was removed and replaced with the 
hybridisation solution containing the labelled probe and the filter was incubated at room 
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temperature overnight. Nonspecifically bound probe was removed by a series of increasingly 
stringent washes. The filter was washed twice in 5x SSPE/0.2 % SDS for 5 minutes at room 
temperature, then twice in 2x SSPE/0.2 % SDS for 30 minutes at room temperature. The filter 
was exposed to a phosphorimager screen overnight and radiolabelled bands quantified by 
image densitometry using ImageQuant software (Molecular Dynamics). 
 
2.3.4 Reverse transcription and polymerase chain reaction 
The polymerase chain reaction (PCR) enables the isolation of a specific target sequence from 
a mixed population of DNA. The basis of PCR is the use of a thermostable DNA polymerase 
(Taq DNA polymerase), which is capable of withstanding high temperatures. Taq DNA 
polymerase catalyses the polymerisation of DNA using a template strand and a primer bound 
to it.  
 
2.3.4.1.1 Reverse transcription 
Materials 
5 mg/ml Rat RNA  
10 mM dNTPs (Amersham Pharmacia Biotech) (appendix I) 
5x Reverse transcriptase buffer (Promega) 
250 mM Tris-HCl, pH 8.3 
250 mM Potassium chloride 
50 mM Magnesium chloride 
2.5 mM Spermidine 
50 mM Dithiothreitol (DTT) 
10 U/µl Avian myoblastoma virus reverse transcriptase (RT) (Promega) 
200 ng/µl Oligo dT (12-18) (Amersham Pharmacia Biotech) 
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Method 
The reaction was set up in a final volume of 20 µl containing 1 mg/ml RNA, 1x RT buffer, 
1 mM dNTPs and 10 mg/ml oligo dT. The solution was heated to 65°C for 5 minutes and 
incubated at room temperature for 30 minutes. Ten units of RT were added and the reaction 
incubated at 42°C for 1 hour. The reaction was then used in PCR (section 2.3.4.2). 
 
2.3.4.1.2 Polymerase chain reaction 
Materials  
10x Taq buffer: 
500 mM Potassium chloride 
100 mM Tris-HCl, pH 9.0 
15 mM Magnesium chloride 
1 % (v/v) Triton x100 
20 µM oligonucleotide primers (Oswell DNA service, Southampton, UK) 
Taq DNA polymerase  
10 mM dNTPs (GE Healthcare) 
Reverse transcription reaction  
 
Method 
Reverse transcription reaction cDNA fragments were amplified using primers corresponding 
to nucleotides specific to the target sequence. Ten microlitres of the reverse transcription 
reaction were added to a thin walled PCR tube containing 1x Taq buffer, 0.2 mM dNTPs, 
200 nM oligonucleotide primers. The reaction was heated to 95°C for 5 minutes after which 
5 U of Taq DNA polymerase were added. The reaction was cycled thirty times through the 
following temperatures: 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 30 seconds. 
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After completion of the reaction, 10 µl of the PCR product was analysed by gel 
electrophoresis on a 1 % (w/v) TAE/agarose gel (section 2.3.4.3). 
 
2.3.4.1.3 Agarose gel electrophoresis 
Materials 
Agarose, type II-A medium EEO 
50x TAE: (appendix I) 
 2 M Tris-acetate, pH 8.5 (appendix I) 
 0.05 M EDTA, pH 8.0 (appendix I) 
10 mg/ml Ethidium bromide  
DNA marker (BRL 1 Kb ladder) (Invitrogen Life technologies, Paisley, UK) 
Gel loading buffer: (appendix I) 
25 % (v/v) glycerol  
0.1 % (w/v) orange G  
25 mM EDTA (appendix I) 
 
Method 
A 1 % (w/v) agarose gel was prepared by dissolving 1.75 g agarose in 175 ml 1x TAE using a 
microwave oven. The gel was cooled to 45°C and ethidium bromide added to a final 
concentration of 0.5 µg/ml. Once set, the gel was placed into an electrophoresis tank 
containing 0.5x TAE with 0.5 µg/ml ethidium bromide. Three microlitres of loading buffer 
were added to 10 µl PCR product; 1 µl of DNA marker was added to 9 µl GDW and treated 
the same way. Samples were loaded onto the gel and electrophoresed at 10 V/cm. DNA was 
visualised by illumination with UV light (300 nm). 
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2.3.5 Cloning of DNA 
One of the most important advances in the field of molecular biology was the ability to cleave 
DNA at specific sites and to ligate the cut ends. Restriction endonucleases (isolated from 
bacteria) recognise specific target sites within double stranded DNA and cleave it. Ligating 
the cut fragments relies on the use of a virus-derived enzyme that catalyses the formation of 
phosphodiester bonds between a free 5’ phosphate and a free 3’ hydroxyl group. 
 
2.3.5.1.1 Restriction endonuclease digestion of DNA (Sambrook J, 1989) 
Materials 
PCR product 
pTRCGW (rAAV plasmid) (gift from Dr. Verhaggen, Amsterdam) 
Restriction endonuclease: enzymes used will be covered in the relevant sections 
10x Restriction buffer (as supplied) 
10x Bovine serum albumin (BSA)  
Phenol/Chloroform  
Absolute ethanol 
2 M Sodium acetate, pH 5.2 (appendix I) 
4 U/µl Shrimp alkaline phosphatase (SAP) (GE Healthcare) 
 
Method 
DNA was dissolved in GDW and added to restriction buffer and BSA to give a final 
concentration of 1x. Restriction endonuclease was added in a 5x excess. The total volume of 
enzyme added was kept below 10 % of the final volume. The reaction was incubated at 37°C 
for at least 1 hour. If the digested DNA was a plasmid, 8 U SAP were added 30 minutes 
before the end of the incubation period. SAP removes 5’ phosphate groups preventing self-
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ligation of the plasmid. The reaction was extracted with an equal volume of 
phenol/chloroform and the phases separated by centrifugation for 3 minutes at 13,000xg. 
DNA was precipitated by addition of 0.1 volumes of sodium acetate pH 5.2 and 2.5 volumes 
of cold absolute ethanol and incubated at -20°C for at least 1 hour. DNA was recovered by 
centrifugation for 7 minutes at 13,000xg (F45-12-11 microfuge, Eppendorf, Hamburg, 
Germany). 
 
2.3.5.1.2 Electroelution of DNA fragments 
Following restriction digestion it is advantageous to purify the DNA fragment of interest and 
remove any contaminating fragments. This is especially true for plasmids as restriction 
digests are not 100 % efficient and a small amount of closed circular DNA can produce a 
high background during transformations. DNA was therefore size fractionated by 
electrophoresis on an agarose gel and the DNA of interest electroeluted. 
 
Materials 
50x TAE (appendix I) 
Dialysis tubing (appendix I) 
Gel loading buffer (appendix I) 
1Kb DNA ladder (Invitrogen) 
 
Method 
A 1 % (w/v) agarose gel was prepared (section 2.3.4.3). DNA was dissolved in 20 µl GDW 
and 0.25 volumes of loading buffer added; 1 µl of 1Kb DNA ladder was added to 9 µl GDW 
and treated in the same way. Samples were loaded onto the gel and electrophoresed at 
10 V/cm. DNA was visualised by illumination with UV light (300 nm) and the band of 
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interest excised from the gel using a scalpel and placed into dialysis tubing sealed at one end 
with a clip. Four hundred microlitres of 0.5x TAE were added to the gel slice, air excluded 
and the end sealed with a clip. DNA was eluted from the gel slice by electrophoresis at 
20 V/cm for 20 minutes. The TAE was removed from the bag, phenol/chloroform extracted 
and the DNA recovered by ethanol precipitation (section 2.3.5.1) after which the DNA was 
dissolved in GDW. An aliquot was quantified visually by running 1 µl on a 1 % agarose gel 
alongside standards of a known concentration and estimating the concentration of the sample 
from relative luminescence under UV illumination (300 nm). 
 
2.3.5.1.3 Ligation of DNA fragments 
Materials 
T4 DNA ligase, 6 U/µl  
10x ligase buffer:  
 500 mM Tris-HCl 
 100 mM Magnesium chloride 
 100 Dithiothreitol (DTT) 
 10 mM ATP 
 250 µg/ml acetylated BSA  
Digested PCR product  
Digested pTRCGW plasmid 
 
Method 
DNA ligation was used to insert the DNA fragments of interest into plasmids. All the 
fragments ligated had overhanging ends, which increases efficiency of ligation as the ends are 
held by hydrogen bonding between the complementary bases. The method was identical for 
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all combinations of plasmids and inserts. Twenty nanograms of plasmid were dissolved in 
GDW and a fourfold molar excess of insert added. Reaction buffer was added to give a final 
concentration of 1x and 1 µl T4 DNA ligase added, to give a final volume of 10 µl. The 
reaction was incubated at 16°C overnight and then used to transform bacteria. 
 
2.3.6 Production of competent bacteria (Hanahan, 1983) 
Gram negative bacteria such as E. Coli have a cell wall that prevents entry of exogenous 
DNA. To allow entry of plasmids into bacteria, they have to be rendered competent to take up 
DNA. There are several ways of achieving this, including electroporation and treatment with 
cations. The method of choice for XL1-B cells is treatment with cations. The method of 
choice for JC8111 cells is electroporation. 
 
2.3.6.1.1 Production of competent bacteria using cations 
Materials 
XL1-B cells (Stratagene Ltd, Amsterdam, The Netherlands) 
LB (appendix I) 
10 mg/ml Tetracycline in absolute ethanol (appendix I) 
TFB I: (appendix I) 
30 mM Potassium acetate 
100 mM Rubidium chloride 
10 mM Calcium chloride 
50 mM Magnesium chloride 
15 % (v/v) Glycerol 
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TFB II: (appendix I) 
10 mM MOPS  
75 mM Calcium chloride 
10 mM Rubidium chloride 
15 % Glycerol 
 
Method 
One hundred millilitres of LB supplemented with 5 µg/ml tetracycline (LBtet) was inoculated 
with a colony of XL1-B cells and incubated overnight with vigorous shaking at 37ºC. One 
millilitre of this culture was inoculated into 100 ml of fresh LBtet (prewarmed to 37ºC) and 
incubated at 37ºC, with vigorous shaking, until the bacteria were in log phase growth (OD580 
= 0.4-0.5). Bacteria were recovered by centrifugation at 800xg for 15 minutes and 4ºC (HB-4 
rotor in RC-5B super speed centrifuge, Du Pont). Bacteria were resuspended in 40 ml ice 
cold TFB I and incubated on ice for 10 minutes. Bacteria were recovered by centrifugation, 
as above, and resuspended in 4 ml TFB II, then incubated on ice for a further 15 minutes. 
Bacteria was aliquoted in 50 µl volumes and stored at -80ºC.  
 
2.3.6.1.2 Production of competent bacteria using electroporation 
Materials 
E. Coli JC8111 cells (LGC Standards, Middlesex, UK) 
LB (appendix I) 
GDW (ice cold) 
10 % (v/v) glycerol in GDW (ice cold) 
SOB medium (appendix I) 
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Method 
Five millilitres of LB was inoculated with a single colony of the JC8111 strain of E. Coli and 
grown overnight at 37ºC with moderate shaking. From this culture, 2.5 ml was used to 
inoculate 500 ml of fresh LB (prewarmed to 37ºC) and incubated at 37ºC with vigorous 
shaking until the bacteria were in the log phase of growth (OD600 = 0.5-0.6). The cells were 
then chilled in an ice bath for 15 minutes before being recovered by centrifugation at 2000xg 
for 20 minutes at 4ºC (HB-4 rotor in RC-5B super speed centrifuge, Du Pont). The 
supernatant was removed and the pellet resuspended in 5 ml ice cold GDW. Following 
resuspension of the cells, a further 5 ml of ice cold GDW was added and mixed well before a 
further centrifugation cycle as above. This step was repeated once more and the resulting cell 
pellet resuspended in 40 ml of ice cold GDW 10 % (v/v) glycerol and mixed well before 
another cycle of centrifugation as above. The volume of the resulting pellet was estimated 
and an equal volume of ice cold 10 % (v/v) glycerol was added and the pellet resuspended. 
Cells were then aliquoted into 50 µl volumes and stored at -80ºC. 
 
2.3.6.1.3 Transformation of competent XL1-B bacteria 
Although treating bacteria with cations renders them competent to take up DNA, to obtain 
efficient transformation requires several additional steps. The initial step, incubation on ice, is 
believed to allow attachment of the plasmid to the bacterial cell membrane. The heat shock 
step is believed to allow the efficient transport of the plasmid into the bacteria. The 
incubation following heat shock allows expression of the resistance genes before exposure to 
antibiotic. 
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Materials 
LB (appendix I) 
LB (antibiotic) plates (section 2.3.6.5) 
Plasmid DNA 
Competent bacteria 
 
Method 
An aliquot of frozen competent bacteria was thawed on ice, 10 ng of plasmid (5 µl ligation 
reaction) was added and the mixture incubated on ice for 20 minutes. The reaction was then 
incubated at 42ºC for 40 seconds followed by incubation on ice for 2 minutes. Two hundred 
microlitres of LB were added and the reaction incubated at 37ºC for 30 minutes. 
Simultaneously, agar plates supplemented with the appropriate antibiotic were dried at 37ºC 
for 10 minutes. The volume of transformed bacteria added to the plate varied depending on 
the source of the DNA (up to 200 µl per 90 mm Petri dish). The bacteria were spread on the 
surface of the agar, the plate inverted and incubated at 37ºC overnight. 
 
2.3.6.1.4 Transformation of competent JC8111 bacteria  
Competent bacteria can be induced to take up DNA via the process of electroporation. 
Passing a voltage across bacteria opens transient pores in the bacteria membrane allowing the 
plasmid to move into the cell. pTRCGW contains an ampicillin resistance gene and 
subsequent incubation allows the expression of the resistance genes before exposure to 
antibiotic. 
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Materials 
Ligation reaction 
LB (appendix I) 
LB (amp) plates (appendix I) 
JC8111 bacteria (ATCC, Middlesex, UK) 
Glycogen (Ambion, Warrington, UK) 
 
Method 
Prior to transformation, all salts must be removed from the reaction mixture to prevent arcing 
during electroporation. One microlitre of glycogen was added to the ligation reaction to act as 
a carrier and the reaction ethanol precipitated (section 2.3.5.1). The ligation reaction was then 
dissolved in 10 µl GDW.  
 
An aliquot of frozen bacteria (JC8111 cells) was thawed on ice, 10 ng of plasmid (5 µl 
ligation reaction) added and the mixture transferred to an electrocuvette with an intra-
electrode distance of 1 mm. A voltage of 1.4 kilovolts was then passed across the cuvette. 
Two hundred microlitres of warmed LB was added and the reaction incubated at 37°C for 
1 hour. Agar plates (supplemented with 100 µg/ml ampicillin) were warmed and 150 µl of 
the transformed bacteria added to the plate. The bacteria were spread over the surface of the 
agar, the plate inverted and incubated at 37°C overnight. 
 
2.3.6.1.5 Production of agar plates 
After transformation of bacteria with plasmid DNA, the bacterial culture was grown on an 
agar plate containing antibiotic. Antibiotic allows the selection of bacteria which carry the 
plasmid of interest. 
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Materials 
LB (appendix I) 
Bacto-agar (Difco Laboratories, MI, USA) 
100 mg/ml Ampicillin (appendix I) 
25mg/ml Chloramphenicol (appendix I) 
50 mg/ml Spectinomycin (appendix I) 
Petri dishes 90 mm (Plastiques Gosslin, Hazebrouck, France) 
 
Method 
Five hundred millilitres of LB was added to 7.5 g of bacto-agar and autoclaved at 120ºC for 
20 minutes to melt and sterilize the agar. Agar was then cooled to below 50ºC before addition 
of 250 µl of the required antibiotic. The agar was then poured into Petri dishes to cover the 
bottom surface. The agar was flamed before the lids were placed back on the dishes. Once the 
agar had set the plates were wrapped in parafilm and stored upside down at 4ºC. 
 
2.3.7 Preparation of plasmids 
2.3.7.1.1 Small scale preparation of plasmid (Sambrook J, 1989) 
Initially, plasmids were isolated on a small scale culture to allow several clones to be 
analysed simultaneously. To isolate plasmids from bacteria it is necessary to disrupt the cell 
wall to release the plasmid. At the same time any contaminants (proteins, genomic DNA and 
RNA) must be removed. Treatment with alkali and SDS disrupts the cell wall and bacterial 
debris is then precipitated using sodium acetate. This step also removes most of the genomic 
DNA since it is anchored to the cell wall in bacteria. RNA is removed at a later stage by 
treatment with RNase A.  
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Materials 
LB (appendix I) 
GTE: (appendix I) 
 25 nm Tris-HCl, pH 8.0 
10 mM EDTA 
50 mM Glucose 
0.2 M Sodium hydroxide/1 % SDS (v/v) (appendix I) 
2 M Sodium acetate, pH 5.2 (appendix I) 
5 M Potassium acetate (appendix I) 
Phenol/Chloroform  
Propan-2-ol 
 
Method 
Two millilitres of LB supplemented with 0.05 mg/ml ampicillin (LB(amp)) were inoculated 
with a single bacterial colony and incubated overnight at 37°C with vigorous shaking. From 
this, 1.5 ml were transferred to a clean tube and underwent centrifugation for 3 minutes at 
13,000xg (F45-12-11 microfuge, Eppendorf, Hamburg, Germany) to pellet the bacteria. The 
remainder was stored at 4°C for future use. The supernatant was discarded and the pellet 
resuspended in 100 µl of GTE. Two hundred microlitres of alkaline SDS were added and the 
sample incubated on ice for 5 minutes, followed by the addition of 150 µl of 5 M potassium 
acetate and a further 5 minute incubation on ice. The precipitated bacterial debris was 
removed by centrifugation for 5 minutes at 13,000xg and room temperature and 350 µl of 
supernatant were transferred to a clean tube. The reaction was extracted with an equal volume 
of phenol/chloroform (section 2.3.5.1) and the DNA precipitated by the addition of 0.6 
volumes of propan-2-ol and incubation at room temperature for 10 minutes. DNA was 
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recovered by centrifugation for 7 minutes at 13,000xg, dissolved in 100 µl of GDW and 
ethanol precipitated (section 2.3.5.1). After precipitation the DNA was recovered by 
centrifugation at 13,000xg and dissolved in 10 µl of GDW. Restriction endonuclease 
digestion was performed (section 2.3.5.1) to indentify clones which contained the correct 
plasmid insert. A clone containing the correct insert was selected for large scale preparation 
of plasmid. 
 
2.3.7.1.2 Large scale plasmid purification 
Materials 
LB(amp) (appendix I) 
GTE (appendix I) 
50,000 U/mg Lysozyme 
0.2 M Sodium hydroxide/1 % SDS (w/v) (appendix I) 
2 M Sodium acetate, pH 5.2 (appendix I) 
5 M Potassium acetate (appendix I) 
Propan-2-ol 
100x TE (appendix I) 
10 mg/ml DNase free RNase A (GE Healthcare) 
Phenol/Chloroform  
 
Method 
A large scale preparation of the plasmid was carried out prior to purification using a caesium 
chloride gradient. A small quantity of bacteria containing the plasmid with the correct size 
insert was inoculated into 500 ml LB(amp) and incubated at 37°C overnight with vigorous 
shaking. The bacteria were recovered by centrifugation for 8 minutes at 3,000xg (4,000 rpm 
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in HS-4 rotor in RC-5B superspeed centrifuge, Du Pont) and 4°C. The pellet was 
resuspended in 25 ml of GTE supplemented with 2 mg/ml lysozyme and the sample 
incubated at room temperature for 5 minutes. Fifty millilitres of 0.2 M sodium hydroxide/1 % 
(w/v) SDS solution were added, the sample mixed by inversion and incubated on ice for 
5 minutes. Thirty eight millilitres of 5 M potassium acetate were added, the sample mixed by 
inversion and incubated on ice for a further 10 minutes. Bacterial debris was removed by 
centrifugation for 15 minutes at 9,000xg (7,000 rpm in HS-4 rotor in RC-5B superspeed 
centrifuge, Du Pont) and 4°C. The supernatant was transferred to a clean tube and 0.6 
volumes propan-2-ol added. The sample was incubated on ice for 15 minutes and the DNA 
recovered by centrifugation for 15 minutes at 9,000xg at 4°C. The pellet was dissolved in 10 
ml 1x TE. RNase A was added at a concentration of 0.1 mg/ml and the reaction incubated at 
37°C for 30 minutes. The reaction was extracted with an equal volume of phenol/chloroform 
(section 2.3.5.1) and the phases separated by centrifugation for 20 minutes at 10,000xg and 
4°C. DNA was recovered from the aqueous phase by addition of 0.1 volumes 2 M sodium 
acetate and one volume of propan-2-ol and incubation at -20°C for 1 hour. DNA was 
recovered by centrifugation for twenty minutes at 24,000xg (12,000 rpm in HBS rotor in 
RC5B superspeed centrifuge, Du Pont) and 4°C. 
 
2.3.7.1.3 Caesium chloride gradient  
Large scale plasmid purification was carried out using a caesium chloride gradient. This 
purification method depends on the decrease in density of nucleic acids when they bind to 
ethidium bromide. Because ethidium bromide binds by intercalation into DNA, it causes 
unwinding of the helix. In closed circular DNA this increases supercoiling of the plasmid, so 
binding of ethidium bromide is limited and the plasmid has a lower buoyant density than 
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linear or nicked plasmids. This difference in buoyant density allows separation of the plasmid 
on a caesium chloride density gradient. 
 
Materials 
TES:  
50 mM Tris-HCL, pH 8.0 (appendix I) 
 50 mM Sodium chloride 
 5 mM EDTA 
Caesium chloride (Boehringer, Lewes, East Sussex, UK) 
10 mg/ml Ethidium bromide  
Propan-2-ol, caesium chloride saturated (appendix I)  
 
Method 
DNA obtained from section 2.3.7.3 was dissolved in 8.25 ml of TES. Eight point four grams 
of caesium chloride were dissolved in the DNA solution, 150 µl of ethidium bromide added 
and the solution mixed. The sample was divided into two polyalumina tubes (Ultracrimp, Du 
Pont), balanced, and overlaid with mineral oil. The tubes were sealed and subjected to 
centrifugation for 16 hours at 20°C and 216,518xg (60,000 rpm in a T-8100 rotor in a Sorvall 
SE100 centrifuge, Fisher Scientific, Loughborough, UK). After centrifugation, DNA bands 
were visualised by UV illumination and the band containing the closed circular DNA 
removed using an 18G needle and a 2 ml syringe. Ethidium bromide was removed from the 
plasmid by repeated extraction with an equal volume of caesium chloride saturated propan-2-
ol, until both phases were colourless. DNA was precipitated by addition of two volumes of 
GDW and six volumes of absolute ethanol at room temperature. DNA was recovered by 
centrifugation for 15 minutes and 24,000xg at 20°C (12,000 rpm in a HB4 rotor of a RC5B 
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super speed centrifuge, Du Pont). The DNA pellet was dissolved in 0.4 ml GDW, ethanol 
precipitated (section 2.3.5.1) and recovered by centrifugation for 7 minutes at 13,000xg. 
DNA was dissolved in 1 ml GDW and quantified spectrophotometrically. Ten microlitres of 
DNA was diluted 1:100 and transferred into a quartz cuvette. Absorbance was read at 260 
and 280 nm on a UV 1101 spectrophotometer (WPA, Cambridgeshire, UK). The reading at 
280 nm gives an indication of the purity of the sample as phenol absorbs more strongly at 280 
nm than DNA. The concentration of the DNA was calculated using the following formula: 
concentration (µg/ml) = (A260 x dilution factor) x 50. DNA was digested using specific 
endonucleases to check insert size. Insert sequences were confirmed by DNA sequencing 
(Genomics core laboratory, Imperial College London, UK). 
 
2.3.8 Production of recombinant AAV particles 
Recombinant adeno-associated virus (rAAV) was produced by using the two plasmid system 
(Grimm et. al, 1998). The rAAV plasmid used, pTRCGW carries the enhanced green 
fluorescent protein (eGFP) transgene. In the first stage of rAAV production, host human 
embroyonic kidney 293T (HEK293T) cells, a cell line permissive to AAV infection, were co-
transfected with rAAV plasmid (Figure 2.06) and the helper plasmid pDG (Figure 2.07) using 
calcium phosphate. There is no homology between the two plasmids so they cannot 
recombine to form a wild-type virus. This results in the production of rAAV particles. In 
subsequent steps, cells were lysed by three freeze/thaw cycles and the rAAV particles 
purified and quantified. This plasmid was a kind gift from Professor J Verhaagen at the 
Netherlands Brain Institute, Amsterdam.  
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2.3.8.1.1 Cell maintenance 
Materials 
Dulbecco’s modified eagle medium (DMEM) (Invitrogen Life Technologies, Paisley, UK): 
4500 mg/l glucose 
  4.5 mM L-glutamine 
110 mg/l pyruvate 
Foetal bovine serum (FBS)  
Trypsin (Invitrogen) 
Versene (appendix I) 
 
Method 
HEK293T cells were cultured in 175 cm2 flasks with 10 ml DMEM supplemented with 10 % 
foetal bovine serum (FBS). Cells were incubated at 37°C in a 5 % carbon dioxide atmosphere 
and medium changed every 3 days. Cells were subcultured when 70-80 % confluent, 
approximately every 6 days, using 0.25 % trypsin in versene. Briefly, the medium was 
aspirated from the flask and the cells were washed using 0.25 % trypsin in versene. This was 
aspirated and the cells incubated at room temperature with fresh 0.25 % trypsin in versene 
until they detached from the flask. The trypsin was inactivated by the addition of 10 ml 
DMEM and the cells recovered by centrifugation for 5 minutes at 100xg. Cells were 
resuspended in fresh DMEM and transferred to two new 175 cm2 flasks at a dilution of 1:10. 
 
2.3.8.1.2 Calcium phosphate transfection 
Untreated mammalian cells, in contrast to bacteria, will readily absorb naked DNA from 
solution. However, the rate of absorption is slow and the proportion of cells transfected is 
low. Such transfection also requires the use of large quantities of the exogenous DNA. 
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Several techniques have been developed to increase the efficiency of the process including 
chemical, membrane disruption (e.g. electroporation) and receptor mediated. The method 
used, calcium phosphate co-precipitation, was one of the first methods described and is still 
one of the most efficient ways of obtaining transient transfection (Graham and van der Eb, 
1973). 
 
Materials 
HEK293T cells 
pTRCGW plasmid (including transgene)  
pDG plasmid 
1x HEBS buffer: 
1.36 M Sodium chloride 
 0.05 M Potassium chloride 
 0.007 M Na2HPO4.2H20 
 0.2 M HEPES (appendix I) 
 0.125 M glucose 
2 M CaCl2 
 
Method 
Cells were subcultured into a ten chamber cell factory (L x W x H (mm): 335 x 205 x 190, 
culture area: 6867 cm2) (Nunc, Thermo Fischer Scientific, Denmark) at 2.5x106 cells per 
chamber and incubated in 2 L DMEM with 10 % (v/v) FBS at 37°C in an atmosphere of 5 % 
carbon dioxide. Twenty-four hours later, when cells were 50 % confluent, the culture medium 
was replaced with 1.75 L of fresh DMEM/10 % FBS. Transfection was performed 2 hours 
later. Transfection mix was prepared consisting of 560 µg pTRCGW, 1.68 mg pDG, 7.2 ml 
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2M CaCl2 and 52 ml GDW. Immediately prior to transfection 12 ml 1x HEBS buffer in 48 ml 
GDW was added and gently mixed. The transfection mixture was allowed to stand for 
1 minute at room temperature, then added slowly to 250 ml DMEM/10 % FBS, and added to 
the cell factory.  
 
2.3.8.1.3 Recovery and purification of rAAV 
Materials 
0.01 M Phosphate buffered saline (PBS)  
Sepharose column (GE Healthcare) 
1.32 g/ml Iodixanol (Life Sciences Technology, Eggenstein, Germany) 
0.3x PBS/0.1 M Sodium chloride 
0.3x PBS/2 mM EDTA 
2 M Magnesium chloride 
250 U/µl Benzonase (Novagen, Nottingham, UK) 
Lysis buffer (appendix I) 
 
Method 
After 48 hours incubation following transfection, cell medium was aspirated from the cells. 
Cells were washed using 500 ml 0.01 M PBS and harvested using 1 L PBS/2 mM EDTA. 
Cells were recovered by centrifugation for 10 minutes at 5,000xg and 4°C (HB-4 rotor in RC-
5 super speed centrifuge, Du Pont), washed in a further 150 ml 0.01 M PBS and recovered by 
centrifugation for 10 minutes at 5,000xg as above. Cells were resuspended in a total of 60 ml 
lysis buffer and aliquoted into four 50 ml falcon tubes. Cells were exposed to three 
freeze/thaw cycles, consisting of dry ice/absolute ethanol for 10 minutes followed by a 37°C 
waterbath for 10 minutes. After the third cycle, 7.3 µl 2 M magnesium chloride and 1.2 µl 
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benzonase were added to each falcon tube and incubated at 37°C for 30 minutes. Cell debris 
was removed by centrifugation for 10 minutes at 2,000xg (Mistral 1000 rotor, MSE, UK). 
The supernatant containing the viral suspension was loaded into four 50 ml polyallomer tubes 
(Beckman, CA) under layered with iodixanol gradient (15 %, 25 %, 40 % and 60 % 
iodixanol). Tubes were balanced, topped up with lysis buffer, heat sealed and subjected to 
centrifugation for 1 hour at 69,000 rpm and 18°C (Type 70 Ti rotor in a Sorvall 100 SE 
centrifuge). To remove the rAAV particles, the top of each tube was punctured with an 18G 
needle and rAAV recovered by puncturing the bottom of the tube and collecting a 5 ml 
fraction from the 60/40 % interface of the iodixanol gradient. Fractions from the four tubes 
were pooled, added to 20 ml 0.3x PBS and loaded onto a Sepharose column (pre-washed with 
25 ml 0.1 M sodium chloride/0.3x PBS and 50 ml 0.3x PBS). The column was washed with 
50 ml 0.3x PBS and the virus eluted with 15 ml 350 mM sodium chloride/0.3x PBS. The 
elutant was transferred to the upper chamber of a pre-wet Apollo Concentrator (Orbital 
Biosciences, MA, USA) containing 10 ml 0.01 M PBS in the lower chamber and subjected to 
centrifugation for 5 minutes at 2,000xg and room temperature. The Apollo Concentrator is an 
ultrafiltration device used for the concentration or purification of proteins. Flow through was 
discarded and a further 5 ml 0.01 M PBS added below and 19.5 ml 0.01 M PBS above the 
filter. The tube was subjected to centrifugation for 5 minutes at 4,000xg (as above). The 0.5 
ml rAAV remaining above the filter was aliquoted into 1.5 ml siliconised eppendorf tubes. 
The viral titre was quantified by dot blot analysis (section 2.3.8.4). 
 
2.3.8.1.4 Determination of total viral particle titre by dot blot analysis 
The level of transgene expression is affected by the rAAV production titre, so total viral 
particle number was determined by dot blot analysis. Dot blot analysis is based on similar 
principles to Southern and northern blots in that a specific probe can be used to quantify a 
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specific DNA or RNA species in a sample. Rather than being separated by size and 
transferred to a membrane, the sample being analysed is placed directly onto a membrane. 
The DNA or RNA species present in the sample is detected and quantified using 
radiolabelled probes.  
 
Materials 
rAAV preparation 
20 ng/µl WPRE probe  
Solution A: (appendix I) 
 10 mM Tris/HCl, pH 8.0 
 10 mM Magnesium chloride 
 10 µg/ml DNase I  
Solution B: (appendix I) 
 10 mM Tris/HCl, pH 8.0 
 100 mM Sodium chloride 
 10 mM EDTA (appendix I) 
 0.5 % (w/v) SDS 
 1 mg/ml Proteinase K 
Phenol/chloroform 
3 M Sodium acetate 
Absolute ethanol 
5 mg/ml Glycogen (Ambion) 
Denaturing solution: 
 1.5 M Sodium chloride 
 0.5 M Sodium hydroxide 
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Neutralising solution: 
 1 M Tris/HCl, pH 7.4 
 1.5 M Sodium chloride 
pTRCGW plasmid  
Hybridisation buffer (appendix I) 
Amasino wash buffer (appendix I) 
Universal wash buffer (appendix I) 
 
Method 
Five microlitres of rAAV stock (section 2.3.8.3) was added to 45 µl of solution A and 
incubated for 30 minutes at 37°C. Two hundred microlitres of solution B was added and the 
sample incubated at 55°C for 1 hour. Viral DNA was extracted with an equal volume of 
phenol/chloroform (section 2.3.5.1). Forty micrograms of glycogen was added to the DNA 
and ethanol precipitated (section 2.3.5.1). DNA was recovered by centrifugation for 
30 minutes at 8,000xg and 4°C (centrifuge 5417 C/R, Eppendorf, Hamberg, Germany). 
Supernatant was removed and the pellet washed with 75 % cold ethanol and dissolved in 
10 µl GDW, of which 1 µl was applied to a nylon membrane (Hybond-N, Amersham 
Pharmacia Biotech) together with a series of dilutions of pTRCGW (50 ng, 25 ng, 10 ng, 5 
ng, 2.5 ng, 1.0 ng and 0.1 ng) to act as a standard curve. The membrane was incubated for 
5 minutes in denaturing solution, followed by a 5 minute wash in neutralising solution and 
then baked for 2 hours at 80°C. The baked membrane was then placed in a heat sealed 
polythene bag with 20 ml of pre-hybridisation solution and incubated for a minimum of 
2 hours (section 2.3.3.3). The WPRE probe was prepared (section 2.3.5) using the primer set 
detailed in Table 2.01. The membrane was then hybridised overnight with a 32P dCTP 
radiolabelled cDNA WPRE probe (section 2.3.2.3) and washed the following day.  
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Primer Primer Sequence Restriction Site 
WPRE 5’ AGC-TGG-ATC-CGC-TAT-GTG-GAT-ACG-CTG-CTT 
 
BamHI 
WPRE 3’ AGC-TGA-ATT-CGG-AAT-TGT-CAG-TGC-CCA-ACA 
 
EcoRI 
 
Table 2.01 Primer sequence for the WPRE DNA probe. The highlighted sequence details 
the restriction site for the particular primer. The WPRE 5’ primer corresponds to nucleotides 
1161-1180, and the WPRE 3’ primer corresponds to nucleotides 1450-1471 in the 
woodchuck hepatitis B virus genome (accession number J04514).
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3 Introduction 
3.1 Glucose homeostasis dysfunction 
Type 2 diabetes mellitus (T2DM) is a metabolic disorder that is characterised by 
hyperglycaemia, and primarily associated with increased insulin resistance (IR). IR is defined 
as a decreased sensitivity to the metabolic actions of insulin, such as insulin mediated glucose 
disposal and inhibition of hepatic glucose production. Obesity is a risk factor for the 
development of T2DM, and different distribution of fat is associated with varying degrees of 
metabolic risk. In particular, central obesity is associated with IR, impaired glucose tolerance 
and T2DM (Kissebah and Krakower, 1994, Goodpaster et al., 2003, Wajchenberg, 2000). 
The metabolic abnormalities observed in the metabolic syndrome are similar to those seen in 
patients suffering from Cushing’s syndrome; a condition where patients exhibit excess 
circulating cortisol. In contrast, obese patients exhibit circulating cortisol concentrations that 
are relatively normal and are largely independent of fat distribution. Instead, it has been 
suggested that subtle alterations of the HPA axis and cortisol homeostasis link the aetio-
pathogensis and metabolic consequences of central obesity (Bjorntorp, 2001).  
 
Glucocorticoids (GCs) are linked to the pathogenesis of obesity and IR. Alterations in 11β-
hydroxysteroid dehydrogenase 1 (11βHSD1), an enzyme that promotes the conversion of 
inactive to active GC at the tissue level in vivo, have been documented in both animal models 
and clinical studies of idiopathic obesity and T2DM. In lean T2DM patients, hepatic 
11βHSD1 activity is mildly impaired, whilst adipose tissue 11βHSD1 activity appears to be 
normal. In obese T2DM patients, 11βHSD1 expression in skeletal muscle myotubes is 
increased, which may contribute to the pathogensis of IR (Abdallah et al., 2005). 
Manipulations of 11βHSD1 expression in mice have confirmed the importance of this 
enzyme in obesity, T2DM and the metabolic syndrome. Overexpression of 11βHSD1 in 
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adipose tissue of mice results in normal circulating GC levels (Masuzaki et al., 2001), as 
observed in human obesity. However, intra-adipose corticosterone concentrations are 
increased, and these animals develop a phenotype similar to that of metabolic syndrome, with 
increased visceral fat mass, glucose intolerance, IR and elevated free fatty acid levels. These 
findings suggest that increased intra-adipose 11βHSD1 may be responsible for the metabolic 
complications of obesity.  
 
Conversely, mice with targeted disruption of the 11βHSD1 gene (11βHSD1-/- mice) resist 
hyperglycaemia provoked by obesity or stress, and on starvation show attenuated activation 
of key hepatic enzymes involved in gluconeogenesis (Morton et al., 2004, Kotelevtsev et al., 
1997). These findings suggest that inhibiting 11βHSD1 pharmacologically, and thereby 
lowering intracellular but not circulating GC levels, may lead to improvements in metabolic 
profiles. Carbenoxolone (a non-selective inhibitor of 11βHSDs) improves insulin sensitivity 
in healthy human controls (Walker et al., 1995) and in diabetic patients decreases hepatic 
glucose output by decreasing glycogenolysis (Andrews et al., 2003). 11βHSD1 inhibition 
might be of particular benefit in patients with T2DM and visceral obesity. Hence, there is 
currently much research focussed on the development of 11βHSD1 inhibitors as a therapeutic 
agent for T2DM. 
 
Intracerebroventricular (ICV) infusion of dexamethasone (a GC analogue) in rats results in 
peripheral alterations in glucose homeostasis, with animals displaying hyperinsulinemia and 
marked IR (Cusin et al., 2001). Therefore an increase in central GC appears to yield a 
phenotype similar to that seen in metabolic syndrome and echoes that seen in Cushing’s 
syndrome. It has been suggested that central GC exerts its effects on energy homeostasis via 
the arcuate nucleus (ARC) of the hypothalamus (Tong et al., 1990, Shimizu et al., 2010). 
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Owing to the fact that 11βHSD1 is expressed in the ARC and that the ARC is a region of the 
hypothalamus intimately involved in glucose homeostasis, I will utilise recombinant adeno-
associated virus (rAAV) to overexpress 11βHSD1, and hence increase corticosterone, in the 
ARC of the hypothalamus in rats fed a normal chow diet and investigate effects on glucose 
homeostasis. 
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3.2 Hypothesis and aims 
Evidence exists for a physiological role of glucocorticoids in the hypothalamic regulation of 
glucose homeostasis. However, their exact effect is unclear, largely due to difficulties in 
manipulating levels of GC in specific hypothalamic nuclei.  
 
3.2.1 Hypothesis 
Glucocorticoids in the hypothalamus physiologically regulate glucose homeostasis. 
 
3.2.2 Aims 
To investigate the physiological role of glucocorticoid in the hypothalamus I will: 
 
• Demonstrate the effect of 11βHSD1 overexpression in the arcuate nucleus of the 
hypothalamus on glucose tolerance 
• Demonstrate the effect of 11βHSD1 overexpression in the arcuate nucleus of the 
hypothalamus on insulin sensitivity 
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3.3 Materials 
Unless stated otherwise all chemicals were purchased from VWR, Poole, Dorset, UK and all 
enzymes from New England Biolabs, Hitchin, Herts, UK. 
 
3.4 Methods 
3.4.1 Effect of rAAV-11βHSD1 bilaterally injected into the arcuate nucleus on 
glucose homeostasis 
3.4.2 Production of rAAV-11βHSD1  
The method of production and purification of rAAV particles is described in chapter 2. 
Briefly, 11βHSD1 cDNA was produced using reverse transcription PCR of rat hypothalamic 
RNA (section 2.3.4) using the primer set detailed in Table 3.01. 11βHSD1 cDNA PCR 
product was subcloned into the expression vector PTRCGW, which carries the enhanced 
green fluorescent protein (eGFP) transgene (Figure 2.06). The first step in subcloning was to 
cut the 11βHSD1 PCR product and the pTRCGW plasmid using the restriction enzymes 
BamHI and BsrGI. The use of the restriction enzymes BamHI and BsrGI linearises the 
pTRCGW plasmid and removes the eGFP gene. The products from the restriction digest were 
loaded on a 1 % (w/v) agarose gel (section 2.3.4.3). The linearised plasmid and the cut 
11βHSD1 PCR cDNA fragment were excised from the gel and electroeluted (section 2.3.5.2). 
The cDNA fragment was subcloned into the plasmid by a ligation reaction (section 2.3.5.3), 
resulting in the modified pTRCGW-11βHSD1 plasmid. The pTRCGW-11βHSD1 plasmid 
was digested with BamHI and BsrGI to check insert size, and also digested with XmaI to 
check for presence of inverted terminal repeats (ITRs). Products were visualised by gel 
electrophoresis. The pTRCGW-11βHSD1 plasmid was then transformed into competent 
bacteria (section 2.3.7). The sequence of the insert was confirmed in both directions on two 
separate occasions (Genomics core laboratory, Imperial College London, UK). 
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pTRCGW-11βHSD1 plasmid was used to produce rAAV-11βHSD1 particles. Total viral 
particle titre was determined by dot blot analysis (section 2.3.8.4). The plasmid pTRCGW 
was a kind gift from Professor J Verhaagen at the Netherlands Brain Institute, Amsterdam, 
The Netherlands. 
 
Primer Primer Sequence Restriction 
Site 
5’ 11βHSD1 AGC-TGG-ATC-CCG-CAC-TTA-TCT-GAA-GCC-TCA 
 
BamHI 
3’ 11βHSD1 AGC-TTG-TAC-ATC-AGT-GTG-AGG-TAA-AGC-CGA 
 
BsrGI 
 
Table 3.01 Primers for PCR amplification of 11βHSD1 for use in rAAV. The sequence in 
red details the restriction site associated with a particular primer. The 5’ primer corresponds 
to nucleotides 1-20, and the 3’ primer corresponds to nucleotides 1239-1258 in the rat 
11βHSD1 mRNA (accession number NM_008288.2). 
 
3.4.2.1 Animals 
Male Wistar rats weighing 220-230 g (specific pathogen free, Charles River UK Ltd, 
Margate, Kent, UK) were individually housed in open top polypropylene cages under a 
controlled environment (temperature 21-23°C, 12 hour light-dark cycle, lights on at 
07:00AM) with ad libitum access to food (RM1 diet, SDS UK Ltd, Witham, Essex, UK) and 
water. All animal procedures were approved under the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project licence number 40/3327). Animals were 
acclimatised to these conditions for 2 weeks prior to surgery. 
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3.4.2.2 Animal allocation 
One week prior to surgery, animals were deprived of food overnight, after which 120 μl 
blood from each animal was collected into lithium heparin coated tubes. Plasma was 
separated by centrifugation for 5 minutes at 2,400xg and 4°C, to produce an aliquot of plasma 
which was frozen (-80°C) and subsequently assayed for glucose and insulin concentration. 
Using this data, animals were allocated into three weight, fasting-glucose and fasting-insulin 
matched treatment groups. Rats were assigned to groups as outlined in Table 3.02. Group sizes 
were determined using power calculations (Appendix III).  
 
Group Treatment n 
Control group 
(rAAV-eGFP) 
rAAV-eGFP 12 
Treatment group 
(rAAV-11βHSD1) 
rAAV-11βHSD1 12 
Sentinel group 
(rAAV-11βHSD1-Sen) 
rAAV-11βHSD1 4 
 
Table 3.02 Allocation of male Wistar rats into experimental groups. Control group 
(rAAV-eGFP, n = 12); treatment group (rAAV-11βHSD1, n = 12); Sentinel group 
(rAAV-11βHSD1-Sen). 
 
3.4.2.3 Animal surgery 
Male Wistar rats (section 3.4.2.2) were injected bilaterally intra-ARC with 1 µl of either 
rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). Animals were anaesthetised with an 
isoflurane system (Vet-Tech Solutions Ltd., UK) and immobilised on a Kopf stereotaxic 
frame (David Kopf Instruments, supplied by Clark Electromedical Instruments, Reading, 
Berkshire, UK). The incisor bar was set 3.0 mm below the interaural plane. The surgical area 
was shaved with an electronic razor and cleaned with 10 % (w/v) povidine-iodine solution 
(Betadine). A small (< 2.0 cm) rostro-caudal incision was made in the scalp. Animals were 
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injected bilaterally into the ARC using coordinates 3.5 mm caudal, 0.5 mm lateral to the 
bregma and 10.0 mm below the skull, determined from the rat brain atlas of Paxinos and 
Watson (Paxinos and Watson, 2007) (Figure 3.01). A stereotaxically mounted drill was used 
to make a 0.65 mm burr hole in the skull. Each animal was injected via a 33G steel injector 
(Plastics-One) projecting 1.0 mm below the tip of the guide cannula. rAAV-11βHSD1 at a 
titre of 2.96 x 1013 genome particles/ml and rAAV-eGFP at a titre of 5.04 x 1013 genome 
particles/ml was produced as described in chapter 2. One microlitre of either 
rAAV-11βHSD1 or rAAV-eGFP was administered bilaterally into the ARC of each rat. The 
pressure was removed from the injector whilst the cannula-injector unit was maintained in 
situ for 5 minutes before being slowly extracted to minimise backflow. The incision was 
sutured with two mattress sutures with 6.0 proline thread. All animals received peri-operative 
care including: antibiotics (floxicillin : amoxicillin equal volumes, 37.5 mg/kg, i.p. 1 ml/rat), 
analgesia (buprenorphine, 45 mg/kg, s.c. 0.05 ml/rat) and rehydration therapy (0.9 % sodium 
chloride, i.p. 2.5 ml/rat; Schering-Plough Ltd., UK). All surgical procedures were performed 
under aseptic conditions. Animals were allowed a recovery period of 7 days following 
surgery and were then handled and weighed regularly. 
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3.4.2.4 Cumulative food intake and bodyweight change 
Food and bodyweight were measured daily at 08.00AM. Prior to recording these 
measurements, animals were handled in order to reduce the effects of stress from the 
necessary handling immediately prior to their decapitation.  
 
3.4.2.5 Collection of tissue samples  
At 89 days post injection animals were killed by decapitation in the early light phase. Brains 
from groups rAAV-eGFP and rAAV-11βHSD1 were rapidly removed. The groups were 
divided into two sub-groups, such that half the animals had lateral sections cut away using a 
razorblade, frozen in isopentane chilled to -80°C and stored at -80°C until punch biopsy 
analysis of corticosterone levels. Whilst the other half of animals had the entire hypothalamus 
isolated, snap-frozen in liquid nitrogen and stored at -80°C until RT-qPCR analysis. Brains 
from group rAAV-11βHSD1-Sen were mounted on cork discs, frozen in isopentane chilled to 
-80°C and stored at -80°C until in situ hybridisation. Blood was collected into heparinised or 
EDTA-chelated tubes containing aprotinin 2000 KIU/tube (Bayer), and immediately placed 
on ice. Plasma was separated by centrifugation, immediately frozen and stored at -80°C until 
radioimmunoassay (RIA) analysis.  
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3.4.3 Confirmation of gene transfer in the hypothalamic arcuate nucleus by in situ 
hybridisation 
3.4.3.1.1 In situ hybridisation 
In situ hybridisation (ISH) is a method for the detection and quantification of mRNA whilst 
maintaining the structural integrity of the tissue. It relies on the hybridisation of a 
complimentary probe, usually radiolabelled, to the target mRNA in tissue mounted on poly-
lysine coated slides. To confirm successful gene transfer and accurate localisation within the 
ARC of the hypothalamus, a radiolabelled riboprobe raised to woodchuck posttranscriptional 
regulatory element (WPRE) was used. The WPRE sequence is part of the expression cassette 
of all vectors used in this study to enhance expression, but is not endogenously expressed in 
rat tissue. The radiolabelled riboprobe was made using pBluescript-WPRE, which contains a 
308 base pair fragment of WPRE. This was constructed using primers that correspond to 
nucleotides 1181 to 1489 of woodchuck hepatitis genome and was made using methods 
described in chapter 2 (section 2.2.5.1). A 35S-labelled sense probe was also used as a control 
to validate that there was no non-specific binding of the antisense probe. 
 
3.4.3.1.2 Production of radiolabelled RNA probe for in situ hybridisation 
Materials 
200 ng/µl Linearised template (for WPRE in situ pBluescript-WPRE linearised by digestion 
with BamHI for antisense probe or EcoR1 for sense) 
100 M DTT/10 mg/ml BSA fraction V (appendix I)   
RNase inhibitor, 30 U/µl 
10x nucleotide mix: 10 mM of each ATP, UTP, GTP 
T7 RNA polymerase, 20 U/µl (Promega) 
T3 RNA polymerase 20 U/µl (Promega) 
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10x RNA polymerase buffer (Promega) 
DNase I, 7.5 U/µl (Amersham Biosciences) 
10x DNase buffer 
5 M Ammonium acetate (appendix I)  
[35S]CTPαS, 46 TBq/mmol, 0.46 GBq/ml (Perkin Elmer, Boston, Massachusetts, USA) 
 
Method 
Two hundred nanograms of template were added to a reaction buffer containing 10 mM DTT, 
1x nucleotide mix, 1x polymerase buffer, 30 U RNase inhibitor and 3.75 MBq [35S]CTPαS in 
a total volume of 9 µl. To this, 20 U of RNA polymerase were added (T3 to the anti-sense 
reaction and T7 to the sense reaction) and the reaction incubated for 2 hours at 37°C. After 
incubation, 6 µl GDW, 3 µl DNase buffer and 1 µl DNaseI were added, followed by a further 
15 minute incubation at 37°C. Following this, ammonium acetate was added to a final 
concentration of 2 M followed by 2.5 volumes of ice cold absolute ethanol and the mixture 
incubated at -20°C for 1 hour to allow RNA to precipitate. RNA was recovered by 
centrifugation for 7 minutes at 8,000xg and the pellet dissolved in 100 µl GDW. To measure 
the activity of the radiolabelled probe, 1 µl was counted on a microbeta counter (Wallac, 
Waltham, MA). 
 
3.4.3.1.3 Preparation of slides 
Materials 
4 % (v/v) Formaldehyde/0.01 M PBS  
0.01 M PBS (appendix I) 
100 % Acetic anhydride  
0.1 M Triethanolamine, pH 8.0 (TEA) (appendix I) 
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20x SSC (appendix I) 
3 M Sodium chloride (appendix I) 
70 % (v/v) Ethanol 
Absolute ethanol 
Chloroform  
 
Method 
Twelve micrometre sections of rat brain were cut on a cryostat at -25˚C (Bright Instrument 
Company, Huntingdon, Cambridge, UK). Sections were mounted onto poly-lysine coated 
slides and stored at -80˚C until hybridisation. ISH was performed on every third slide. The 
selected slides were placed in a rack and fixed in 4 % formaldehyde/0.01 M PBS on ice for 
20 minutes. Slides were washed twice in 0.01 M PBS for 5 minutes and subsequently washed 
in 0.1 M TEA for 2 minutes and acetylated in 0.25 % (v/v) acetic anhydride in 0.1 M TEA for 
10 minutes. Slides were then rinsed twice in 0.01 M PBS for 2 minutes and placed in 70 % 
(v/v) ethanol for 3 minutes. Finally, slides were delipidated in chloroform for 5 minutes, and 
chloroform removed by sequential immersion in 99% and 96% (v/v) ethanol in water and 
allowed to air dry for 1 hour. 
 
3.4.3.1.4 Hybridisation of radiolabelled probe to slides  
Materials 
1x RNAse buffer 
10 mM Tris, pH 8.0 (appendix I) 
1 mM EDTA (appendix I) 
0.5 M Sodium chloride (appendix I) 
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Hybridisation buffer: 
50 % (v/v) Formamide 
600 mM Sodium chloride (appendix I) 
80 mM Tris-HCl, pH 7.5 (appendix I) 
4 mM EDTA (appendix I) 
100 mM DTT (appendix I) 
2 % (w/v) Dextran sulphate (appendix I) 
Biomax film (Kodak) 
Developer (Jet X-Ray)  
Fixer (Jet X-Ray) 
 
Method 
Enough 35S labelled probe for one million counts per slide was added to the hybridisation 
buffer and 70 μl of this hybridisation buffer was applied to each slide. A coverslip was placed 
on each slide and they were incubated overnight at 60˚C. Excess hybridisation buffer/probe 
mix was removed by washing the following day. Slides were soaked in 4x SSC with gentle 
agitation to remove coverslips and washed four times in 4x SSC for 5 minutes. Slides were 
RNase treated by incubation for 30 minutes at 37˚C in 1x RNase buffer containing 100 μg/ml 
RNase, followed by two, 5 minute washes in 10 mM DTT/2x SSC, followed by a 10 minute 
wash in 10 mM DTT/1x SSC and a 10 minute wash in 10 mM DTT/0.5x SSC, all performed 
at room temperature. Finally, slides were washed in 10 mM DTT/0.1x SSC at 60˚C for 
30 minutes, rinsed briefly in 10 mM DTT/0.1x SSC at room temperature and washed for 
3 minutes in 70 % (v/v) ethanol and 3 minutes in absolute ethanol and air dried. After 
washing and dehydration, slides were exposed to Bio-Max film at room temperature. After 
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3 days of exposure, the film was developed and WPRE distribution determined by 
observation of specific hybridisation. 
 
3.4.4 Radioimmunoassay 
The measurement of peptides by radioimmunoassay (RIA) relies on competition between a 
radiolabelled and non-radiolabelled antigen for a fixed number of specific antibody binding 
sites. As increasing amounts of unlabelled antigen are added, either from samples or 
standards, to a constant quantity of labelled antigen and a constant and limited quantity of 
antibody, there is a decrease in the labelled antigen bound to antibody at equilibrium. The 
antibody-bound antigen is then separated from the free antigen either by addition of dextran-
coated charcoal (which binds free antigen in the charcoal pellet) or by complexing the 
primary antibody with a secondary antibody (free antigen remains in the supernatant). 
Following separation, the activity in the bound and free components is measured in a gamma 
counter and the data used to construct a standard curve.  
 
3.4.4.1 Radioimmunoassay of plasma corticosterone  
Plasma corticosterone was measured by RIA. Plasma samples were analysed using a specific 
rabbit antiserum (MP Biomedicals LLC, Orangeburg, NY). Corticosterone antisera were 
highly specific, with the highest cross-reactivity being attributable to desoxycorticosterone 
(< 0.35 %). Free and bound molecules were separated using secondary antibody PEG and 
Goat anti-rabbit γ-globulins in Tris solution. 
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3.4.4.2 Quantification of hypothalamic mRNA by Real Time quantitative-PCR 
Real Time quantitative PCR (RT-qPCR) was used to analyse the expression of a range of 
mRNA sequences in dissected hypothalami. 
 
3.4.4.2.1 RNA extraction using RNAqueous-4PCR kit 
Materials 
Tri-reagent  
64 % (v/v) Ethanol 
Absolute ethanol 
Wash solution 1 
Wash solution 2 
Elution solution (0.1 mM EDTA) 
10x DNase I buffer 
DNase I (2 U/µl, RNase-free) 
DNase inactivation reagent 
5 M Ammonium acetate 
Linear acrylamide (5 mg/ml) 
GDW 
 
Method 
Total RNA was extracted using an RNAqueous-4PCR kit (Ambion) according to the 
manufacturer’s protocol. Frozen hypothalami were homogenised in Tri-reagent (750 µl per 
hypothalamus) before subsequent transfer to 1.5 ml eppendorfs and incubation at room 
temperature for 5 minutes. An equal volume of 64 % (v/v) ethanol was added and gently 
mixed. The mixture was then transferred into a filter cartridge and centrifuged at 13,500 rpm 
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for 1 minute. The flow-through was disposed of and 700 µl wash solution 1 was added to the 
filter cartridge. The wash solution was passed through the filter cartridge and the flow-
through again discarded. This step was repeated a further two times using 500 µl wash 
solution 2 each time. The filter was placed in a fresh collection tube and 50 µl elution 
solution, preheated to 80ºC, was added to the filter cartridge. The solution was passed 
through the cartridge into the collection tube by centrifugation at 13,500 rpm for 30 seconds. 
This step was repeated with another 50 µl elution solution to yield a final volume of 100 µl. 
The collected solution was added to 0.1 volumes of 10x DNase I buffer and DNase I (2 U per 
100 µl) and the mixture incubated at 37ºC for 30 minutes. Following this, 0.1 volumes of 
DNase inactivation agent were added, gently mixed and incubated for 2 minutes at room 
temperature. The mixture was passed through the column by centrifugation for 1 minute at 
13,500 rpm and the supernatant collected. The RNA solution was concentrated by adding 
0.1 volumes of 5 M ammonium acetate, 0.01 volumes of linear acrylamide and 2.5 volumes 
of absolute ethanol and incubated at -20°C for 1 hour. The mixture was passed through the 
column by centrifugation at 13,500 rpm for 15 minutes and the pellet dissolved in 20 µl 
GDW. The concentration of RNA was determined spectrophotometrically (section 2.3.1). 
RNA was diluted in GDW accordingly to a final concentration of 0.05 µg/µl. 
 
3.4.4.2.2 Reverse transcription using a high capacity cDNA reverse 
transcription kit 
Materials 
Rat hypothalamic RNA (0.05 µg/µl) 
2x RT master mix (per 20 µl reaction): 
2 µl 10x RT buffer 
0.8 µl 25x dNTP mix (100 mM) 
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2 µl 10x RT random primers 
50 U MultiScribe reverse transcriptase 
4.2 µl GDW  
 
Method 
cDNA was synthesised from RNA using a high capacity cDNA reverse transcription kit 
(Applied Biosystems) according to the manufacturer’s protocol. Ten microlitres of RT master 
mix was pipetted to each well of a 96-well reaction plate. Ten microlitres of RNA sample at 
0.05 µg/µl was added to each well in triplicate and pipetted up and down twice to ensure 
thorough mixing. RNA used for 18S RNA normalisation was initially diluted 1:10 in GDW 
before adding to the reaction well plate. The 96-well plate was sealed with aluminium film 
and loaded into a thermal cycler (Techne Genius, Techne Ltd) under the following 
conditions: 1) 25°C for 10 minutes, 2) 37°C for 120 minutes, 3) 85°C for 5 seconds, 4) 4°C 
until transferred to -20°C for storage.  
 
3.4.4.2.3 Real-Time quantitative PCR 
Materials 
TaqMan universal PCR master mix (Applied Biosystems) 
20x TaqMan gene expression assay (Applied Biosystems) 
cDNA synthesised from rat hypothalamic RNA 
 
Method 
Ten microlitres of TaqMan universal PCR master mix, 1 µl TaqMan gene expression assay 
(18S RNA primer assay ID: 4310893E, NPY primer assay ID: Rn01410145_m1, POMC 
primer assay ID: Rn00595020_m1, AgRP primer assay ID: Rn01431702_g1, CART primer 
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assay ID: Rn00567382_m1) and 7 µl GDW was added to each well in a 384-well reaction 
plate. Approximately 50 ng of cDNA was then added in triplicate to each well and pipetted 
up and down twice to ensure thorough mixing. The 384-well reaction plate was covered with 
optical adhesive film and centrifuged briefly to minimise air bubbles. The reaction well plate 
was then loaded into a quantitative PCR machine (7900HT quantitative PCR machine, 
Applied Biosystems) under the following conditions: 1) 50°C for 2 minutes, 2) 95°C for 
10 minutes, 3) 95°C for 15 seconds and 4) 60°C for 1 minute (steps (3) and (4) were repeated 
for forty cycles). Gene expression was quantified relative to 18S RNA and analysed using the 
2-∆∆CT method. 
 
3.4.4.3 Quantification of uncoupling protein-1 mRNA expression in brown adipose 
tissue by northern blot 
Northern blot analysis was used to analyse the size and quantity of uncoupling protein-1 
(UCP-1) RNA in brown adipose tissue (BAT). One hundred milligrams of brown adipose 
tissue was homogenised per 1 ml of Tri-reagent and total RNA extracted (section 2.3.1). 
RNA integrity was confirmed using a RNA denaturing gel (section 2.3.1.1). BAT UCP-1 
mRNA expression was determined by northern blot analysis (section 2.3.2) of 30 µg of BAT 
RNA. A 32P labelled UCP-1 DNA probe was generated using a primer set specific for the 
UCP-1 gene, detailed in Table 3.03 (accession number BC012701). To correct for variation 
in gel loading and RNA transfer when performing northern analysis, total mRNA on filters 
was quantified by oligo dT probing (section 2.3.3.5). 
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Primer Primer Sequence Restriction  
Site 
UCP-1 5’ AGC-TGG-ATC-CAA-GGC-CAG-GCT-TCC-AGT-ACT 
 
BamHI 
UCP-1 3’ AGC-TGA-ATT-CGG-TTT-GAT-CCC-ATG-CAG-ATG 
 
EcoRI 
 
Table 3.03 Primer sequence for the UCP-1 DNA probe. The sequence in red details the 
restriction site of the particular primer. The primer UCP-1 5’ corresponds to nucleotides 350-
369 and the primer UCP-1 3’ corresponds to nucleotides 638-657 of the rat mitochondrial 
BAT mRNA sequence (accession number M11814). 
 
 
3.4.4.4 Isolation of specific hypothalamic nuclei by punch biopsy 
Hypothalamic nuclei were isolated by punch biopsy to determine the effect of 11βHSD1 
overexpression on corticosterone content of the ARC. Hypothalamic nuclei collected from 
the rat brain are detailed in Figure 3.02. Frozen brains were mounted upon a freezing sled 
microtome (Shandon Southern Products Ltd, Runcorn, UK). Eight hundred micrometer 
sections from the rostro-caudal extent of the hypothalamus were cut and mounted onto poly-
lysine slides. Slides were kept on dry ice to re-freeze sections and nuclei were identified 
using ‘The rat brain atlas’ (Paxinos and Watson, 2007) and removed using a neuropunch 
1.0 mm in diameter (Harvard). The ARC and PVN were isolated bilaterally (the PVN as an 
internal control). Biopsies were pooled and homogenised using a micro-homogeniser 
(Camlab, Cambridge, U.K.). Cell debris was removed by centrifugation for 3 minutes at 
13,000xg (F45-12-11 microfuge, Eppendorf, Hamburg, Germany). The supernatant was 
transferred to a new tube and extracted of total steroidal content overnight in 1 ml of 90 % 
methanol (v/v) in a drying centrifuge at 30°C and vacuum (Thermo Scientific Savant 
SpeedVac). The residual pellet obtained was dissolved in 500 μl kit buffer before assaying 
for corticosterone in triplicate by ELISA (Cayman Chemicals Inc., USA), according to the 
manufacturer’s protocol. 
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3.4.4.4.1 Protein assay of punch biopsy samples 
There is inherent variability in the amount of hypothalamic tissue collected by punch biopsy. 
To compensate for this, protein content of the punch biopsy homogenate must be calculated 
in order to standardise the results of the corticosterone assay. Homogenate protein content 
was measured using the well-established bicinchoninic (BCA) protein assay (Thermo 
Scientific, UK). The cell debris pellet obtained in section 3.4.4.4 was dissolved in 500 μl 
0.2 M NaOH before assaying for protein in triplicate according to the manufacturer’s 
protocol. 
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Figure 3.02 Diagram detailing the location of punch biopsies in the rat brain. Eight 
hundred micrometer thick coronal sections of brain were cut through the length of the rat 
hypothalamus. Punch biopsies of hypothalamic nuclei were then collected from each section 
using a neuropunch (Harvard) 1 mm in diameter. Like biopsies were then pooled and 
homogenised. Punch biopsies were collected from: A) the paraventricular nucleus and B) the 
arcuate nucleus. Adapted from Paxinos and Watson (1998) (Paxinos and Watson, 2007). 
Bregma -1.08 mm 
Bregma -1.92 mm 
Bregma -2.72 mm 
Bregma -3.60 mm 
A 
A 
B 
B 
B 
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3.4.4.5 Oral glucose tolerance testing 
An oral glucose tolerance test (OGTT) is a test performed to investigate the animal’s ability 
to clear glucose after a glucose load. Following an overnight fast, a bolus of glucose is 
administered. Blood glucose is then measured at specific intervals to determine the ability of 
the animal to clear glucose from circulation.  
 
Typically, blood glucose is expected to show a 1.5 to 2-fold increase, followed by a slow 
decline towards baseline values. In insulin resistant states, peak glucose is usually higher 
and, at a minimum, the following decline is delayed. An increase in the composite area under 
the curve (AUC) measurement is typically a strong indication of stimulated IR (an extract 
from: ((Heikkinen et al., 2007)). 
 
Method 
Animals were deprived of food overnight (food removed at 16.00 h) but had free access to 
water (animals were allowed a recovery period of 7 days following an overnight fast). At 
09.00 h the following morning, animals were subjected to an OGTT. On the morning of the 
OGTT, animals were weighed and then cannulated into the lateral tail vein using a 24G 
cannula (Anicath 24G/19mm, Millpledge, UK) with a one way valve (Anisite, Millpledge). 
All animals were cannulated 45 minutes prior to the baseline blood sampling to reduce stress 
and allow the animals to become accustomed to the indwelling cannula. A baseline blood 
sample was taken 5 minutes before D-glucose was administered (2 g/kg, 3 ml/kg) by oral 
gavage. Blood sampling was then performed 10, 20, 30, 60, and 120 minutes post glucose 
administration. Five minutes before each time-point, animals were placed in heated chambers 
(maintained at 37ºC) to aid the blood-sampling procedure. Between blood-sampling time-
points, animals were returned to their home cage and given free access to water. After the 
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final time-point, animals were returned to the feeding laboratory and food was returned. One 
hundred and twenty microlitres of blood was taken at each time point and all blood samples 
were collected into lithium-heparin coated tubes. Plasma was separated by centrifugation for 
5 minutes at 2,400xg and 4°C, and immediately frozen and stored at -80°C.  
 
3.4.4.5.1 Homeostasis model assessment  
Plasma glucose and insulin can be measured after an overnight fast, to provide fasting plasma 
glucose and insulin concentrations. Knowledge of basal plasma glucose and insulin 
concentrations provides important information regarding β-cell function and insulin action 
(Cobelli et al., 2007). In healthy animals, the fasting condition represents a basal steady state 
where glucose is homeostatically maintained in the normal range such that insulin levels are 
not significantly changed and hepatic glucose production is constant i.e. basal insulin 
secretion by pancreatic β-cells determines a relatively constant level of insulinemia that will 
be lower or higher in accordance with insulin sensitivity or resistance such that hepatic 
glucose production matches whole body glucose disposal under fasting conditions. Data can 
be used to give an indication of IR using the homeostasis model assessment of IR (HOMA-
IR), pancreatic β-cell function using the homeostasis model assessment of beta cell function 
(HOMA %β) and insulin sensitivity using the homeostasis model assessment of insulin 
sensitivity (HOMA %S). 
 
In models where IR is being induced, increased insulin is usually the first observed effect, 
and hyperglycaemia may or may not follow. As such, elevated fasting glucose level indicates 
basal IR, which is most often attributed to impaired suppression of hepatic glucose output 
(gluconeogenesis and glycogen breakdown) by insulin, especially in cases where an increase 
in glucose is accompanied by an increase in insulin. On the other hand, low or normal 
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insulin and high glucose levels in a fasting state is often indicative of advanced IR, including 
inadequate insulin secretion, or even β-cell failure. Low insulin with normal glucose often 
indicates enhanced insulin sensitivity. In addition to conclusions drawn from these separate 
observations, HOMA indices for IR and β-cell function are useful for initial estimates of the 
phenotype (an extract from: (Heikkinen et al., 2007)). 
 
Method 
HOMA-IR, HOMA %β and HOMA %S were calculated using HOMA2 analysis of fasting 
plasma glucose and insulin levels using a computer program available from 
www.OCDEM.ox.ac.uk. 
 
3.4.4.6 Insulin tolerance testing 
The insulin tolerance test (ITT) measures glucose levels subsequent to a standardised insulin 
load and gives an estimate of insulin sensitivity. Following a 4 hour fast, a solution of insulin 
is administered intraperitoneally (i.p.) and plasma glucose is then measured at specific 
intervals to determine the animal’s ability to cope with the resulting hypoglycaemia.  
 
Excluding the hyperinsulinemic-euglycemic clamp, the i.p. insulin tolerance test is the most 
direct test of basal insulin sensitivity. Upon insulin injection, glucose typically falls from the 
fasting level until a point where it stabilises and starts to climb back towards the baseline 
level upon degradation of the injected insulin. A slower rate of decline in the initial phase of 
the test typically indicates impaired insulin sensitivity, mostly in skeletal muscle. During the 
later stages of the test, especially at the final timepoints, slower recovery from the 
hypoglycaemic state may indicate delayed activation of counter regulatory signals, or 
impaired hepatic glucose output (an extract from: (Heikkinen et al., 2007)). 
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 Method 
On the morning of the ITT, animals were deprived of food for 4 hours (food removed at 
08.00 h) but had free access to water. At 12.00 h the same day, animals were subjected to an 
ITT. 
 
Animals were weighed and then cannulated by the same method outlined in section 3.4.4.5. A 
baseline blood sample was taken 5 minutes before soluble human insulin (Actrapid, Novo 
Nordisk; supplied as 10mL 100IU/mL) was administered, (0.5 IU/kg, 2 ml/kg i.p.). Blood 
sampling was then performed 30, 45, 60, and 120 minutes post insulin administration. 
Between blood-sampling time-points, animals were returned to their home cage and given 
free access to water. After the final time-point, animals were returned to the feeding 
laboratory and food was returned. One hundred and twenty microlitres of blood was taken at 
each time point and blood samples were treated in the same manner outlined in section 
3.4.4.5.  
 
After insulin administration, animals can approach hypoglycaemic shock. In such an 
incidence, animals become inactive, and may exhibit a flattened posture and/or ptosis. If 
blood glucose approaches 3.5 mmol/L and is descending, then there is a danger of the animal 
going into hypoglycaemic shock and losing consciousness. To minimise the likelihood of this 
occurrence, a glucose solution was prepared in advance and was available throughout the 
ITT. If an animal appeared to approach hypoglycaemic shock, a glucose solution would be 
administered (1 g/kg, 3 ml/kg, i.p.). No further blood samples would be taken from such 
animals. 
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3.4.4.7 Statistical analysis 
Data are presented as arithmetic means ± standard error of mean (SEM). Differences in 
bodyweight were analysed using a generalised estimating equation (GEE) for repeated 
measures (Stata, StataCorp LP, USA). The GEE was performed with an exchangeable 
working correlation structure. This model assumes that all pairs of times for the same animals 
are equally correlated. Group differences in tissue weight, RIA, RT-qPCR, GTT AUC, ITT 
AUC, UCP-1 mRNA expression and ELISA data were analysed using unpaired Student’s t-
test. Differences in OGTT and ITT data were analysed by multiple unpaired Student’s t-test 
with Holm-Bonferroni post hoc analysis. Differences were considered statistically significant 
at the 95% confidence level (P<0.05). Data analysis was performed using Graphpad Prism 4 
software.  
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3.5 Results  
3.5.1 Determination of total viral particle titre by dot blot analysis 
Dot blot analysis using linear regression of standard curve values (Figure 3.03A and B) 
revealed that rAAV-eGFP contained 5.04 x 1013 genome particles/ml (Figure 3.04A and 
Table 3.04) and rAAV-11βHSD1 contained 2.96 x 1013 genome particles/ml (Figure 3.04B 
and Table 3.04). 
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Figure 3.03 Dot blot analysis of standard curve. Total viral particle titre was detected using 
a 32P labelled WPRE DNA probe. (A) Triplicate standard curves (0.1, 0.25, 0.5, 1.0, 2.5, 5, 
10, 25, 50 ng) of pTRCGW. (B) Sample standards were used to plot a standard curve.  
 
 
 
 
 
 
 
 
Standard curve 1 
(50 ng-0.1 ng) 
 
 
Standard curve 2 
(50 ng-0.1 ng) 
 
 
Standard curve 3 
(50 ng-0.1 ng) 
A 
B 
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Figure 3.04 Dot blot analysis of rAAV to determine viral titre. Total viral particle titre 
was detected using a 32P labelled WPRE DNA probe. Triplicate rAAV samples (either 
undiluted or diluted 1:10) were analysed for (A) rAAV-eGFP and (B) rAAV-11βHSD1. 
 
 
Sample 
 
Viral Titre (genome particles/ml) 
 
rAAV-eGFP 5.04 x 1013 
rAAV-11βHSD1 2.96 x 1013 
 
Table 3.04 Total viral particle titre of rAAV samples. Total viral particle titre was detected 
by dot blot and analysed for rAAV-eGFP and rAAV-11βHSD1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
Undiluted 
1:10 
dilution Undiluted Undiluted 
1:10 
dilution 
1:10 
dilution 
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3.5.2 Recombinant adeno-associated virus mediated gene transfer of 11βHSD1 into 
the hypothalamic arcuate nucleus of rats fed a regular chow diet 
3.5.2.1 Effect of bilateral arcuate nucleus injection of rAAV-11βHSD1 on 
hypothalamic WPRE expression, hypothalamic and plasma hormones, 
hypothalamic neuropeptide expression, BAT weight and UCP-1 expression 
In situ hybridisation for WPRE, a component of the viral construct, was performed to confirm 
gene transfer in the ARC and representative images are shown in Figure 3.05. Additionally, 
there was a significant increase in 11βHSD1 mRNA expression in the hypothalamus of 
rAAV-11βHSD1 treated animals relative to controls (Figure 3.06A) as measured by 
RT-qPCR, using 18S as an internal control gene (relative expression (arbitrary units): rAAV-
eGFP vs. rAAV-11βHSD1 : 1.00 ± 0.45 vs. 1.52 ± 0.76, P<0.01). There was no difference in 
hypothalamic expression of NPY (Figure 3.06B). 
 
At the start of the study (day 7) there was no difference in bodyweight between the two 
groups (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 372.34 ± 6.06 vs. 378.16 ± 7.62, 
n.s.). Over the course of the study, there was no change in bodyweight between the two 
groups (Figure 3.07A). There was no difference in plasma corticosterone concentration 
between the two groups (Figure 3.07B) (corticosterone (ng/ml): rAAV-eGFP vs. rAAV-
11βHSD1: 99.80 ± 25.44 vs. 90.39 ± 18.72, n.s.). However, there was a significant increase 
in corticosterone measured in the ARC in rAAV-11βHSD1 treated animals compared to 
controls (Figure 3.08A) (corticosterone (ng/pg protein): rAAV-eGFP vs. rAAV-11βHSD1 : 
89.06 ± 38.64 vs. 242.94 ± 34.42, P<0.05). There was no difference between the two groups 
in corticosterone measured in the PVN (a punch biopsy site chosen as an internal control) 
(Figure 3.08B) (corticosterone (ng/pg protein): rAAV-eGFP vs. rAAV-11βHSD1 : 241.56 ± 
79.18 vs. 222.07 ± 35.62, n.s.). 
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There was no difference in BAT weight between the two groups (Figure 3.09) (BAT weight 
(mg/g bodyweight): rAAV-eGFP vs. rAAV-11βHSD1: 1.70 ± 0.08 vs. 1.72 ± 0.14, n.s.) and 
no difference in UCP-1 expression in BAT (Figure 3.10) (UCP-1 expression (arbitrary units): 
rAAV-eGFP vs. rAAV-11βHSD1: 12.66 ± 0.49 vs. 11.40 ± 0.69, n.s.). 
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Figure 3.05 In situ hybridisation demonstrating WPRE mRNA expression in the 
arcuate nucleus. Representative images of in situ hybridisation using 35S labelled WPRE 
riboprobe showing expression of WPRE (a component of the rAAV-11βHSD1 construct not 
endogenously expressed in rat CNS) in 12µm coronal brain sections of a male Wistar rat 
brain approximately 3.5 mm caudal from bregma. Binding of WPRE anti-sense riboprobe 
used to detect WPRE expression is shown in (A). Binding of WPRE sense riboprobe is 
shown in (B) to highlight specificity. A reference coronal section through the rat brain -
3.48 mm from bregma showing the ARC inside the red box is shown in (C). Reproduced 
from ‘The rat brain in stereotaxic coordinates’, (Paxinos and Watson, 2007). Brains were 
collected 89 days after bilateral intra-ARC injection of 1 µl rAAV-11βHSD1 (n = 4).  
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Figure 3.06 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on hypothalamic 
mRNA in male Wistar rats fed a normal chow diet. (A) Animals were injected with 1 µl 
of either rAAV-eGFP (n = 5) or rAAV-11βHSD1 (n = 6) and hypothalami collected, mRNA 
extracted and quantified by RT-qPCR following termination on day 89. Values shown as 
relative expression ± SEM. ** = P<0.01 by unpaired Student’s t-test. (B) Animals were 
injected with 1 µl of either rAAV-eGFP (n = 5) or rAAV-11βHSD1 (n = 6) and hypothalami 
collected, mRNA extracted and quantified by RT-qPCR following termination on day 89. 
Values shown as relative expression ± SEM. Non-significant by unpaired Student’s t-test. 
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Figure 3.07 Effect of intra-ARC injection of rAAV-11βHSD1 on bodyweight and plasma 
corticosterone in male Wistar rats fed a normal chow diet. (A) Animals were injected 
with 1 µl of either rAAV-eGFP (green circles; n = 12) or rAAV-11βHSD1 (blue circles; 
n = 12) and bodyweight measured for 96 days post injection. Values shown as grams mean ± 
SEM. NS by generalised estimating equation. Arrows indicate periods of fasting. 
(B) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (n = 11) or 
rAAV-11βHSD1 (n = 12) and corticosterone measured from trunk blood by RIA following 
termination on day 89. Values shown as ng/ml mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.08 Effect of intra-ARC injection of rAAV-11βHSD1 on hypothalamic 
corticosterone in male Wistar rats fed a normal chow diet. Animals were injected 
bilaterally with 1 µl of either rAAV-eGFP (n = 6) or rAAV-11βHSD1 (n = 6). At 89 days 
post injection, animals were terminated by decapitation and brains collected and frozen in 
isopentane chilled to -80°C. Eight hundred micrometer thick coronal sections of brain were 
cut through the hypothalamus using a sled microtome. Punch biopsies of hypothalamic nuclei 
were then collected using a neuropunch (Harvard) 1.0 mm in diameter. Like biopsies were 
pooled and homogenised prior to methanol extraction and subsequent measurement of 
corticosterone by ELISA. Corticosterone concentration was determined for A) the arcuate 
nucleus and B) the paraventricular nucleus (as an internal control). All samples were 
normalised for protein content. Values shown as mean ± SEM. * = P<0.05 by unpaired 
Student’s t-test.  
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Figure 3.09 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on BAT weight in 
male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either 
rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and BAT collected and weighed following 
termination on day 89. Values shown as mg/g bodyweight mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
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Figure 3.10 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on UCP-1 mRNA 
expression in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and interscapular BAT collected, 
UCP-1 mRNA extracted and quantified following termination on day 89. Values shown as 
relative optical density to oligo dT (arbitrary units) mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
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3.5.2.2 Effect of bilateral arcuate injection of rAAV-11βHSD1 on glucose tolerance, 
glucose stimulated insulin release and HOMA at the beginning of the study 
period  
An OGTT was performed at the beginning of the study period (one week post rAAV 
injection) (Figure 3.11A). rAAV-11βHSD1 treated animals displayed reduced glucose 
clearance compared to controls, seen as significantly increased plasma glucose concentration 
10 minutes post glucose load and a 13% increase in the peak plasma glucose at 20 minutes 
post glucose load (plasma glucose (mmol/l): at 10 minutes: rAAV-eGFP vs. rAAV-11βHSD1 
: 7.69 ± 0.32 vs. 9.29 ± 0.32, P<0.01; at 20 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 
11.56 ± 0.52 vs. 13.17 ± 0.34, P<0.0125). Fasting plasma glucose levels were not 
significantly different from controls (fasting plasma glucose (mmol/l): rAAV-eGFP vs. 
rAAV-11βHSD1 : 5.45 ± 0.22 vs. 5.45 ± 0.17, P=0.99) and rAAV-11βHSD1 treated animals 
displayed reduced glucose tolerance for the entire 120 minute study period. Reduced glucose 
tolerance was further corroborated by an 8% elevation in area under the curve (AUC) for 
rAAV-11βHSD1 treated animals compared to controls (Figure 3.11B) (AUC (mmol/l x 120 
minute): rAAV-eGFP vs. rAAV-11βHSD1 : 1094.66 ± 42.24 vs. 1180.00 ± 22.44, P<0.05). 
 
Glucose stimulated insulin secretion (GSIS) was measured throughout the OGTT (Figure 
3.12A). rAAV-11βHSD1 treated animals displayed exaggerated GSIS compared to controls, 
seen as a significant increase in plasma insulin concentration 10 minutes post glucose load 
and a 82% increase in peak plasma insulin at 20 minutes post glucose load (plasma insulin 
(ng/ml): at 10 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 0.29 ± 0.04 vs. 0.91 ± 0.17, 
P<0.01; at 20 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 1.26 ± 0.24 vs. 2.29 ± 0.37, 
P<0.0125). Fasting plasma insulin levels were not significantly different from controls 
(fasting plasma insulin (ng/ml): rAAV-eGFP vs. rAAV-11βHSD1 : 0.11 ± 0.02 vs. 
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0.19 ± 0.03, P=0.07) and rAAV-11βHSD1 treated animals displayed increased GSIS for the 
entire 120 minute study period. Exaggerated GSIS was further corroborated by a 92% 
elevation in AUC for rAAV-11βHSD1 treated animals compared to controls (Figure 3.12B) 
(AUC (ng/ml x 120 minute): rAAV-eGFP vs. rAAV-11βHSD1 : 57.90 ± 8.78 
vs.111.14 ± 14.74, P<0.05). 
 
These results suggest that rAAV-11βHSD1 treated animals were less glucose tolerant and 
less insulin sensitive than control rAAV-eGFP animals at 1 week post rAAV injection; a 
finding that is further supported by HOMA analysis. By measuring fasting plasma glucose 
and insulin to perform HOMA analysis, rAAV-11βHSD1 treated animals displayed 
significantly increased insulin resistance, (Figure 3.13) (HOMA-IR: rAAV-eGFP vs. rAAV-
11βHSD1 : 0.38 ± 0.06 vs. 0.63 ± 0.08, P<0.05), significantly reduced insulin sensitivity 
(Figure 3.14) (HOMA %S: rAAV-eGFP vs. rAAV-11βHSD1 : 363.11 ± 61.81 vs. 
215.94 ± 29.17, P<0.05), and an increase in β-cell function, but this did not reach 
significance (Figure 3.15) (HOMA %β: rAAV-eGFP vs. rAAV-11βHSD1 : 40.94 ± 5.58 vs. 
59.55 ± 7.44, n.s.) 
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Figure 3.11 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an oral glucose tolerance test in male Wistar rats fed a normal chow diet after 8 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 7 days post injection, animals were deprived of 
food overnight. The following day glucose (2 g/kg) was administered (3 ml/kg, p.o.). Blood 
glucose was measured 0, 10, 20, 30, 60, and 120 minutes after glucose administration. Values 
shown as mean ± SEM. * = P<0.05 by multiple unpaired Student’s t-test with 
Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve for blood glucose 
profiles. Values shown as mean mmol/l x 120 minutes ± SEM. * = P<0.05 by unpaired 
Student’s t-test.  
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Figure 3.12 Effect of intra-ARC injection of rAAV-11βHSD1 on glucose stimulated 
insulin secretion following an oral glucose tolerance test in male Wistar rats fed a 
normal chow diet after 8 days. (A) Animals were injected bilaterally with 1 µl of either 
rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12). At 7 days post 
injection, animals were deprived of food overnight. The following day glucose (2 g/kg) was 
administered (3 ml/kg, p.o.). Plasma insulin was measured 0, 10, 20, 30, 60, and 120 minutes 
after glucose administration. Values shown as mean ± SEM. * = P<0.05 by multiple unpaired 
Student’s t-test with Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve 
for plasma insulin profiles. Values shown as mean ng/ml x 120 minutes ± SEM. * = P<0.05 
by unpaired Student’s t-test.  
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Figure 3.13 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA-IR in male 
Wistar rats fed a normal chow diet after 8 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 7 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. * = P<0.05 by unpaired 
Student’s t-test.  
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Figure 3.14 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %S in male 
Wistar rats fed a normal chow diet after 8 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 7 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. * = P<0.05 by unpaired 
Student’s t-test.  
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Figure 3.15 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %β in male 
Wistar rats fed a normal chow diet after 8 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 7 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test.  
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3.5.2.3 Effect of bilateral arcuate injection of rAAV-11βHSD1 on insulin tolerance at 
the beginning of the study period  
An ITT was performed at the beginning of the study period (two weeks post rAAV injection) 
(Figure 3.16A). rAAV-11βHSD1 treated animals displayed reduced insulin sensitivity 
compared to controls, with increased plasma glucose for the entire 120 minute study period, 
however, at no point did this reach statistical significance. Fasting plasma glucose levels were 
not significantly different from controls (fasting plasma glucose (mmol/l): rAAV-eGFP vs. 
rAAV-11βHSD1 : 6.86 ± 0.49 vs. 7.24 ± 0.34, n.s.). Reduced insulin sensitivity was further 
corroborated by a 7% elevation in AUC for rAAV-11βHSD1 treated animals compared to 
controls, however this did not reach significance (Figure 3.16B) (AUC (mmol/l x 120 
minute): rAAV-eGFP vs. rAAV-11βHSD1 : 623.53 ± 23.14 vs. 669.75 ± 24.06, n.s.). 
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Figure 3.16 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an insulin tolerance test in male Wistar rats fed a normal chow diet after 15 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 15 days post injection, animals were deprived 
of food for 4 hours in the early light phase. Insulin (0.5 IU/kg) was administered (2 ml/kg, 
i.p.). Plasma glucose was measured 0, 30, 45, 60, and 120 minutes after insulin 
administration. Values shown as mean ± SEM. Non-significant by multiple unpaired 
Student’s t-test with Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve 
for plasma insulin profiles. Values shown as mean mmol/l x 120 minutes ± SEM. Non-
significant by unpaired Student’s t-test. 
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3.5.2.4 Effect of bilateral arcuate injection of rAAV-11βHSD1 on glucose tolerance, 
glucose stimulated insulin secretion midway through the study period  
An OGTT was performed midway through the study period (at 6 weeks post rAAV injection) 
(Figure 3.17A). Similarly to the first OGTT performed (Figure 3.11), rAAV-11βHSD1 
treated animals displayed reduced glucose clearance compared to controls, seen as increased 
plasma glucose concentration for the entire 120 minute study period and an 13% increase in 
peak plasma glucose at 30 minutes post glucose load (plasma glucose (mmol/l): at 
30 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 9.43 ± 0.33 vs. 10.62 ± 0.54, n.s.). Fasting 
plasma glucose levels were not significantly different from controls (fasting plasma glucose 
(mmol/l): rAAV-eGFP vs. rAAV-11βHSD1 : 5.08 ± 0.13 vs. 5.35 ± 0.24, n.s.). Reduced 
glucose tolerance was further substantiated by an elevation in AUC for rAAV-11βHSD1 
treated animals compared to controls, however this did not reach significance (Figure 3.17B) 
(AUC (mmol/l x 120 minute): rAAV-eGFP vs. rAAV-11βHSD1 : 988.08 ± 17.40 vs. 
1074.61 ± 46.34, n.s. (P=0.08)). 
 
rAAV-11βHSD1 treated animals displayed exaggerated GSIS compared to controls, seen as a 
27% increase in peak plasma insulin at 10 minutes post glucose load and a significant 
increase in plasma insulin concentration 20 minutes post glucose load (Figure 3.18A) (plasma 
insulin (ng/ml): at 10 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 1.90 ± 0.41 vs. 
2.42 ± 0.40, n.s.; at 20 minutes: rAAV-eGFP vs. rAAV-11βHSD1 : 1.07 ± 0.16 vs. 
1.70 ± 0.17, P<0.01). Fasting plasma insulin levels were not significantly different from 
controls (fasting plasma insulin (ng/ml): rAAV-eGFP vs. rAAV-11βHSD1 : 0.27 ± 0.06 vs. 
0.32 ± 0.08, n.s.) and rAAV-11βHSD1 treated animals displayed increased GSIS for the 
entire 120 minute study period. Exaggerated GSIS was further corroborated by a significant 
47% elevation in AUC for rAAV-11βHSD1 treated animals compared to controls 
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(Figure 3.18B) (AUC (ng/ml x 120 minute): rAAV-eGFP vs. rAAV-11βHSD1 : 
101.03 ± 10.92 vs.148.25 ± 20.11, P<0.05). 
 
These results agree with the previous OGTT (Figure 3.11) and again suggest that rAAV-
11βHSD1 treated animals were less glucose tolerant and less insulin sensitive than control 
rAAV-eGFP animals, albeit to a lesser extent than seen in the first OGTT. This finding is 
again reflected by HOMA analysis. rAAV-11βHSD1 treated animals displayed increased 
insulin resistance, (Figure 3.19) (HOMA-IR: rAAV-eGFP vs. rAAV-11βHSD1 : 0.85 ± 0.19 
vs. 1.06 ± 0.28, n.s.), reduced insulin sensitivity (Figure 3.20) (HOMA %S: rAAV-eGFP vs. 
rAAV-11βHSD1 : 212.95 ± 55.97 vs. 150.46 ± 32.31, n.s.) and no change in β-cell function 
(Figure 3.21) (HOMA %β: rAAV-eGFP vs. rAAV-11βHSD1 : 79.61± 13.85 
vs. 79.09 ± 10.90, n.s.). 
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Figure 3.17 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an oral glucose tolerance test in male Wistar rats fed a normal chow diet after 35 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 34 days post injection, animals were deprived 
of food overnight. The following day glucose (2 g/kg) was administered (3 ml/kg, p.o.). 
Blood glucose was measured 0, 10, 20, 30, 60, and 120 minutes after glucose administration. 
Values shown as mean ± SEM. Non-significant by multiple unpaired Student’s t-test with 
Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve for blood glucose 
profiles. Values shown as mean mmol/l x 120 minutes ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.18 Effect of intra-ARC injection of rAAV-11βHSD1 on glucose stimulated 
insulin secretion following an oral glucose tolerance test in male Wistar rats fed a 
normal chow diet after 35 days. (A) Animals were injected bilaterally with 1 µl of either 
rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12). At 34 days 
post injection, animals were deprived of food overnight. The following day glucose (2 g/kg) 
was administered (3 ml/kg, p.o.). Plasma insulin was measured 0, 10, 20, 60, and 120 minutes 
after glucose administration. Values shown as mean ± SEM. * = P<0.05 by multiple unpaired 
Student’s t-test with Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve 
for plasma insulin profiles. Values shown as mean ng/ml x 120 minutes ± SEM. * = P<0.05 
by unpaired Student’s t-test. 
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Figure 3.19 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA-IR in male 
Wistar rats fed a normal chow diet after 35 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 34 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.20 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %S in male 
Wistar rats fed a normal chow diet after 35 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 34 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.21 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %β in male 
Wistar rats fed a normal chow diet after 35 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 34 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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3.5.2.5 Effect of bilateral arcuate injection of rAAV-11βHSD1 on insulin tolerance 
midway through the study period 
An ITT was performed midway through the study period (at 7 weeks post rAAV injection) 
(Figure 3.22A). Similarly to the first ITT performed at two weeks post rAAV injection 
(Figure 3.16), rAAV-11βHSD1 treated animals displayed reduced insulin sensitivity 
compared to controls, with increased plasma glucose for the entire 120 minute study period, 
however, at no point did this reach statistical significance. Fasting plasma glucose levels were 
not significantly different from controls (fasting plasma glucose (mmol/l): rAAV-eGFP vs. 
rAAV-11βHSD1 : 6.58 ± 0.15 vs. 6.95 ± 0.19, n.s.). Reduced insulin sensitivity was further 
corroborated by a 14% elevation in AUC for rAAV-11βHSD1 treated animals compared to 
controls, however this did not reach significance (Figure 3.22B) (AUC (mmol/l x 120 
minute): rAAV-eGFP vs. rAAV-11βHSD1 : 557.83 ± 20.28 vs. 635.65 ± 35.36, n.s.). 
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Figure 3.22 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an insulin tolerance test in male Wistar rats fed a normal chow diet after 42 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 42 days post injection, animals were deprived 
of food for 4 hours in the early light phase. Insulin (0.5 IU/kg) was administered (2 ml/kg, 
i.p.). Plasma glucose was measured 0, 30, 60, and 120 minutes after insulin administration. 
Values shown as mean ± SEM. Non-significant by multiple unpaired Student’s t-test with 
Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve for plasma insulin 
profiles. Values shown as mean mmol/l x 120 minutes ± SEM. Non-significant by unpaired 
Student’s t-test. 
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3.5.2.6 Effect of bilateral arcuate injection of rAAV-11βHSD1 on glucose tolerance, 
glucose stimulated insulin secretion at the end of the study period  
A final OGTT was performed at the end of the study period (12 weeks post rAAV injection) 
(Figure 3.23A). The results from this OGTT do not support the first two OGTTs (Figures 
3.11 and 3.17 respectively) as no difference was observed in glucose tolerance between 
rAAV-11βHSD1 treated animals and controls for the entire 120 minute study period. Fasting 
plasma glucose levels were not significantly different from controls (fasting plasma glucose 
(mmol/l): rAAV-eGFP vs. rAAV-11βHSD1 : 5.74 ± 0.21 vs. 5.76 ± 0.20, n.s.). Additionally 
there was no change in AUC (Figure 3.23B) suggesting that the effects on glucose 
homeostasis were no longer present later in the study period. 
 
There was no change in GSIS between the two groups for the entire 120 minute study period 
(Figure 3.24A). Fasting plasma insulin levels were not significantly different from controls 
(fasting plasma insulin (ng/ml): rAAV-eGFP vs. rAAV-11βHSD1 : 0.51 ± 0.10 vs. 
0.59 ± 0.09, n.s.). There was no change in AUC for rAAV-11βHSD1 treated animals 
compared to controls (Figure 3.24B). 
 
There was no change in insulin resistance evaluated by HOMA-IR (Figure 3.25). rAAV-
11βHSD1 treated animals displayed reduced insulin sensitivity but this did not reach 
statistical significance (Figure 3.26). Finally, there was no change in β-cell function between 
the two groups (Figure 3.27). 
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Figure 3.23 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an oral glucose tolerance test in male Wistar rats fed a normal chow diet after 76 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 75 days post injection, animals were deprived 
of food overnight. The following day glucose (2 g/kg) was administered (3 ml/kg, p.o.). 
Blood glucose was measured 0, 10, 20, 30, 60, and 120 minutes after glucose administration. 
Values shown as mean ± SEM. Non-significant by multiple unpaired Student’s t-test with 
Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve for blood glucose 
profiles. Values shown as mean mmol/l x 120 minutes ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.24 Effect of intra-ARC injection of rAAV-11βHSD1 on glucose stimulated 
insulin secretion following an oral glucose tolerance test in male Wistar rats fed a 
normal chow diet after 76 days. (A) Animals were injected bilaterally with 1 µl of either 
rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12). At 75 days 
post injection, animals were deprived of food overnight. The following day glucose (2 g/kg) 
was administered (3 ml/kg, p.o.). Plasma insulin was measured 0, 10, 20, 60, and 120 minutes 
after glucose administration. Values shown as mean ± SEM. Non-significant by multiple 
unpaired Student’s t-test with Holm-Bonferroni post hoc analysis. (B) Calculated area under 
the curve for plasma insulin profiles. Values shown as mean ng/ml x 120 minutes ± SEM. 
Non-significant by unpaired Student’s t-test. 
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Figure 3.25 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA-IR in male 
Wistar rats fed a normal chow diet after 76 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 75 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.26 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %S in male 
Wistar rats fed a normal chow diet after 76 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 75 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 3.27 Effect of intra-ARC injection of rAAV-11βHSD1 on HOMA %β in male 
Wistar rats fed a normal chow diet after 76 days. Animals were injected bilaterally with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12). At 75 days post injection, 
animals were deprived of food overnight. The following day fasting plasma glucose and 
plasma insulin were measured. Values shown as mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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3.5.2.7 Effect of bilateral arcuate injection of rAAV-11βHSD1 on insulin tolerance at 
the end of the study period  
A final ITT was performed at the end of the study period (13 weeks post rAAV injection) 
(Figure 3.28A). Similarly to the first two ITTs performed (Figure 3.16 and 3.22), rAAV-
11βHSD1 treated animals displayed reduced insulin sensitivity compared to controls, with 
increased plasma glucose for the entire 120 minute study period, however, at no point did this 
reach statistical significance. Fasting plasma glucose levels were increased in 
rAAV-11βHSD1 treated animals but this was not significantly different from controls 
(fasting plasma glucose (mmol/l): rAAV-eGFP vs. rAAV-11βHSD1 : 6.87 ± 0.09 vs. 
7.34 ± 0.24, n.s. (P=0.08)). Reduced insulin sensitivity was further corroborated by a 13% 
elevation in AUC for rAAV-11βHSD1 treated animals compared to controls however this did 
not reach significance (Figure 3.28B) (AUC (mmol/l x 120 minute): rAAV-eGFP vs. rAAV-
11βHSD1 : 537.80 ± 19.14 vs. 609.42 ± 36.36, n.s.). 
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Figure 3.28 Effect of intra-ARC injection of rAAV-11βHSD1 on blood glucose following 
an insulin tolerance test in male Wistar rats fed a normal chow diet after 83 days. 
(A) Animals were injected bilaterally with 1 µl of either rAAV-eGFP (green circles; n = 11) 
or rAAV-11βHSD1 (blue circles; n = 12). At 83 days post injection, animals were deprived 
of food for 4 hours in the early light phase. Insulin (0.5 IU/kg) was administered (2 ml/kg, 
i.p.). Plasma glucose was measured 0, 30, 60, and 120 minutes after insulin administration. 
Values shown as mean ± SEM. Non-significant by multiple unpaired Student’s t-test with 
Holm-Bonferroni post hoc analysis. (B) Calculated area under the curve for plasma insulin 
profiles. Values shown as mean mmol/l x 120 minutes ± SEM. Non-significant by unpaired 
Student’s t-test. 
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3.6 Discussion  
11βHSD1 acts as a local modulator of GC levels, increasing local GC concentration in a 
variety of tissues; most notably liver, lung, adipose, vascular tissue, ovaries and CNS (Seckl, 
1997). In the brain, endogenous expression of 11βHSD1 is expressed in arcuate neurons and 
tends to be colocalised with GRs (Monder, 1991). In these studies, rAAV was utilised as a 
tool to investigate the effects of GCs in the ARC on glucose homeostasis. 
 
Recombinant adeno-associated virus was selected to overexpress 11βHSD1 as it allows stable 
transgene expression which can be introduced at any point during an animal’s lifespan, 
thereby circumventing developmental compensation. Also, rAAV has the ability to transfect 
non-dividing cells, meaning it is suitable for use in the CNS. Recombinant AAV serotype 2 
was chosen for use in this work because it has a tropism for neurons and lacks a tropism for 
glia (Bartlett et al., 1998). In addition, it has been widely used in CNS gene transfer studies 
with no reports of toxicity and low immune reaction (Tenenbaum et al., 2004). In the 
production of rAAV, the plasmid pTRCGW was selected for modification with the 11βHSD1 
gene because it contains the sequence elements required for in vivo rAAV mediated transgene 
expression. Total viral particle titre for the rAAV produced was quantified by dot blot 
analysis. This is important as viral titre is a major factor affecting efficiency of transfection. 
rAAV-11βHSD1 and rAAV-eGFP were both produced with a sufficiently high titre to 
achieve efficient transfection of neurons. 
 
The coordinates chosen for rAAV injection into the ARC were determined from the Rat 
Brain Atlas (Paxinos and Watson, 2007). Coordinates were confirmed by ink injection 
(appendix II) and by in situ hybridisation. Both of these studies support the accurate targeting 
of the ARC using the chosen coordinates. In addition, in situ hybridisation confirmed 
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expression of the rAAV transgene cassette. The probe used for this was against WPRE; an 
integral component of the viral construct used to enhance in vivo mRNA transcription (Xu et 
al., 2003). This is advantageous as WPRE is not endogenously expressed in mammalian 
tissues, therefore use of a probe against WPRE results in reduced background compared to 
use of a probe directed against 11βHSD1, which is widely expressed throughout the brain 
(Seckl, 1997). These data agree with RT-qPCR analysis of 11βHSD1 mRNA expression in 
the hypothalamus, which showed a significant one and a half fold increase in rAAV-
11βHSD1 treated animals compared to the control group.  
 
In addition to showing the successful expression of correctly targeted mRNA, it is important 
to demonstrate an increase in 11βHSD1 enzyme activity. However, this is a complex and 
expensive assay; therefore local corticosterone concentration in hypothalamic nuclei was 
used as a surrogate measure of enzyme activity. This demonstrated significantly increased 
levels of corticosterone in the ARC of rAAV-11βHSD1 treated animals compared to controls 
injected with rAAV-eGFP. No difference in corticosterone concentration was observed in the 
PVN, an area selected as an internal control, isolated from the same animals. This suggests 
that increased 11βHSD1 activity had been achieved and was correctly targeted to the ARC.  
 
This study investigated the effects of increased 11βHSD1 expression in the ARC on glucose 
homeostasis and IR. There are several indicators of IR, including elevated fasting glucose and 
insulin concentrations and impaired glucose tolerance. Various procedures are available to 
investigate this, but the gold-standard for determining in vivo insulin sensitivity is the 
euglycemic-hyperinsulinemic glucose clamp, as it directly measures the capacity of insulin to 
promote glucose utilisation under steady state conditions (Heikkinen et al., 2007). However, 
the clamp is a complicated procedure which is time-consuming and requires anaesthesia 
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(Cacho et al., 2008). For these reasons, glucose tolerance and insulin sensitivity were 
investigated in this study using the OGTT, the ITT and derivations of fasting glucose and 
insulin levels.  
 
The GTT provides a measure of the ability of the pancreas to secrete the necessary insulin 
concentration for the clearance of a specific glucose load, and the whole-body response to the 
secreted insulin. Glucose tolerance is an expression of the efficiency with which homeostatic 
mechanisms restore glycaemia to basal levels after perturbation. However, glucose tolerance 
and insulin sensitivity are not equivalent concepts, and in addition to metabolic actions of 
insulin, insulin secretion, incretin effects, amongst other factors, contribute importantly to 
glucose tolerance. Thus the GTT provides useful information about glucose tolerance, but not 
necessarily insulin sensitivity and IR. To investigate these, a number of indexes of insulin 
sensitivity and IR were used to further analyse the results of the GTT. The ITT measures 
glucose levels subsequent to a standardised insulin load and provides a further estimate of 
insulin sensitivity. The AUC was also calculated for both GTTs and ITTs as it provides 
critical information for the evaluation of the resulting glucose or insulin curve. Total AUC 
was calculated and presented because it is not dependent upon an ever-changing baseline 
level for glucose and insulin (Potteiger et al., 2002).  
 
For a GTT, the glucose bolus is usually administered either orally (an OGTT) or 
intravenously (an IVGTT). The oral route was chosen for use in these studies as it is more 
physiological than the i.v. route. An OGTT takes into account intestinal aspects of glucose 
absorption, and the incretin effect remains intact as it is not bypassed. 
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Insulin sensitivity is affected by stress and increased adrenaline and corticosterone levels due 
to stress can increase hepatic glucose output and consequently affect assessment of IR. To 
minimise this, animals were well handled prior to testing and underwent sham procedures so 
that they were accustomed to the routes of administration for both OGTTS and ITTs. Finally, 
to minimise stress levels, blood samples were taken via an indwelling tail-vein cannula in 
both OGTTs and ITTs. Animals were always allowed 45 minutes to acclimatise to the 
cannula prior to any blood samples being taken.  
 
OGTTs were performed in the morning as the time of day is an important determinant of IR. 
Corticosterone exhibits a diurnal rhythm with a significant increase later in the day leading to 
higher hepatic glucose output that can inflate IR. Of note is that fasting glucose levels were 
elevated in the ITTs vs. the OGTTs. This is the result of reduced fasting time in the ITTs 
(4 hour fast vs. overnight fast) and the fact that ITTs were performed later in the day; hence a 
rise in glucose levels are to be expected. 
 
OGTTs were performed after an overnight fast, thereby minimising interference from dietary 
glucose intake. Additionally, an overnight fast permitted the measurement of fasting glucose 
and insulin concentration prior to the administration of the glucose bolus; thereby allowing 
calculation of a surrogate measure of IR based on these measurements; HOMA. Because 
HOMA is obtained from a single fasting blood sample, it is a simple tool for assessing IR, % 
insulin sensitivity and % β-cell function. HOMA provides a measure of basal insulin 
sensitivity and is calculated on the premise that circulating glucose and insulin levels are 
determined by a feedback loop between the liver and the pancreas i.e. glucose concentrations 
are regulated by insulin-dependent hepatic glucose production, whereas insulin release 
depends on pancreatic β-cell response to glucose concentrations. The fasting plasma insulin 
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concentration is largely determined by the glucose concentration and the basal 
hyperglycaemia in diabetes appears to arise from the feedback loop between the liver and the 
β-cells, thereby maintaining an effective insulin action in the liver and at the periphery. The 
degree of basal hyperglycaemia is thus determined by a combination of β-cell deficiency and 
IR and deficient β-cell function reflects diminished response of β-cell to GSIS. Likewise IR is 
reflected by diminished suppressive effect of insulin on hepatic glucose production 
(Muniyappa et al., 2008) and HOMA essentially reflects on changes in hepatic insulin 
sensitivity. The HOMA-IR has been validated for use in Wistar rats, against the euglycemic 
clamp (Cacho et al., 2008) where similar correlations were obtained for the overall insulin 
sensitivity derived from HOMA-IR with the euglycemic clamp. However, HOMA %β and 
HOMA %S have not been validated for use in rodents. 
 
Increased GC levels in the ARC resulted in a mild, but significant, reduction in glucose 
tolerance and insulin sensitivity. The results from the first OGTT (1 week post injection) 
suggest that rAAV-11βHSD1 treated animals were less able to clear glucose from circulation 
compared to controls. After fasting, there was no significant difference in baseline glucose 
and insulin concentration; however, when assessed by HOMA, rAAV-11βHSD1 treated 
animals displayed values implying increased IR, decreased insulin sensitivity and increased 
(but not significantly so) β-cell function. Additionally, these animals displayed exaggerated 
GSIS and a reduction in insulin sensitivity as measured by ITT (2 weeks post injection). 
These results were replicated, albeit to a lesser extent, midway through the study period (6 
and 7 weeks post injection). Taken together, this data suggests that rAAV-11βHSD1 treated 
animals had reduced insulin sensitivity as a result of increased IR. The effects were no longer 
apparent later in the animal’s lifespan (beyond week 12), at which point animals showed no 
difference in glucose tolerance, but remained less insulin sensitive in response to the ITT. 
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Increased levels of corticosterone in the ARC resulted in reduced whole-body glucose 
clearance and reduced insulin sensitivity in rats fed a normal chow diet. These findings are 
consistent with previous data, in which ICV dexamethasone induced a reduction in whole-
body insulin sensitivity in rats (Cusin et al., 2001). The findings in this study suggest that the 
effects of 11βHSD1, and hence corticosterone, in the ARC play a role in glucose homeostasis 
and reduce insulin sensitivity by increasing IR. 
 
There was no difference in food intake or bodyweight gain seen between rAAV-11βHSD1 
treated animals and the controls (appendix III). Hence, the effects on glucose homeostasis 
occurred independently of changes in weight gain. Certainly, had the animals shown a change 
in bodyweight, then altered glucose tolerance and insulin sensitivity might be expected. The 
fact that there was no change in bodyweight between the two groups adds validity to the 
changes observed in glucose homeostasis. Additionally, BAT weight and levels of UCP-1 
mRNA in BAT were unchanged between rAAV-11βHSD1 treated animals and eGFP 
controls. This implies that levels of adaptive thermogenesis, and hence energy expenditure, 
remained unchanged. 
 
GCs stimulate gluconeogenesis and inhibit peripheral glucose uptake, therefore it is possible 
that part of the phenotype could be explained by changes in the HPA axis and circulating GC 
levels. To investigate this possibility, plasma levels of corticosterone were measured. One 
difficulty of such a measure is that, by its very nature, the HPA axis is activated by stress. 
Therefore, it was necessary to ensure blood was collected with minimal stress, and to achieve 
this decapitation was used to terminate the study. To the same end, animals were handled 
daily to reduce the effects of stress from the necessary handling immediately prior to their 
decapitation. Somewhat surprisingly, corticosterone plasma levels were not altered in the 
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rAAV-11βHSD1 treated animals compared to the controls. It was expected that there would 
be some change in the circulating levels of this hormone since there is a classic negative 
feedback mechanism with GCs in the hypothalamus acting to inhibit the HPA axis; however 
this effect is mediated by CRH neurons in the PVN. The stereotactic injections were targeted 
to ARC and therefore may not have affected the HPA axis.  
 
Alternatively, the effects of GC on glucose homeostasis could be partially explained by 
pancreatic β-cell dysfunction. Indeed, failure of pancreatic β-cells to compensate for 
peripheral IR is a major factor in the development of T2DM (Kahn, 2001, Leahy, 2005). 
However, the effects on glucose homeostasis seen in this study are unlikely to be the result of 
β-cell dysfunction for several reasons. Firstly, the results from the HOMA estimate of β-cell 
function indicate that there was no reduction in β-cell function in rAAV-11βHSD1 treated 
animals throughout the entire study. In fact, at week 1 post injection the HOMA %β results 
indicate that β-cell function was increased in rAAV-11βHSD1 treated animals; a result that 
was somewhat surprising. However, HOMA %β is not necessarily an accurate measure of β-
cell function. Instead it is a tool used to provide preliminary insights into β-cell function. 
Additionally, although it is widely used in human studies, unlike HOMA-IR, HOMA %β has 
not been validated against the euglycemic-hyperinsulinemic glucose clamp for use in Wistar 
rats. In spite of this, the results of HOMA %β were supported by the GSIS results as 
rAAV-11βHSD1 treated animals displayed severely exaggerated GSIS compared to control 
animals. This indicates that animals were still able to produce and release sufficient insulin 
into circulation to deal with the glucose bolus meaning that a reduction in β-cell function 
would be unlikely. 
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Results from the HOMA %S and HOMA-IR suggest that rAAV-11βHSD1 treated animals 
exhibited reduced insulin sensitivity due to increased IR. Insulin resistance is reflected by a 
diminished suppressive effect of insulin on hepatic glucose production (Muniyappa et al., 
2008) thus, HOMA-IR essentially reflects changes in hepatic insulin sensitivity. These 
findings were further supported by the ITT results, where rAAV-11βHSD1 treated animals 
displayed reduced sensitivity to an insulin load. It is possible that the phenotype can be partly 
explained by altered hepatic glucose production and reduced hepatic insulin sensitivity. 
Hypothalamic control of endogenous glucose production is well documented (Lam et al., 
2009) and is thought to involve the hypothalamic signalling of insulin. Indeed, ICV infusion 
of insulin inhibits endogenous glucose production (Obici et al., 2002b) and downregulation of 
hypothalamic insulin receptors prevents suppression of endogenous glucose production by 
circulating insulin (Obici et al., 2002a, Obici et al., 2002b). Insulin inhibits NPY producing 
neurons in the ARC (van den Hoek et al., 2004). ICV administration of NPY causes IR 
independent of changes in food intake (van den Hoek et al., 2004) and ICV infusion of NPY 
prevents the inhibition of, primarily hepatic, endogenous glucose production elicited by 
circulating insulin. This suggests that the primary neurophysiological effect of insulin is to 
silence NPY neurons and consequently inhibit neuronal NPY release. Therefore 
downregulation of NPY release is a prerequisite for insulin’s ability to suppress hepatic 
glucose production via the vagal nerve (van den Hoek et al., 2008). This contributes to the 
inhibitory effect of ICV insulin administration on the reduction of hepatic glucose production 
(van den Hoek et al., 2008).  
 
It has been proposed that central GC administration exerts effects on energy homeostasis by 
increasing NPY release in the ARC (Zakrzewska et al., 1999b). Certainly, GRs are expressed 
on NPY neurons in the hypothalamus (Harfstrand et al., 1989) and chronic GC administration 
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increases NPY mRNA expression in the ARC (Larsen et al., 1994). Thus, it is possible that 
overexpression of arcuate 11βHSD1 resulted in an increase in NPY release and subsequent 
reduction in the ability of insulin to decrease endogenous glucose production, primarily in the 
liver. In this study, NPY mRNA in the ARC remained unchanged. At first glance, this 
disagrees with the proposed mechanism of NPY on IR. However, a lack of change in mRNA 
expression does not necessarily preclude this neuropeptide from involvement in the altered 
phenotype. For instance, neuropeptides such as NPY are stored in abundance, so an increase 
in neuron firing may not require an increase in neuropeptide transcription. Consequently, the 
fact that NPY mRNA was not increased in these animals, does not mean that NPY peptide 
release was unchanged. Additionally, receptor expression and sensitivity were not measured 
in this study, which again could have an effect on ARC activity.  
 
Perhaps the most likely explanation for the phenotype exhibited in this study is that an 
overexpression of 11βHSD1 in the ARC resulted in IR specifically in this region of the brain. 
Insulin is well known to exert effects centrally, and decreased insulin receptor expression in 
the ARC elicits IR in rats (Obici et al., 2002a). In addition, increased 11βHSD1 expression in 
adipose tissue has a well-established link with IR (Masuzaki et al., 2001). Therefore it is 
entirely possible that increased 11βHSD1 expression in the ARC resulted in partial central 
IR, thereby promoting hyperinsulinemia and whole body glucose intolerance. Central IR 
would also agree with the mild, rather than extreme, effects on glucose homeostasis seen in 
this study.  
 
The effects on glucose homeostasis in rAAV-11βHSD1 treated animals became less 
substantial as the study progressed. The difference in glucose tolerance between the two 
groups was reduced midway through the study (week 6) and was no longer present at the end 
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of the study (week 12). Interestingly, GSIS was still exaggerated midway through the study, 
but this too was no longer apparent at the end of the study. Of course, it could be argued that 
rAAV-11βHSD1 was no longer overexpressing 11βHSD1 as at the beginning of the study, 
but this seems unlikely for several reasons. Firstly, rAAV has been shown to continue 
expressing for longer than the length of time it was used in this study (Klein et al., 2002). 
Additionally, the results of the in situ hybridisation and hypothalamic RT-qPCR analysis 
showed increased expression of WPRE and 11βHSD1 respectively at the end of the study. 
Also, the results of the corticosterone assay from punch biopsies showed increased 
corticosterone in the ARC at the end of the study. Therefore it would appear that rAAV-
11βHSD1 was still successfully increasing expression of 11βHSD1 at the end of the study. 
Alternatively, increased levels of intracellular GC may have resulted in downregulation of 
GR expression, thereby blunting the effects of 11βHSD1 overexpression. More likely is that 
the changes in glucose homeostasis, despite being significant, were subtle and therefore 
easily masked by age and weight gain, two factors known to promote IR.  
 
The results of this study support the role of the CNS in control of glucose homeostasis. I have 
shown that central 11βHSD1 and GCs may play a more important role in glucose 
homeostasis than previously thought. 11βHSD1 is thought to be implicated in the 
pathogenesis of T2DM and the peripheral role of 11βHSD1 in IR and T2DM is an area 
currently being thoroughly investigated; however, the role of 11βHSD1 in the brain and its 
effects on glucose homeostasis are an area that requires much further research.  
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Chapter 4 
Effects of 11βHSD1 
overexpression in the arcuate 
nucleus on a regular chow 
diet vs. high-fat diet 
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4 Introduction 
4.1 Glucocorticoids and obesity 
The link between glucocorticoid (GC) metabolism and idiopathic obesity is not entirely 
understood, but the similarities between patients suffering from Cushing’s syndrome and 
patients displaying idiopathic obesity are undeniable. Although patients with simple obesity 
exhibit circulating cortisol levels that are normal or reduced, they display increased 
expression of 11β-hydroxysteroid dehydrogenase 1 (11βHSD1) in central adipose tissue 
(Rask et al., 2001, Stewart et al., 1999, Kannisto et al., 2004, Stewart, 2003, Andrews et al., 
2002), suggesting that this enzyme may play a role in energy homeostasis. 
 
Impairment of cortisol metabolism has been demonstrated in obese men who, compared to 
normal weight controls, show no difference in whole body regeneration of cortisol from 
cortisone, but display increased cortisol regeneration in subcutaneous adipose tissue (Sandeep 
et al., 2005). Genetic association studies support this work. In a group of adult monozygous 
twins, the intra-pair differences in body mass index (BMI) and insulin resistance (IR) 
positively correlated with those in adipose 11βHSD1 expression (Stewart, 2003). In addition, 
weight loss in obese individuals is associated with decreased 11βHSD1 mRNA expression in 
adipose tissue (Draper et al., 2002), although the significance of this local GC amplification 
is unclear. 
 
Animal models have demonstrated dysregulation of 11βHSD1 activity in obesity. Zucker rats 
have tissue specific alterations in 11βHSD1 expression and activity, with a marked increase 
in adipose tissue and a decrease in hepatic tissue (Livingstone et al., 2000). In addition, 
transgenic mice with an overexpression of 11βHSD1 in white adipose tissue (similar to that 
seen in obese humans) exhibit IR, hyperlipidemia and hyperphagia, despite exhibiting 
175 
 
hyperleptinemia (Masuzaki et al., 2001). Transgenic mice with a knockout of 11βHSD1 
(11βHSD1-/-) do not display dislipidemia or IR and are protected from weight gain on a high-
fat diet (Kotelevtsev et al., 1997). This evidence suggests that 11βHSD1 activity may play an 
important aetiological role in the pathogenesis of obesity in rodents and in humans.  
 
4.1.1 Central glucocorticoids and obesity  
GCs appear to regulate energy homeostasis, at least in part, via the CNS (in particular the 
hypothalamus) and centrally acting GCs have been implicated in the pathogenesis of obesity. 
Continuous infusion of GC in rats increases food intake and bodyweight compared to 
controls treated with saline (Zakrzewska et al., 1999a, Cusin et al., 2001). 
Intracerebroventricular (ICV) infusion of GC causes hyperinsulinemia, hypertriglyceridemia 
and hyperleptinemia (Zakrzewska et al., 1999a); three abnormalities characteristic of the 
metabolic syndrome. This is hypothesised to occur via the parasympathetic nervous system, 
since vagotomy prevents this effect (Cusin et al., 2001). In rats, ICV administration of GC 
increases hypothalamic NPY expression after adrenalectomy (ADX) (Sainsbury et al., 
1997b). ICV GC also blocks the effects of ICV leptin on food intake and blocks leptin 
induced phosphorylation of signal transducer and activator of transcription (STAT-3). In 
contrast, ADX increases hypothalamic expression of leptin receptor and STAT-3, whilst it 
decreases the expression of suppressor of cytokine signalling (SOCS-3), thereby suggesting a 
direct interaction between GC and leptin within the arcuate nucleus (ARC) (Madiehe et al., 
2001). 
 
GCs interact with powerful regulators of food intake, namely NPY, the melanocortin system 
and leptin. GCs appear to play a permissive role in regulation of food intake by NPY. 
Infusion of NPY, either ICV or intra-paraventricular nucleus (PVN), into ADX rats does not 
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produce an increase in food intake or weight gain as seen in control rats that have normal 
circulating GC levels. Restoration of the orexigenic effects of NPY occurs after replacement 
of GC either by intraperitoneal (i.p.) or ICV-injection (Jeanrenaud and Rohner-Jeanrenaud, 
2000). Thus, GCs may be necessary for the central action of NPY on feeding.  
 
GCs play a modulatory role with respect to the melanocortin system. Mice with targeted 
deletion of POMC (POMC-/-) have undetectable GC levels (Yaswen et al., 1999) due to a lack 
of ACTH production. POMC-/- mice are more sensitive to the orexigenic effects of 
administration of exogenous GC than wild-type mice (Coll et al., 2005). In addition, 
transgenic rescue of pituitary POMC expression in POMC-/- mice restores normal adrenal 
function and results in increased food intake, thereby worsening the obese phenotype 
(Michailidou et al., 2007).  
 
GCs display a complex relationship with regard to leptin. Genetic deficiency of leptin, or its 
receptor, results in hypercorticosteronemia in rodents (Ahima et al., 1999). In leptin deficient 
ob/ob animals, leptin replacement reduces GC levels (Ahima et al., 1998) and after ADX, 
ICV leptin administration further reduces food intake and bodyweight. This increase in leptin 
sensitivity is reversed after GC treatment, suggesting that GCs attenuate the response to 
leptin. However, GCs have been shown to stimulate the production of leptin (Zakrzewska et 
al., 1997) so it seems the relationship is not yet fully understood. 
 
In the brain, 11βHSD1 is mostly expressed in sites of GC negative feedback, including the 
hippocampus, the cerebral cortex and the PVN. However, 11βHSD1 is also expressed in the 
ARC (Densmore et al., 2006), an area intimately involved in the regulation of energy 
homeostasis. Expression of 11βHSD1 in the ARC is increased in rodents fed a high-fat diet 
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(Densmore et al., 2006), suggesting a possible role for GCs in the development of diet 
induced obesity. Additionally, within the ARC, the GR is expressed in both NPY/AgRP and 
POMC/CART neurons and the promoter regions of these hormones have glucocorticoid 
regulatory elements (GREs) within them (Drouin et al., 1993).  
 
Despite the evidence for a role of GCs in the hypothalamic regulation of energy homeostasis, 
their physiological effect and site of action is as yet undefined. One reason for this is the 
difficulty in manipulating GC levels in specific hypothalamic nuclei. To address this 
problem, I have utilised recombinant adeno-associated virus (rAAV) to overexpress 
11βHSD1, and hence increase corticosterone, in the ARC of the hypothalamus in rats fed a 
normal chow diet and rats fed a high-fat diet. 
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4.2 Hypothesis and aims 
Evidence exists for a physiological role of GCs in the hypothalamic regulation of energy 
homeostasis. However, their exact effect and site of action is unclear largely due to 
difficulties in manipulating GC levels in specific hypothalamic nuclei.  
 
4.2.1 Hypothesis 
Glucocorticoids in the hypothalamus physiologically regulate food intake and energy 
expenditure. 
 
4.2.2 Aims 
To investigate the physiological role of glucocorticoid in the hypothalamus I will: 
 
• Demonstrate the effect of 11βHSD1 overexpression in the arcuate nucleus of the 
hypothalamus on food intake and bodyweight in rats fed a regular chow diet. 
• Demonstrate the effect of 11βHSD1 overexpression in the arcuate nucleus of the 
hypothalamus on food intake and bodyweight in rats fed a high-fat diet. 
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4.3 Materials 
Unless stated otherwise all chemicals were purchased from VWR, Poole, Dorset, UK and all 
enzymes from New England Biolabs, Hitchin, Herts, UK. 
 
4.4 Methods 
4.4.1 Production of rAAV-11βHSD1  
The method of production of rAAV particles is described in chapter 2. Briefly, 11βHSD1 
cDNA was produced using reverse transcription PCR of rat hypothalamic RNA 
(section 2.3.4) using the primer set detailed in Table 4.01. 11βHSD1 cDNA PCR product was 
subcloned into the expression vector PTRCGW which carries the eGFP transgene 
(Figure 2.06). The first step in subcloning was to cut the 11βHSD1 PCR product and the 
pTRCGW plasmid using the restriction enzymes BamHI and BsrGI. The use of the restriction 
enzymes BamHI and BsrGI linearises the pTRCGW plasmid and removes the enhanced 
green fluorescent protein (eGFP) gene. The products from the restriction digest were loaded 
on a 1 % (w/v) agarose gel (section 2.3.4.3). The linearised plasmid and the cut 11βHSD1 
PCR cDNA fragment were excised from the gel and electroeluted (section 2.3.5.2). The 
cDNA fragment was subcloned into the linearised plasmid by a ligation reaction 
(section 2.3.5.3), resulting in the modified pTRCGW-11βHSD1 plasmid. The pTRCGW-
11βHSD1 plasmid was digested with BamHI and BsrGI to check insert size and also digested 
with XmaI to check for presence of inverted terminal repeats (ITRs) and visualised by gel 
electrophoresis. The ligated plasmid was then transformed into competent bacteria 
(section 2.3.7). The sequence of the insert was confirmed in both directions on two separate 
occasions (Genomics core laboratory, Imperial College London, UK). The plasmid 
pTRCGW-11βHSD1 was used to produce rAAV-11βHSD1 particles. Total viral particle titre 
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was determined by dot blot analysis (section 2.3.8.4). The plasmid pTRCGW was a kind gift 
from Professor J Verhaagen at the Netherlands Brain Institute, Amsterdam, The Netherlands. 
 
Primer Primer Sequence Restriction 
Site 
5’ 11βHSD1 AGC-TGG-ATC-CCG-CAC-TTA-TCT-GAA-GCC-TCA 
 
BamHI 
3’ 11βHSD1 AGC-TTG-TAC-ATC-AGT-GTG-AGG-TAA-AGC-CGA 
 
BsrGI 
 
Table 4.01 Primers for PCR amplification of 11βHSD1 for use in rAAV. The sequence in 
red details the restriction site associated with a particular primer. The 5’ primer corresponds 
to nucleotides 1-20, and the 3’ primer corresponds to nucleotides 1239-1258 in the rat 
11βHSD1 mRNA (accession number NM_008288.2). 
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4.4.2 Effect of rAAV-11βHSD1 bilaterally injected into the arcuate nucleus on a 
regular chow diet (NC cohort) 
4.4.2.1 Animals  
Male Wistar rats weighing 220-230 g (specific pathogen free, Charles River UK Ltd, 
Margate, Kent, UK) were individually housed in open top polypropylene cages under a 
controlled environment (temperature 21-23°C, 12 hour light-dark cycle, lights on at 
07:00AM) with ad libitum access to food (RM1 diet, SDS UK Ltd, Witham, Essex, UK) and 
water. All animal procedures were approved under the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project licence number 70/6377). Animals were 
acclimatised to these conditions for two weeks prior to surgery.  
 
4.4.2.2 Animal allocation 
Animals were allocated into two weight matched treatment groups (matched on median 
bodyweight) as outlined in Table 4.02. 
 
Group Treatment n 
Control group 
(rAAV-eGFP) 
rAAV-eGFP 12 
Treatment group 
(rAAV-11βHSD1) 
rAAV-11βHSD1 12 
 
Table 4.02 Allocation of male Wistar rats into experimental groups. Control group 
(rAAV-eGFP, n = 12); treatment group (rAAV-11βHSD1, n = 12). 
 
4.4.2.3 Animal surgery 
Animal surgery was performed as described in section 3.4.2.3.  
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4.4.2.4 Cumulative food intake and bodyweight change 
Food intake and bodyweight were measured three times per week (between 09.00 -
11.00AM). Cumulative energy intake (kilocalories) was calculated as the product of 
cumulative food weight (grams) and energy value of the RM1 diet (3.523 kcal/g).  
 
4.4.2.5 Collection of tissue samples  
At 82 days post injection, animals were killed by carbon dioxide asphyxiation in the early 
light phase. Brains were rapidly removed and hypothalami isolated, which were subsequently 
snap-frozen in liquid nitrogen and stored at -80°C until RT-qPCR analysis. Blood was taken 
by cardiac puncture and collected into heparinised or EDTA-chelated tubes containing 
aprotinin 2000 KIU/tube (Bayer), and immediately placed on ice. Plasma was separated by 
centrifugation, immediately frozen and stored at -80°C until radioimmunoassay (RIA) 
analysis. Epididymal fat pads were dissected and weighed. Interscapular BAT was dissected, 
weighed, frozen in liquid nitrogen and stored at -80°C until RNA extraction.  
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4.4.3 Effect of rAAV-11βHSD1 bilaterally injected into the arcuate nucleus on a 
high-fat diet (HFD cohort) 
4.4.3.1 Animals 
Male Wistar rats weighing 220-230 g (specific pathogen free, Charles River UK Ltd, 
Margate, Kent, UK) were individually housed in open top polypropylene cages under a 
controlled environment (temperature 21-23°C, 12 hour light-dark cycle, lights on at 
07:00AM) with ad libitum access to food (D12451 diet, 45 kcal% fat, Research Diets, New 
Brunswick, NJ) and water. All animal procedures were approved under the British Home 
Office Animals (Scientific Procedures) Act 1986 (Project licence number 40/3327). Animals 
were acclimatised to these conditions for two weeks prior to surgery.  
 
Animals in the HFD cohort were housed in a different animal house to the animals in the NC 
cohort (section 4.4.2.1). An attempt was made to minimise variables between the animal 
houses, but the differing environments may have had an effect on the results of the studies. 
 
4.4.3.2 Animal allocation 
Animals were allocated into two weight matched treatment groups (matched on median 
bodyweight) as outlined in Table 4.03. 
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Group Treatment n 
Control group 
(rAAV-eGFP) 
rAAV-eGFP 12 
Treatment group 
(rAAV-11βHSD1) 
rAAV-11βHSD1 12 
 
Table 4.03 Allocation of male Wistar rats into experimental groups. Control group 
(rAAV-eGFP, n = 12) and treatment group (rAAV-11βHSD1, n = 12). 
 
4.4.3.3 Animal surgery 
Animal surgery was performed as described in section 3.4.2.3.  
 
4.4.3.4 Cumulative food intake and bodyweight change  
Food and bodyweight were measured daily at 08.00AM. Prior to recording these 
measurements, animals were handled in order to reduce the effects of stress from the 
necessary handling immediately prior to their decapitation. Cumulative energy intake 
(kilocalories) was calculated as the product of cumulative food weight (grams) and energy 
value of the D12451 diet (4.730 kcal/g). 
 
4.4.3.5 Collection of tissue samples  
At 112 days post injection animals were killed by decapitation in the early light phase. Blood 
was collected into heparinised or EDTA-chelated tubes containing aprotinin 2000 KIU/tube 
(Bayer), and immediately placed on ice. Plasma was separated by centrifugation, immediately 
frozen and stored at -80°C until RIA analysis. Carcasses were stored at -20°C until body 
composition analysis. 
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4.4.3.6 Cortisone administration: to assess acute food intake (two-part crossover 
study) 
Animals from groups rAAV-eGFP and rAAV-11βHSD1 were randomly allocated into one of 
two new subgroups (groups A and B). At 83 days post injection, group A were injected with 
saline (0.9 % sodium chloride, i.p., 3ml/kg) and group B were injected with cortisone 
(10 mg/kg, i.p., 3 ml/kg). Animals were returned to their home cage with ad libitum access to 
water and food. Food was weighed 0, 1, 2, 4, 8 and 24 hours post injection. Bodyweight and 
water were also weighed at 0 and 24 hours. At the end of the study period, animals were 
permitted a 1 week washout period before the experiment was repeated with groups being 
crossed over. 
 
At 91 days post injection animals were reassigned to groups A and B, and crossed over, such 
that group A were injected with cortisone (10 mg/kg, i.p., 3 ml/kg) and group B injected with 
saline (0.9 % sodium chloride, i.p., 3ml/kg). Food intake was assessed in the same way as the 
first part of the experiment. At the end of the study animals were re-assigned to their original 
groups. 
 
4.4.3.7 Cortisone administration: to assess glucocorticoid metabolism 
Animals from groups rAAV-eGFP and rAAV-11βHSD1 were injected with cortisone 
(10 mg/kg, i.p., 3 ml/kg) in the early light phase consecutively for 4 days prior to termination 
(days 108-112). Cortisone metabolism was assessed by assaying terminal blood samples for 
cortisol (which is not produced endogenously in rodents). 
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4.4.3.8 Body composition analysis (Dickinson et al., 2001) 
Frozen carcasses were stored at -20˚C until required. Carcasses were cooled in liquid nitrogen 
and milled using a Fritsch Pulverisette 15 Laboratory cutting mill pre-cooled using dry ice. 
Milled carcasses were thoroughly mixed and transferred to plastic vials. Samples were 
allowed to reach room temperature before measuring water, fat and protein content using a 
Foodscan Near Infrared (NIR) analyser (FOSS, Cheshire, U.K.) according to the 
manufacturer’s protocol. The Foodscan method of body composition was validated for use 
against chemical methods (appendix IV). 
 
4.4.4 Radioimmunoassay 
Radioimmunoassay was used to quantify circulating corticosterone. This was performed as 
described in section 3.4.4. 
 
4.4.4.1 Immuno-radiometric assay of plasma adrenocorticotropic hormone 
Plasma ACTH concentration was measured in duplicate by a two site immune-radiometric 
assay (IRMA). The assay is based on the simultaneous addition of 125Iodine labelled sheep 
antihuman ACTH peptide immunoglobulin G antibody and rabbit antihuman ACTH peptide 
antiserum to standards and unknowns, followed by incubation at room temperature for 
18 hours (Euro Diagnostica, The Netherlands). Antibodies for ACTH tested negative for 
cross-reactivity with similar peptides. Unbound fractions were decanted and the tubes 
counted. Sample concentrations were calculated against a non-linear standard curve 
(SlideWrite, Advanced Graphics Software, Inc., USA). 
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4.4.4.2 Quantification of hypothalamic mRNA by real time quantitative-PCR 
Real time-quantitative PCR (RT-qPCR) was used to analyse the expression of a range of 
mRNA sequences in dissected hypothalami. This was performed as described in section 
3.4.4.2 
 
4.4.4.3 Quantification of uncoupling protein-1 mRNA expression in brown adipose 
tissue by northern blot 
Northern blot analysis was used to analyse the size and quantity of uncoupling protein-1 
(UCP-1) RNA in brown adipose tissue (BAT). This was performed as described in section 
3.4.4.3. 
 
4.4.4.4 Statistical analysis 
Data are presented as arithmetic means ± standard error of mean (SEM). Differences in 
bodyweight and cumulative food intake were analysed using a generalised estimating 
equation (GEE) for repeated measures (Stata, StataCorp LP, USA). The GEE was performed 
with an exchangeable working correlation structure. This model assumes that all pairs of 
times for the same animals are equally correlated. Group differences in RIA and ELISA 
results were analysed using unpaired Student’s t-test, and differences in response to cortisone 
administration were analysed using a 2-way repeated measures ANOVA. Differences were 
considered statistically significant at the 95 % confidence level (P<0.05). Data analysis was 
performed using Graphpad Prism 4 software and Stata 9.  
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4.5 Results  
4.5.1 Recombinant adeno-associated virus mediated gene transfer of 11βHSD1 into 
the hypothalamic arcuate nucleus of rats fed a regular chow diet (NC cohort) 
4.5.1.1 Effect of bilateral arcuate injection of rAAV-11βHSD1 on bodyweight, 
bodyweight gain, and food intake  
At the start of the study (day 7) there was no difference in bodyweight between the two 
groups (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 299.55 ± 4.64 vs. 308.75 ± 3.81, 
n.s.). Over the course of the study, animals injected with rAAV-11βHSD1 displayed 
increased bodyweight, seen as a significant longitudinal trend, P<0.05 (Figure 4.01). By the 
end of the study (day 82) bodyweight was significantly higher in rAAV-11βHSD1 animals 
(Figure 4.02) (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 527.55 ± 10.53 vs. 
559.67 ± 10.14, P<0.05). Correspondingly, bodyweight gain was increased in animals 
injected with rAAV-11βHSD1, although this longitudinal increase did not reach statistical 
significance (Figure 4.03). At the end of the study (day 82) total bodyweight gain was higher 
in rAAV-11βHSD1 animals (Figure 4.04) but this increase did not reach statistical 
significance (total bodyweight gain (g): rAAV-eGFP vs. rAAV-11βHSD1 : 228.00 ± 10.03 
vs. 250.91 ± 10.42, n.s.). 
 
Cumulative food intake was increased in animals injected with rAAV-11βHSD1, seen as a 
significant longitudinal trend over the study period, P<0.01 (Figure 4.05). Thus, cumulative 
energy intake was also significantly increased over the study period in animals injected with 
rAAV-11βHSD1, P<0.01 (Figure 4.07). At the end of the study (day 82) total food intake, 
and total energy intake, were significantly increased in rAAV-11βHSD1 animals 
(Figures 4.06 and 4.08 respectively) (total food intake (g): rAAV-eGFP vs. rAAV-11βHSD1 
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: 2347.86 ± 32.33 vs. 2489.61 ± 38.52, P<0.05; total energy intake (kcal): rAAV-eGFP vs. 
rAAV-11βHSD1 : 8271.52 ± 113.89 vs. 8770.92 ± 135.72, P<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
190 
 
7 14 21 28 35 42 49 56 63 70 77 84
300
400
500
600
*
Days Post Injection
Bo
dy
w
ei
gh
t (
g)
 
Figure 4.01 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on bodyweight in 
male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either 
rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12) and 
bodyweight measured for 82 days post injection. Values shown as grams mean ± SEM. 
* = P<0.05 by generalised estimating equation.  
 
rAAV-eGFP rAAV-11 βHSD1
0
200
400
600 *
Fi
na
l B
od
yw
ei
gh
t (
g)
 
Figure 4.02 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on final 
bodyweight in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and terminated on day 82 post 
injection. Values shown as grams mean ± SEM. * = P<0.05 by unpaired Student’s t-test. 
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Figure 4.03 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
bodyweight gain in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12) 
and bodyweight gain measured for 82 days post injection. Values shown as grams mean 
± SEM. Non-significant by generalised estimating equation.  
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Figure 4.04 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total 
bodyweight gain in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and terminated on day 82 
post injection. Values shown as grams mean ± SEM. Non-significant by unpaired Student’s 
t-test. 
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Figure 4.05 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
food intake in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12) and 
cumulative food intake measured for 82 days post injection. Values shown as grams 
mean ± SEM. ** = P<0.01 by generalised estimating equation.  
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Figure 4.06 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total food 
intake in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and terminated on day 82 post 
injection. Values shown as grams mean ± SEM. * = P<0.05 by unpaired Student’s t-test. 
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Figure 4.07 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
energy intake in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (green circles; n = 11) or rAAV-11βHSD1 (blue circles; n = 12) 
and energy intake measured for 82 days post injection. Values shown as kcal mean ± SEM. 
** = P<0.01 by generalised estimating equation.  
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Figure 4.08 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total energy 
intake in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and terminated on day 82 post 
injection. Values shown as kcal mean ± SEM. * = P<0.05 by unpaired Student’s t-test. 
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4.5.1.2 Effect of bilateral arcuate injection of rAAV-11βHSD1 on plasma hormones, 
hypothalamic neuropeptide expression, fat pad weight and UCP-1 expression 
There was no difference in plasma ACTH or corticosterone concentration between the two 
groups (Figures 4.09 and 4.10 respectively) (ACTH (pg/ml): rAAV-eGFP vs. 
rAAV-11βHSD1 : 1085.86 ± 83.80 vs. 993.48 ± 106.25, n.s.; corticosterone (ng/ml): 
rAAV-eGFP vs. rAAV-11βHSD1 : 57.60 ± 17.70 vs. 51.70 ± 9.05, n.s.). 
 
There was no difference in hypothalamic expression of NPY, AgRP or POMC mRNA 
between the two groups (Figure 4.11) (hypothalamic mRNA relative expression: 
rAAV-eGFP vs. rAAV-11βHSD1 : NPY 1.00 ± 0.10 vs. 0.86 ± 0.05 : AgRP 1.00 ± 0.12 vs. 
0.81 ± 0.09 : POMC 1.00 ± 0.08 vs. 0.99 ± 0.12, n.s). Hypothalamic expression of CART 
mRNA was significantly reduced in rAAV-11βHSD1 treated animals compared to controls 
(hypothalamic mRNA relative expression: rAAV-eGFP vs. rAAV-11βHSD1 : CART 
1.00 ± 0.09, vs. 0.73 ± 0.07, P<0.05). 
 
The weight of epididymal adipose tissue was significantly increased in rAAV-11βHSD1 
treated animals compared to controls (Figure 4.12) (WAT weight (g): rAAV-eGFP vs. 
rAAV-11βHSD1 : 8.47 ± 0.52 vs. 10.08 ± 0.53, P<0.05). The weight of interscapular BAT 
was increased in rAAV-11βHSD1 treated animals compared to controls (Figure 4.13), 
although this did not reach statistical significance (BAT weight (mg/g bodyweight): 
rAAV-eGFP vs. rAAV-11βHSD1 : 1.15 ± 0.09 vs. 1.30 ± 0.10, n.s.). However, there was no 
difference in BAT UCP-1 mRNA expression between the two groups (Figure 4.14) (BAT 
UCP-1 mRNA relative optical density (arbitrary units): rAAV-eGFP vs. rAAV-11βHSD1 : 
11.08 ±1.07 vs. 11.51±0.79, n.s.). 
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Figure 4.09 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on plasma ACTH 
in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either 
rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and ACTH measured from trunk blood by 
IRMA following termination on day 82. Values shown as pg/ml mean ± SEM. Non-
significant by unpaired Student’s t-test. 
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Figure 4.10 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on plasma 
corticosterone in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and corticosterone measured 
from trunk blood by RIA following termination on day 82. Values shown as ng/ml mean ± 
SEM. Non-significant by unpaired Student’s t-test. 
 
196 
 
NPY AgRP POMC CART
0.0
0.5
1.0
1.5
*
Re
la
tiv
e 
Ex
pr
es
si
on
 
Figure 4.11 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on hypothalamic 
mRNA in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and hypothalami collected, mRNA 
extracted and quantified by RT-qPCR following termination on day 82. Values shown as 
relative expression ± SEM. * = P<0.05 by unpaired Student’s t-test. 
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Figure 4.12 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on epididymal 
WAT weight in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and WAT collected and weighed 
following termination on day 82. Values shown as grams mean ± SEM. * = P<0.05 by 
unpaired Student’s t-test. 
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Figure 4.13 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on BAT weight in 
male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either 
rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and BAT collected and weighed following 
termination on day 82. Values shown as mg/g bodyweight mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
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Figure 4.14 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on UCP-1 mRNA 
expression in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 11) or rAAV-11βHSD1 (n = 12) and interscapular BAT collected, 
UCP-1 mRNA extracted and quantified following termination on day 82. Values shown as 
relative optical density to oligo dT (arbitrary units) mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
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4.5.2 Recombinant adeno-associated virus mediated gene transfer of 11βHSD1 into 
the hypothalamic arcuate nucleus of rats fed a high-fat diet (HFD cohort) 
4.5.2.1 Effect of bilateral arcuate injection of rAAV-11βHSD1 on bodyweight, 
bodyweight gain, and food intake  
At the start of the study (day 7) there was no difference in bodyweight between the two 
groups (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 291.43 ± 5.79 vs. 293.07 ± 4.71, 
n.s.). Over the course of the study, there was no change in bodyweight or bodyweight gain 
between the two groups (Figures 4.15 and 4.17 respectively). At the end of the study (day 
112) bodyweight and bodyweight gain remained unchanged (Figures 4.16 and 4.18 
respectively). 
 
Cumulative food intake was unchanged between the two groups over the course of the study 
(Figure 4.19). Therefore, cumulative energy intake was also unchanged between the two 
groups (Figure 4.21). At the end of the study (day 112) total food intake was unchanged 
between the two groups (Figures 4.20) (total food intake (g): rAAV-eGFP vs. 
rAAV-11βHSD1 : 2366.81 ± 53.21 vs. 2371.37 ± 34.06, n.s.). Total energy intake was also 
unchanged at the end of the study (total energy intake (kcal): rAAV-eGFP vs. 
rAAV-11βHSD1 : 11195.01 ± 251.72 vs. 11216.58 ± 161.12, n.s.). For comparison with the 
NC cohort, total energy intake is displayed at day 82 of the study (Figure 4.22).   
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Figure 4.15 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on bodyweight in 
male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of either rAAV-eGFP 
(green circles; n = 10) or rAAV-11βHSD1 (blue circles; n = 10) and bodyweight measured 
for 112 days post injection. Values shown as grams mean ± SEM. Non-significant by 
generalised estimating equation.  
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Figure 4.16 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on final 
bodyweight in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and bodyweight measured for 
112 days post injection. Values shown as grams mean ± SEM. Non-significant by unpaired 
Student’s t-test. 
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Figure 4.17 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
bodyweight gain in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl 
of either rAAV-eGFP (green circles; n = 10) or rAAV-11βHSD1 (blue circles; n = 10) and 
bodyweight gain measured for 112 days post injection. Values shown as grams mean ± SEM. 
Non-significant by generalised estimating equation.  
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Figure 4.18 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total 
bodyweight gain in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and bodyweight gain measured 
for 112 days post injection. Values shown as grams mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
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Figure 4.19 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
food intake in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (green circles; n = 10) or rAAV-11βHSD1 (blue circles; n = 10) and 
bodyweight gain measured for 112 days post injection. Values shown as grams mean ± SEM. 
Non-significant by generalised estimating equation.  
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Figure 4.20 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total food 
intake in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of either 
rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and food intake measured for 112 days 
post injection. Values shown as grams mean ± SEM. Non-significant by unpaired Student’s t-
test. 
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Figure 4.21 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on cumulative 
energy intake in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (green circles; n = 10) or rAAV-11βHSD1 (blue circles; n = 10) and 
energy intake measured for 112 days post injection. Values shown as kcal mean ± SEM. 
Non-significant by generalised estimating equation.  
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Figure 4.22 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on total energy 
intake in male Wistar rats fed a high-fat diet after 82 days. Animals were injected with 
1 µl of either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and energy intake measured 
for 112 days post injection. Values shown as grams mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
 
 
203 
 
4.5.2.2 Effect of bilateral arcuate injection of rAAV-11βHSD1 on acute food intake 
when administered with cortisone 
Peripherally administered cortisone significantly reduced 24 hour food intake in both 
rAAV-11βHSD1 treated animals and rAAV-eGFP treated control animals (Figure 4.23) 
(24 hour food intake (g): cortisone rAAV-eGFP vs. rAAV-11βHSD1 : 20.12 ± 1.16 vs. 
19.79 ± 1.17; saline rAAV-eGFP vs. rAAV-11βHSD1 : 21.78 ± 0.99 vs. 21.47 ± 1.02, 
P<0.01). Food intake at 0-2 hours, 0-4 hours and 0-8 hours was unaffected by cortisone 
administration. 
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Figure 4.23 Effect of cortisone on food intake after bilateral intra-ARC injection of 
rAAV-11βHSD1 in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10). 83 days post injection, animals 
were subjected to a two part randomised cross-over study (with a one week wash out period) 
and injected with either saline (0.9 % sodium chloride, i.p., 3ml/kg) or cortisone (10 mg/kg, 
i.p., 3 ml/kg) after which food intake was measured 0, 1, 2, 4, 8 and 24 hours post injection. 
Values shown as grams mean ± SEM. ** = P<0.01 by two way repeated measures ANOVA 
with Bonferroni post hoc test. 
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4.5.2.3 Effect of bilateral arcuate injection of rAAV-11βHSD1 on glucocorticoid 
metabolism 
Cortisone was administered peripherally to assess glucocorticoid metabolism by measuring 
cortisol production (a hormone that is not endogenously produced in rodents). There was no 
change in cortisol production between rAAV-11βHSD1 treated animals and rAAV-eGFP 
treated control animals (Figure 4.24).  
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Figure 4.24 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on glucocorticoid 
metabolism in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10). 109 days post injection, animals 
were subjected to a 4 day study and injected in the early light phase daily with cortisone 
(10 mg/kg, i.p., 3 ml/kg). Cortisol production was measured by ELISA following termination 
on day 112. Values shown as pg/ml mean ± SEM. Non-significant by unpaired Student’s t-
test. 
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4.5.2.4 Effect of bilateral arcuate injection of rAAV-11βHSD1 on plasma 
corticosterone and body composition  
There was no difference in plasma corticosterone concentration between the groups (Figure 
4.25) (corticosterone (ng/ml): rAAV-eGFP vs. rAAV-11βHSD1: 19.9 ± 6.48 vs. 23.1 ± 9.51, 
n.s.). Further, there was no difference in body composition (measured by foodscan) between 
the two groups (Figure 4.26) (body composition (%): rAAV-eGFP vs. rAAV-11βHSD1 : 
water 55.44 ± 0.92 vs. 54.75 ± 1.20, n.s.; fat 21.87 ± 1.27 vs. 23.06 ± 1.49, n.s.; protein 
18.14 ± 0.41 vs. 17.89 ± 0.45, n.s.).  
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Figure 4.25 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on plasma 
corticosterone in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and corticosterone measured from 
trunk blood plasma by RIA following termination on day 112. Values shown as ng/ml mean 
± SEM. Non-significant by unpaired Student’s t-test. 
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Figure 4.26 Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on body 
composition in male Wistar rats fed a high-fat diet. Animals were injected with 1 µl of 
either rAAV-eGFP (n = 10) or rAAV-11βHSD1 (n = 10) and carcass body composition 
measured by foodscan following termination on day 112. Values shown as percentage of total 
carcass mean ± SEM. Non-significant by unpaired Student’s t-test. 
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4.6 Discussion 
Injection of rAAV-11βHSD1 into the ARC resulted in a significant increase in cumulative 
food intake and bodyweight when animals were fed a regular chow diet (NC cohort). This 
agrees with previous studies that implicate central GC in the regulation of energy 
homeostasis (Zakrzewska et al., 1999a, Cusin et al., 2001, Asensio et al., 2004). Interestingly, 
the effects of central GCs on bodyweight and food intake were lost when the study was 
repeated using a high-fat diet (HFD cohort).  
 
The production and quantification of both rAAV-eGFP and rAAV-11βHSD1 was detailed in 
chapters 2 and 3. The coordinates chosen for stereotaxic rAAV injection into the ARC were 
confirmed by ink injection (appendix II). In addition, in situ hybridisation confirmed 
successful and sustained delivery of the rAAV transgene cassette (Figure 3.05). 
Unfortunately, it is not possible to localise the injection site in every animal as brain tissue is 
used for a multitude of experiments. For instance, brain tissue in chapter 4 was used for 
RT-qPCR analysis. Hence, the coordinates chosen for stereotaxic injection into the ARC 
were confirmed by in situ hybridisation in chapter 3, but were not confirmed in Chapter 4. 
Ideally, all experiments would contain a sentinel group that would permit in situ hybridisation 
to be performed on at least some of the animals in each group, however cost limitations 
prevented this. Quantitative-PCR analysis detected significantly increased expression of 
11βHSD1 mRNA in the hypothalamus (Figure 3.06A). Finally, levels of corticosterone in the 
ARC were significantly increased in rAAV-11βHSD1 treated animals compared to controls 
injected with rAAV-eGFP (Figure 3.08A). Taken together, this data suggests that injection of 
rAAV-11βHSD1 using the chosen coordinates, resulted in increased GC levels in the ARC. 
For this reason, it is probable that successful gene delivery was achieved in the studies 
detailed in this chapter as well.  
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Animals injected with rAAV-11βHSD1 in the NC cohort displayed a significant increase in 
cumulative food intake, which is presumably responsible for the observed increase in 
bodyweight. Therefore, it seems that increased GC concentration in the ARC resulted in an 
increase in appetite and consequently food intake; however, there are other factors for 
consideration. For instance, rAAV-11βHSD1 treated animals displayed a slight increase in 
BAT weight when compared to the rAAV-eGFP control group. BAT is the site of 
thermoregulation in rodents and contains UCP-1. Uncoupling protein-1 is located in the inner 
mitochondrial membrane, where it permits proton flow across the mitochondrial membrane, 
down the electrochemical gradient, dissipating stored energy as heat. UCP-1 is a surrogate 
marker for thermogenesis (Margareto et al., 2001), thus an increase in BAT weight might 
imply that rAAV-11βHSD1 treated animals exhibited increased energy expenditure. Indeed, 
intracerebroventricular (ICV) infusion of GC has been shown to decrease expression of 
UCP-1 in BAT (Zakrzewska et al., 1999a). However, levels of UCP-1 mRNA in BAT were 
unchanged; therefore, levels of thermogenesis are likely to be unchanged between the two 
groups in this study. For this reason, the observed increase in bodyweight was likely to be the 
result of increased food intake rather than reduced energy expenditure. Measurement of UCP-
1 mRNA expression in BAT is, at best, a very loose indicator of energy expenditure and 
alternative methods for the assessment of energy expenditure should be considered in future 
experiments. The increase in BAT weight was likely due to infiltration of WAT with the 
dissected BAT as a result of increased body fat content. Indeed, rAAV-11βHSD1 treated 
animals displayed a significant increase in epididymal WAT weight compared to the 
rAAV-eGFP controls, suggesting that the increased bodyweight of the rAAV-11βHSD1 
treated animals was the result of increased body fat. Epididymal fat pads can be quickly 
dissected, hence their selection as a surrogate measure of body fat; however, they are not 
necessarily the most sensitive fat pad to changes in body fat and as such are not an ideal 
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candidate to reflect body fat. A more reliable method of assessing body fat would be to 
analyse whole body composition, which was performed in the HFD cohort. 
 
A logical assertion for the observed hyperphagia, and resultant increase in bodyweight in the 
rAAV-11βHSD1 treated animals, could be the altered release of neuropeptides from the 
hypothalamic circuitry involved in food intake. In particular, the increased food intake in 
these animals could be attributed to a GC mediated change in ARC NPY physiology. 
Immunohistochemistry (IHC) has confirmed a high density of GRs colocalised with NPY 
neurons (Harfstrand et al., 1989, la Fleur, 2006, Hisano et al., 1988). Therefore, a direct 
regulation of NPY release by GCs is possible. Also, glucocorticoid response elements 
(GREs) have been identified upstream of the rat NPY gene (Misaki et al., 1992). ICV 
infusion of GCs results in increased NPY peptide levels and decreased CRH release 
(Zakrzewska et al., 1999a) and central administration of GCs increases arcuate NPY and 
AgRP mRNA expression (Shimizu et al., 2008). Conversely, the removal of circulating GCs 
in vivo by ADX causes a decrease in NPY mRNA in the ARC (Strack et al., 1995, Hanson et 
al., 1997), whilst replacement of circulating GCs restores neuropeptide levels (Strack et al., 
1995). Collectively, these studies suggest that central administration of GCs favours anabolic 
processes by acting on the parasympathetic nervous system and that these effects are 
mediated by increased hypothalamic NPY. Indeed, NPY is thought to exert peripheral effects 
by activation of the parasympathetic nervous system (Zakrzewska et al., 1999b). In addition, 
ADX rats appear to be resistant to the obesity-like effects associated with ICV NPY 
administration (Zakrzewska et al., 1999b), thus adding support to the theory that GCs are 
critical to stimulate NPY. GCs are thought to increase arcuate NPY mRNA expression via 
stimulation of hypothalamic adenosine monophosphate-activated protein kinase (AMPK) 
signalling (Shimizu et al., 2008) and inhibition of hypothalamic mammalian target of 
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rapamycin (mTOR) signalling (Shimizu et al., 2010). There are several studies demonstrating 
that GCs inhibit mTOR signalling in peripheral tissues (Otulakowski et al., 2007, Wang et al., 
2006) and hypothalamic AMPK is thought of as a master regulator of energy homeostasis 
(Minokoshi et al., 2004). Additionally, recent studies suggest there is a highly regulated 
crosstalk between mTOR and AMPK signalling in the hypothalamus (Cota et al., 2007). 
Interestingly, in the NC cohort of the present study, RT-qPCR analysis of hypothalamic 
neuropeptides revealed that mRNA expression of the orexigenic neuropeptides NPY and 
AgRP remained unchanged when compared to controls. As discussed in chapter 3, a lack of 
change in mRNA expression does not necessarily preclude these neuropeptides from 
involvement. For instance, neuropeptides such as NPY are stored in abundance, therefore an 
increase in neuronal firing may not require an increase in neuropeptide transcription. For this 
reason, the fact that NPY mRNA was not increased in these animals, does not necessarily 
mean that NPY peptide release was unchanged. Additionally, receptor expression and 
sensitivity were not measured in this study which again could have an effect on arcuate 
activity. Additionally, mRNA analysis in this study measured levels in the entire 
hypothalamus, rather than in specific nuclei. It is possible therefore, that changes in arcuate 
mRNA were masked by measuring changes in the entire hypothalamus. Had the changes 
been measured specifically in the ARC, the results may well have been different, and this is 
something that should be considered in future studies. Additionally, no attempt was made to 
measure AMPK or mTOR activity in these studies, which would have helped to elucidate a 
mechanism for hyperphagia observed in these animals. 
 
It has been proposed that GCs affect appetite by acting on ARC neurons to alter the release of 
α-MSH, a MC4R agonist and POMC cleavage product (Drazen et al., 2003). The levels of 
endogenous ligands for the MC4R could alter the ability of exogenous compounds to bind 
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and alter the activity of MC4R signalling. Also, POMC is downregulated in the medial basal 
hypothalamus (MBH) by ADX, in opposition to the well-known upregulation of POMC by 
ADX in the anterior pituitary (Savontaus et al., 2002). In addition, GREs have been identified 
in the POMC gene. However, RT-qPCR analysis of hypothalamic neuropeptides revealed 
that mRNA expression of the anorexigenic neuropeptide POMC was unchanged, although 
MC4R activity could be upregulated without significant changes in gene expression. 
 
The expression of the neuropeptide CART was significantly reduced in rAAV-11βHSD1 
treated animals as detected by RT-qPCR. The role of CART in the regulation of energy 
balance is unclear. ICV administration of CART decreases food intake in satiated and fasted 
rats (Kristensen et al., 1998). However, injection of CART into the ARC (amongst other 
discrete hypothalamic nuclei) produces orexigenic effects (Abbott et al., 2001). Circulating 
CART peptide concentrations exhibit a diurnal rhythm that positively correlates with 
circulating corticosterone in rats (Stulnig and Waldhausl, 2004). Conversely, ADX decreases 
the number of CART-immunoreactive neurons in the ARC and PVN of rats (White et al., 
1990, Cowley, 2003, Landry et al., 2003) and levels are restored after GC replacement, 
indicating that GCs are responsible for the decrease. Hence, the reduction of CART mRNA is 
a potential mechanism for the increase in food intake seen in the rAAV-11βHSD1 treated 
animals. However, due to lack of consensus in the literature, a reduction in CART mRNA 
remains a questionable mechanism for the increase in food intake seen in this study. 
 
Similarly to the results observed in chapter 3, it is possible that some, or all, of the effects on 
food intake and bodyweight seen in the NC cohort, are the result of changes in the HPA axis, 
induced by altered central GC levels. For this reason, effects on the HPA axis were assessed 
in this study by measuring the circulating levels of both ACTH and corticosterone. 
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Unfortunately, animals in the NC cohort were terminated by carbon dioxide asphyxiation, 
meaning that these animals were exposed to prolonged stress at the time of death. This is 
reflected by the terminal plasma ACTH levels, which are much higher than might be 
expected had the animals been killed by decapitation (Vahl et al., 2005). Importantly, there 
was no difference between the plasma corticosterone levels of the rAAV-eGFP and rAAV-
11βHSD1 for the NC cohort, implying that the observed phenotype was not the result of 
altered HPA axis activity. 
 
The effects of rAAV-11βHSD1 observed in the NC cohort are fairly convincing; with rAAV-
11βHSD1 treated animals having eaten almost 6 % more than control animals by the end of 
the 82 day study, resulting in a 6 % increase in bodyweight and a 9 % increase in bodyweight 
gain. This study was repeated to investigate whether exposure to a high-fat diet would 
exacerbate the rAAV-11βHSD1 phenotype, as high-fat diets are associated with increased 
body fat, hypertriglyceridemia, hyperinsulinemia and insulin resistance. Surprisingly, use of a 
high-fat diet completely extinguished the previous rAAV-11βHSD1 phenotype, with no 
changes observed in food intake or bodyweight between the rAAV-11βHSD1 treated animals 
and controls. Additionally, body composition was analysed which showed no difference in 
fat, protein or water content between the two groups. 
 
There is substantial variation in the dietary composition of high-fat rodent diets available for 
purchase; hence careful selection of diet for this study was important. Typically, high-fat 
diets used in research range from 32 – 60 % of kcal from fat. The D12451 diet (Research 
Diets) selected for use in this study was chosen because it consists of 45 kcal% as fat. Diets 
higher than this in fat, for example the D12492 diet (Research Diets) which consists of 
60 kcal% as fat, are usually selected to induce obesity in rodents more quickly. However, a 
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diet with 60 kcal% as fat is extreme, therefore in this study a diet with 45 kcal% as fat was 
chosen as it is more reflective of a Western diet.  
 
The rAAV-11βHSD1 treated animals of the NC cohort were hyperphagic, and at the end of 
the study (day 82), rAAV-11βHSD1 treated animals had consumed significantly more 
calories than the rAAV-eGFP controls. In comparison, the rAAV-11βHSD1 treated animals 
in the HFD cohort were normophagic. Resultantly at day 82 in the HFD cohort, there was no 
significant difference in caloric intake between the rAAV-11βHSD1 and rAAV-eGFP treated 
groups. Total caloric intake consumed by day 82 for both rAAV-11βHSD1 treated and 
control animals in the HFD cohort, was roughly equivalent to the total calories consumed by 
the control animals in the NC cohort. The lack of change in caloric intake between the control 
groups of the NC and HFD cohorts is not surprising, as calorie intake is a highly regulated 
process; however, it appears that the high-fat diet attenuated the hyperphagic effects of 
rAAV-11βHSD1. Consequently there was no difference in bodyweight between the two 
groups in the HFD cohort. Effects of rAAV-11βHSD1 on food intake in the HFD cohort were 
further investigated by assessing the effects of peripherally administered GC on acute food 
intake. As expected, food intake was significantly reduced in both groups of animals in the 
HFD cohort over a 24 hour period. However, there was no difference in acute food intake 
between the two groups at any timepoint, thereby adding further strength to the argument that 
rAAV-11βHSD1 has no effect on food intake on a high-fat diet. 
 
Diets high in fat are known to affect HPA axis activity by elevating adrenal GC production 
(Brindley et al., 1981). Raised circulating GCs stimulate hepatic secretion of triglycerides 
(Bartlett et al., 1998) and decrease levels of lipoprotein lipase, thereby exaggerating 
hypertriglyceridemia (Taylor and Agius, 1988). Additionally, GCs increase the breakdown of 
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protein, glycogen and triacylglycerol hence promoting gluconeogenesis. In this study, plasma 
corticosterone levels were measured on termination as a surrogate measure of HPA axis 
activity. There was no difference in plasma corticosterone levels between the rAAV-eGFP 
and rAAV-11βHSD1 treated animals for the HFD cohort, implying that HPA axis activity 
was unaffected by rAAV-11βHSD1. Interestingly, circulating corticosterone levels, for both 
rAAV-eGFP and rAAV-11βHSD1 treated animals, were lower in the HFD cohort than the 
NC cohort. It is plausible that increased stress at the time of death in the NC cohort, due to 
carbon dioxide asphyxiation, induced an increase in ACTH levels which subsequently 
promoted increased release of corticosterone from the adrenal glands. However, this is 
unlikely as the time taken for carbon dioxide asphyxiation is almost certainly too short to 
provoke a change in plasma corticosterone. Additionally, one would expect to see a much 
higher release of corticosterone as a result of increased stress. More likely is that, rather than 
corticosterone levels being raised in the NC cohort, corticosterone levels were reduced in the 
HFD cohort. Peripheral cortisone administration during the final 4 days of the experiment 
may have suppressed endogenous corticosterone production, hence resulting in reduced 
plasma corticosterone concentration on termination.  
 
Corticosterone is the endpoint hormone of the HPA axis, thus measuring circulating levels 
offers a partial, but incomplete, assessment of HPA axis activity. Additionally, corticosterone 
exhibits a circadian rhythm, meaning that levels are affected by the time of day at which the 
blood was collected. For these reasons, it is sensible not to over-interpret plasma 
corticosterone levels as an accurate measurement of HPA axis activity. To further investigate 
HPA axis activity, animals in the HFD cohort were peripherally injected for 4 days with the 
inactive GC, cortisone; a hormone not endogenously synthesised in rodents. GC turnover was 
assessed by measuring the active GC cortisol (again a hormone not endogenously synthesised 
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in rodents). There was no difference in plasma cortisol measured after termination, implying 
that there was no change in peripheral GC metabolism. This finding adds validity to the 
measurement of plasma corticosterone, further implying that increased central GC had 
limited or no effect on peripheral GC or HPA axis activity.  
 
A recent study suggests that high-fat diet causes ghrelin resistance in the ARC (Briggs et al., 
2010). Ghrelin is the only known peripheral orexigenic hormone. Ghrelin o-acyl-transferase 
(GOAT) acetylates ghrelin to produce the active form. Acylated ghrelin is an endogenous 
ligand for the growth hormone secretagogue receptor (GHSR) which is expressed throughout 
the hypothalamus. Within the ARC, GHSR is expressed on NPY and AgRP expressing 
neurons (Willesen et al., 1999) and binding of acylated ghrelin promotes NPY and AgRP 
mRNA expression and food intake (Chen et al., 2004). ICV or peripheral injection of ghrelin 
promotes food intake in regular chow fed mice, however this effect is lost in animals fed a 
high-fat diet (Briggs et al., 2010). High-fat diet is thought to suppress central ghrelin activity 
by reducing plasma ghrelin, decreasing ghrelin and GOAT mRNA in the stomach and 
decreasing expression of GHSR in the hypothalamus. By suppressing ghrelin activity in the 
hypothalamus, high-fat diet reduces NPY and AgRP mRNA expression in the ARC. 
However, ICV injection of NPY in high-fat fed animals promotes food intake, suggesting that 
downstream NPY neural targets remain intact (Briggs et al., 2010). If the hyperphagic effects 
observed in the rAAV-11βHSD1 group of the NC cohort were indeed the result of increased 
ARC NPY activity, then is possible that ghrelin resistance in ARC neurons, promoted by 
high-fat diet feeding, prevented an increase in NPY mRNA expression. This might explain 
why the rAAV-11βHSD1 group of the HFD cohort were normophagic, and the unchanged 
bodyweight between the two groups.  
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The hyperphagia observed in rAAV-11βHSD1 treated animals of the NC cohort may have 
been the result of hypothalamic resistance to peripheral anorexigenic signals such as leptin 
and insulin. Both leptin and insulin act on the ARC to alter the expression of neuropeptides 
NPY, AgRP, POMC, and CART. Loss of leptin or insulin signalling in the hypothalamus is 
known to induce obesity (Balthasar et al., 2004, Bruning et al., 2000). Certainly, ICV GC 
infusion results in hyperleptinemia and hyperinsulinemia (Zakrzewska et al., 1999a) and 
hyperphagia has been linked to leptin and insulin resistance (Wang et al., 2001). 
Additionally, high-fat diet feeding induces inflammatory signalling in the hypothalamus and 
promotes leptin and insulin resistance (De Souza et al., 2005, Moraes et al., 2009). Therefore 
it is possible that high-fat diet feeding in the HFD cohort altered leptin and insulin signally in 
the hypothalamus, thereby altering appetite and accounting for the extinguished phenotype in 
the HFD cohort. Unfortunately, circulating leptin and insulin levels were not assessed in this 
study and this is something that should be considered in future studies. 
 
The results from the NC cohort support the hypothesis that central GCs play a role in energy 
homeostasis. 11βHSD1 is endogenously expressed in the hypothalamus and it seems it may 
have an important role in the regulation of food intake. There is currently much interest in 
11βHSD1 as a potential peripheral therapeutic target for treating T2DM because of its role in 
glucose homeostasis. The results from the NC cohort in this study suggest that this enzyme 
might also have an important central role in energy homeostasis as well. The results from the 
HFD cohort are less straightforward to interpret and require further investigation.  
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5 Introduction 
5.1 Adaptive thermogenesis 
Adaptive thermogenesis is the production of heat energy, which can be used to maintain 
body-temperature during periods of low environmental-temperature, or to elevate body-
temperature during febrile response to infection (Lowell and Spiegelman, 2000). Skeletal 
muscle and brown adipose tissue (BAT) are the sites at which most thermogenic activity 
occurs in rodents; shivering-thermogenesis occurs in skeletal muscle during cold exposure, 
whilst non-shivering-thermogenesis occurs in BAT (Silva, 2006, Cannon and Nedergaard, 
2004).  
 
Non-shivering thermogenesis is regulated by CNS sympathetic innervation of BAT. Injection 
of viral tracer into BAT retrogradely labels neurons originating in, amongst other areas, the 
paraventricular nucleus (PVN) of the hypothalamus (Bamshad et al., 1999, Cano et al., 2003, 
Oldfield et al., 2002). The PVN is thought to mediate energy expenditure and thermogenesis 
by regulating sympathetic outflow to BAT. Non-shivering thermogenesis in BAT relies on 
the presence of uncoupling protein-1 (UCP-1), which is expressed at high levels in the inner 
mitochondrial membrane of BAT mitochondria; hence BAT mitochondria are the site of non-
shivering thermogenic heat production. UCP-1 uncouples the mitochondrial proton-gradient 
from adenosine triphosphate (ATP) synthesis, thus UCP-1 facilitates the leaking of protons 
across the mitochondrial membrane, down the proton gradient, without passing through 
ATPase, resulting in the production of energy which is dissipated as heat (Cannon and 
Nedergaard, 2004). Rodents that lack UCP-1 develop obesity on a normal chow diet in a 
thermoneutral environment (Feldmann et al., 2009). The role of BAT in humans is less clear. 
Metabolically active BAT has been identified in humans (Virtanen et al., 2009, Cypess et al., 
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2009, van Marken Lichtenbelt et al., 2009) however, whether it is as functionally relevant in 
humans, as it is in rodents, is still an area of much debate. 
 
5.2 The hypothalamic-pituitary-adrenal-axis and sympathetic outflow 
The PVN also regulates the hypothalamic-pituitary-adrenal (HPA) axis, partly by regulating 
sympathetic outflow. The PVN receives signalling from central stress circuits that regulate 
HPA axis activity, such as brainstem catecholamine-producing pathways, circumventricular 
organs, local hypothalamic regions and the bed nucleus of the stria terminalis (BST). 
Activation of the HPA axis, by an acute stressor, initiates the ‘fight or flight mechanism’, 
resulting in increased activation of the sympathetic nervous system and ultimately increased 
glucocorticoid (GC) secretion from the adrenal cortex, thus readying the body for action. The 
PVN mediates GC feedback and is therefore an area intimately involved in the regulation of 
the HPA axis. Indeed, lesions in the PVN markedly reduce stress-induced GC secretion 
(Makara, 1992).  
 
11β-hydroxysteroid dehydrogenase 1 (11βHSD1) plays a role in the regulation of the HPA 
axis, generating significant amounts of active GC from intracellular inactive GC in peripheral 
tissues such as the liver, adipose and muscle. Interestingly, most strains of animal with a 
global knockout of 11βHSD1 (11βHSD1-/-) are, for the most part, phenotypically normal. 
However, on some genetic backgrounds, 11βHSD1-/- results in abnormalities in the regulation 
of the HPA axis, with animals exhibiting high basal levels of corticosterone (Harris et al., 
2001). 11βHSD1 is also expressed in areas throughout the CNS and is highly expressed in 
PVN neurons (Sakai et al., 1992, Seckl, 1997), however the role of central 11βHSD1 in the 
HPA axis is, as yet, unclear. 
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5.3 Hypothesis and aims 
Evidence exists for a physiological role of GCs in the hypothalamic regulation of energy 
homeostasis. However, their exact effect and site of action is unclear largely due to 
difficulties in manipulating levels of GC in specific hypothalamic nuclei.  
 
5.3.1 Hypothesis 
Glucocorticoids in the hypothalamus physiologically regulate food intake and energy 
expenditure. 
 
5.3.2 Aims 
To investigate the physiological role of glucocorticoid in the hypothalamus I will: 
 
• Demonstrate the effect of 11βHSD1 overexpression in the paraventricular nucleus of 
the hypothalamus on food intake and bodyweight in rats fed a regular chow diet 
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5.4 Materials 
Unless stated otherwise all chemicals were purchased from VWR, Poole, Dorset, UK and all 
enzymes from New England Biolabs, Hitchin, Herts, UK. 
 
5.5 Methods 
5.5.1 Production of rAAV-11βHSD1  
The method of production of rAAV particles is described in chapter 2. Briefly, 11βHSD1 
cDNA was produced using reverse transcription PCR of rat hypothalamic RNA 
(section 2.3.4) using the primer set detailed in Table 5.01. 11βHSD1 cDNA PCR product was 
subcloned into the expression vector PTRCGW which carries the eGFP transgene 
(Figure 2.06). The first step in subcloning was to cut the 11βHSD1 PCR product and the 
pTRCGW plasmid using the restriction enzymes BamHI and BsrGI. The use of the restriction 
enzymes BamHI and BsrGI linearises the pTRCGW plasmid and removes the enhanced 
green fluorescent protein (eGFP) gene. The products from the restriction digest were loaded 
on a 1 % (w/v) agarose gel (section 2.3.4.3). The linearised plasmid and the cut 11βHSD1 
PCR cDNA fragment were excised from the gel and electroeluted (section 2.3.5.2). The 
cDNA fragment was subcloned into the linearised plasmid by a ligation reaction 
(section 2.3.5.3), resulting in the modified pTRCGW-11βHSD1 plasmid. The pTRCGW-
11βHSD1 plasmid was digested with BamHI and BsrGI to check insert size and also digested 
with XmaI to check for presence of inverted terminal repeats (ITRs) and visualised by gel 
electrophoresis. The ligated plasmid was then transformed into competent bacteria 
(section 2.3.7). The sequence of the insert was confirmed in both directions on two separate 
occasions (Genomics core laboratory, Imperial College London, UK). The plasmid 
pTRCGW-11βHSD1 was used to produce rAAV-11βHSD1 particles. Total viral particle titre 
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was determined by dot blot analysis (section 2.3.8.4). The plasmid pTRCGW was a kind gift 
from Professor J Verhaagen at the Netherlands Brain Institute, Amsterdam, The Netherlands. 
 
Primer Primer Sequence Restriction 
Site 
5’ 11βHSD1 AGC-TGG-ATC-CCG-CAC-TTA-TCT-GAA-GCC-TCA 
 
BamHI 
3’ 11βHSD1 AGC-TTG-TAC-ATC-AGT-GTG-AGG-TAA-AGC-CGA 
 
BsrGI 
 
Table 5.01 Primers for PCR amplification of 11βHSD1 for use in rAAV. The sequence in 
red details the restriction site associated with a particular primer. The 5’ primer corresponds 
to nucleotides 1-20, and the 3’ primer corresponds to nucleotides 1239-1258 in the rat 
11βHSD1 mRNA (accession number NM_008288.2). 
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5.5.2 Effects of rAAV-11βHSD1 bilaterally injected into the paraventricular nucleus 
on a regular chow diet  
5.5.2.1 Animals  
Male Wistar rats weighing 220-230 g (specific pathogen free, Charles River UK Ltd, 
Margate, Kent, UK) were individually housed in open top polypropylene cages under a 
controlled environment (temperature 21-23°C, 12 hour light-dark cycle, lights on at 
07:00AM) with ad libitum access to food (RM1 diet, SDS UK Ltd, Witham, Essex, UK) and 
water. All animal procedures were approved under the British Home Office Animals 
(Scientific Procedures) Act 1986 (Project licence number 70/6377). Animals were 
acclimatised to these conditions for two weeks before surgery.  
 
5.5.2.2 Animal allocation 
Animals were allocated into two weight matched treatment groups as outlined in Table 5.02. 
 
Group Treatment n 
Control group 
(rAAV-eGFP) 
rAAV-eGFP 12 
Treatment group 
(rAAV-11βHSD1) 
rAAV-11βHSD1 12 
 
Table 5.02 Allocation of male Wistar rats into experimental groups. Control group 
(rAAV-eGFP, n = 12); treatment group (rAAV-11βHSD1, n = 12). 
 
5.5.2.3 Animal surgery 
Male Wistar rats (section 5.5.2.2) were injected bilaterally intra-PVN with 1 µl of either 
rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12). Animals were anaesthetised with an 
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isoflurane system (Vet-Tech Solutions Ltd., UK) and immobilised on a Kopf stereotaxic 
frame (David Kopf Instruments, supplied by Clark Electromedical Instruments, Reading, 
Berkshire, UK). The incisor bar was set 3.0 mm below the interaural plane. The surgical area 
was shaved with an electronic razor and cleaned with 10 % (w/v) povidine-iodine solution 
(Betadine). A small (< 2.0 cm) rostro-caudal incision was made in the scalp. Animals were 
injected bilaterally into the PVN using coordinates 1.8 mm caudal, 0.3 mm lateral to the 
bregma and 8.0 mm below the skull, determined from the rat brain atlas of Paxinos and 
Watson (Paxinos and Watson, 2007) (Figure 5.01). A stereotaxically mounted drill was used 
to make a 0.65 mm burr hole in the skull. Each animal was injected via a 33G steel injector 
(Plastics-One) projecting 1.0 mm below the tip of the guide cannula. rAAV-11βHSD1 at a 
titre of 2.96 x 1013 genome particles/ml and rAAV-eGFP at a titre of 5.04 x 1012 genome 
particles/ml was produced as described in chapter 2. One microlitre of either 
rAAV-11βHSD1 or rAAV-eGFP was administered bilaterally into the PVN of each rat. The 
pressure was removed from the injector whilst the cannula-injector unit was maintained in 
situ for 5 minutes before being slowly extracted to minimise backflow. The incision was 
sutured with two mattress sutures with 6.0 proline thread. All animals received peri-operative 
care including: antibiotics (floxicillin : amoxicillin equal volumes, 37.5 mg/kg, i.p. 
1.0 ml/rat), analgesia (buprenorphine, 45 mg/kg, s.c. 0.05 ml/rat) and rehydration therapy 
(0.9 % sodium chloride, i.p. 2.5 ml/rat; Schering-Plough Ltd., UK). All surgical procedures 
were performed under aseptic conditions. Animals were allowed a recovery period of 7 days 
following surgery and were then handled and weighed regularly. 
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5.5.2.4 Cumulative food intake and bodyweight change 
Food intake and bodyweight were measured three times per week (between 09.00 -
 11.00AM). Prior to recording these measurements, animals were handled in order to reduce 
the effects of stress from the necessary handling immediately prior to their decapitation. 
Cumulative energy intake (kilocalories) was calculated as the product of cumulative food 
weight (grams) and energy value of the RM1 diet (3.523 kcal/g). 
 
5.5.2.5 Collection of tissue samples  
At 28 days post injection, rats were killed by decapitation in the early light phase. Brains 
were rapidly removed. The groups were divided into two sub-groups, such that half the 
animals had lateral sections cut away using a razorblade, frozen in isopentane chilled to 
-80°C and stored at -80°C until punch biopsy analysis of corticosterone levels. Brains from 
the other half of animals were mounted on cork discs, frozen in isopentane chilled to -80°C 
and stored at -80°C until in situ hybridisation (ISH). Blood was collected into heparinised or 
EDTA-chelated tubes containing aprotinin 2000 KIU/tube (Bayer), and immediately placed 
on ice. Plasma was separated by centrifugation, immediately frozen and stored at -80°C until 
radioimmunoassay (RIA) analysis.  
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5.5.3 Confirmation of gene transfer in the hypothalamic paraventricular nucleus by 
in situ hybridisation 
In situ hybridisation is a method for the detection and quantification of mRNA whilst 
maintaining the structural integrity of the tissue. This was performed as described in section 
3.4.3. 
 
5.5.4 Radioimmunoassay 
RIA was used to quantify circulating corticosterone. This was performed as described in 
section 3.4.4. 
 
5.5.4.1 Immuno-radiometric assay of plasma ACTH 
Plasma ACTH concentration was measured in duplicate by a two site immune-radiometric 
assay (IRMA). This was performed as described in section 4.4.4.1. 
 
5.5.4.2 Isolation of specific hypothalamic nuclei by punch biopsy 
Hypothalamic nuclei were isolated by punch biopsy to determine the effect of 11βHSD1 
overexpression on corticosterone content of the PVN. Hypothalamic nuclei collected from the 
rat brain are detailed in Figure 5.02. Frozen brains were mounted upon a freezing sled 
microtome (Shandon Southern Products Ltd, Runcorn, UK). Eight hundred micrometer 
sections from the rostro-caudal extent of the hypothalamus were cut and mounted onto poly-
lysine slides. Slides were kept on dry ice to re-freeze sections and nuclei were identified 
using ‘The rat brain atlas’ (Paxinos and Watson, 2007) and removed using a neuropunch 
1.0 mm in diameter (Harvard). The PVN and VMH were isolated bilaterally (the VMH as an 
internal control). Biopsies were pooled and homogenised using a micro-homogeniser 
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(Camlab, Cambridge, U.K.). Cell debris was removed by centrifugation for 3 minutes at 
13,000xg (F45-12-11 microfuge, Eppendorf, Hamburg, Germany). The supernatant was 
transferred to a new tube and extracted of total steroidal content overnight in 1.0 ml of 90 % 
methanol (v/v) in a drying centrifuge at 30°C and under vacuum (Thermo Scientific Savant 
SpeedVac). The residual pellet obtained was dissolved in 500 μl kit buffer before assaying 
for corticosterone in triplicate by ELISA (Cayman Chemicals Inc., USA), according to the 
manufacturer’s protocol. 
 
5.5.4.2.1 Protein assay of punch biopsy samples 
There is inherent variability in the amount of hypothalamic tissue collected by punch biopsy. 
In order to compensate for this, the protein content of the punch biopsy homogenate must be 
calculated in order to standardise the results of the corticosterone assay. Homogenate protein 
content was measured using the well-established bicinchoninic (BCA) protein assay (Thermo 
Scientific, UK). The cell debris pellet obtained in section 5.5.4.2 was dissolved in 500 μl 
0.2 M NaOH before assaying for protein in triplicate by according to the manufacturer’s 
protocol. 
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Figure 5.02 Diagram detailing the location of punch biopsies in the rat brain. This 
diagram shows A) the PVN, B) the VMH and C) the ARC. Eight hundred micrometer thick 
coronal sections of brain were cut through the length of the rat hypothalamus. Punch biopsies 
of hypothalamic nuclei were then collected from each section using a neuropunch (Harvard) 
1.0 mm in diameter. Like biopsies were then pooled and homogenised. Punch biopsies were 
collected from the PVN and the VMH. Adapted from (Paxinos and Watson, 2007).  
Bregma -1.08 mm 
Bregma -1.92 mm 
Bregma -2.72 mm 
Bregma -3.60 mm 
A 
A 
B 
B 
B 
C 
C 
C 
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5.5.4.3 Statistical analysis 
Data are presented as arithmetic means ± standard error of mean (SEM). Differences in 
bodyweight and cumulative food intake were analysed using a generalised estimating 
equation (GEE) for repeated measures (Stata, StataCorp LP, USA). The GEE was performed 
with an exchangeable working correlation structure. This model assumes that all pairs of 
times for the same animals are equally correlated. Group differences in RIA and ELISA 
results were analysed using unpaired Student’s t-test. Differences were considered 
statistically significant at the 95 % confidence level (P<0.05). Data analysis was performed 
using Graphpad Prism 4 software and Stata 9.  
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5.6 Results  
5.6.1 Recombinant adeno-associated virus mediated gene transfer of 11βHSD1 into 
the hypothalamic paraventricular nucleus of rats fed a regular chow diet 
5.6.1.1 Effect of bilateral paraventricular nucleus injection of rAAV-11βHSD1 on 
hypothalamic WPRE expression and hypothalamic and plasma hormones 
Correct injection of viral particles was verified by ISH for WPRE mRNA expression (Figure 
5.03). The results of the ISH provide spatial information that confirms the successful 
expression of rAAV-11βHSD1 in the PVN at 28 days post injection. 
 
There was no difference in either plasma ACTH concentration (Figure 5.04) (ACTH (pg/ml): 
rAAV-eGFP vs. rAAV-11βHSD1: 31.12 ± 2.68 vs. 29.72 ± 2.67, n.s.) or plasma 
corticosterone concentration (Figure 5.05) (corticosterone (ng/ml): rAAV-eGFP vs. rAAV-
11βHSD1: 22.75 ± 5.97 vs. 24.49 ± 6.17, n.s.) between the two groups. However, there was a 
significant increase in corticosterone measured in the PVN in rAAV-11βHSD1 treated 
animals compared to controls (Figure 5.06A) (corticosterone (ng/pg protein): rAAV-eGFP vs. 
rAAV-11βHSD1 : 235.88 ± 23.07 vs. 381.54 ± 35.62, P<0.05). There was no difference 
between the two groups in corticosterone measured in the VMH (a punch biopsy site chosen 
as an internal control) (Figure 5.06B) (corticosterone (ng/pg protein): rAAV-eGFP vs. rAAV-
11βHSD1 : 209.69 ± 17.08 vs. 225.74 ± 16.79, n.s.). 
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Figure 5.03 In situ hybridisation demonstrating WPRE mRNA expression in the 
paraventricular nucleus. Representative images of in situ hybridisation using 35S labelled 
WPRE riboprobe showing expression of WPRE (a component of the rAAV-11βHSD1 
construct not endogenously expressed in rat CNS) in 12µm coronal brain sections of a male 
Wistar rat brain approximately 1.8 mm caudal from bregma. Binding of WPRE anti-sense 
riboprobe used to detect WPRE expression is shown in (A). Binding of WPRE sense 
riboprobe is shown in (B) to highlight specificity. A reference coronal section through the rat 
brain -1.80 mm from bregma showing the PVN inside the red box is shown in (C). 
Reproduced from ‘The rat brain in stereotaxic coordinates’, (Paxinos and Watson, 2007). 
Brains were collected 28 days after bilateral intra-PVN injection of 1 µl rAAV-11βHSD1 (n 
= 6). 
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Figure 5.04 Effect of intra-PVN injection of rAAV-11βHSD1 on plasma ACTH in male 
Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either rAAV-eGFP 
(n = 12) or rAAV-11βHSD1 (n = 12) and ACTH measured from trunk blood by IRMA 
following termination on day 28. Values shown as pg/ml mean ± SEM. Non-significant by 
unpaired Student’s t-test. 
 
rAAV-eGFP rAAV-11 βHSD1
0
10
20
30
40
Pl
as
m
a 
C
or
tic
os
te
ro
ne
 (n
g/
m
l)
 
Figure 5.05 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 on plasma 
corticosterone in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12) and corticosterone measured 
from trunk blood by RIA following termination on day 28. Values shown as ng/ml mean 
± SEM. Non-significant by unpaired Student’s t-test. 
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Figure 5.06 Effect of intra-PVN injection of rAAV-11βHSD1 on hypothalamic 
corticosterone in male Wistar rats fed a normal chow diet. Animals were injected 
bilaterally with 1 µl of either rAAV-eGFP (n = 6) or rAAV-11βHSD1 (n = 6). At 28 days 
post injection, animals were terminated by decapitation and brains collected and frozen in 
isopentane chilled to -80°C. Eight hundred micrometer thick coronal sections of brain were 
cut through the hypothalamus using a sled microtome. Punch biopsies of hypothalamic nuclei 
were then collected using a neuropunch (Harvard) 1.0 mm in diameter. Like biopsies were 
pooled and homogenised prior to methanol extraction and subsequent measurement of 
corticosterone by ELISA. Corticosterone concentration was determined for A) the 
paraventricular nucleus and B) the ventromedial hypothalamic nucleus (as an internal 
control). All samples were normalised for protein content. Values shown as mean ± SEM. 
* = P<0.05 by unpaired Student’s t-test.  
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5.6.1.2 Effect of bilateral paraventricular injection of rAAV-11βHSD1 on bodyweight, 
bodyweight gain, and food intake  
At the beginning of the study (day 7), there was no difference in bodyweight between the two 
groups (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 298.75 ± 4.48 vs. 
306.42 ± 3.36 g, n.s.). Over the study period, animals injected with rAAV-11βHSD1 
displayed increased bodyweight, seen as a significant longitudinal trend, P<0.05 
(Figure 5.07). At the end of the study (day 28) bodyweight was significantly higher in 
rAAV-11βHSD1 animals (Figure 5.08) (bodyweight (g): rAAV-eGFP vs. rAAV-11βHSD1 : 
380.21 ± 6.77 vs. 412.67 ± 9.78, P<0.05). Correspondingly, bodyweight gain was increased 
in animals injected with rAAV-11βHSD1 seen as a significant longitudinal trend, P<0.01 
(Figure 5.09). At the end of the study (day 82) total bodyweight gain was significantly higher 
in rAAV-11βHSD1 animals (Figure 5.10) (bodyweight gain (g): rAAV-eGFP vs. 
rAAV-11βHSD1 : 81.46 ± 3.43 vs. 106.25 ± 7.51, P<0.01).  
 
There was no difference in food intake between animals injected with rAAV-11βHSD1 and 
controls (Figures 5.11 and 5.12). Correspondingly, there was no difference in energy intake 
between the two groups (Figures 5.13 and 5.14).  
 
239 
 
7 10 13 16 19 22 25 28
250
300
350
400
450 *
Days Post Injection
Bo
dy
w
ei
gh
t (
g)
 
Figure 5.07 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on 
bodyweight in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (green circles; n = 12) or rAAV-11βHSD1 (blue circles; n = 12) and 
bodyweight measured for 28 days post injection. Values shown as grams mean ± SEM. 
* = P<0.05 by generalised estimating equation.  
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Figure 5.08 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on final 
bodyweight in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12) and terminated on day 28 post 
injection. Values shown as grams mean ± SEM. * = P<0.05 by unpaired Student’s t-test. 
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Figure 5.09 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on 
bodyweight gain in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (green circles; n = 12) or rAAV-11βHSD1 (blue circles; n = 12) 
and bodyweight gain measured for 28 days post injection. Values shown as grams 
mean ± SEM. ** = P<0.01 by generalised estimating equation.  
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Figure 5.10 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on total 
bodyweight gain in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12) and terminated on day 28 
post injection. Values shown as grams mean ± SEM. ** = P<0.01 by unpaired Student’s t-
test. 
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Figure 5.11 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on 
cumulative food intake in male Wistar rats fed a normal chow diet. Animals were 
injected with 1 µl of either rAAV-eGFP (green circles; n = 12) or rAAV-11βHSD1 (blue 
circles; n = 12) and cumulative food intake measured for 28 days post injection. Values 
shown as grams mean ± SEM. Non-significant by generalised estimating equation.  
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Figure 5.12 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on total 
food intake in male Wistar rats fed a normal chow diet. Animals were injected with 1 µl 
of either rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12) and terminated on day 28 post 
injection. Values shown as grams mean ± SEM. Non-significant by unpaired Student’s t-test. 
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Figure 5.13 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on 
cumulative energy intake in male Wistar rats fed a normal chow diet. Animals were 
injected with 1 µl of either rAAV-eGFP (green circles; n = 12) or rAAV-11βHSD1 (blue 
circles; n = 12) and cumulative energy intake measured for 28 days post injection. Values 
shown as kcal mean ± SEM. Non-significant by generalised estimating equation.  
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Figure 5.14 Effect of bilateral intra-PVN injection of rAAV-11βHSD1 injection on total 
energy intake in male Wistar rats fed a normal chow diet. Animals were injected with 
1 µl of either rAAV-eGFP (n = 12) or rAAV-11βHSD1 (n = 12) and terminated on day 28 
post injection. Values shown as kcal mean ± SEM. Non-significant by unpaired Student’s t-
test. 
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5.7 Discussion 
Injection of rAAV-11βHSD1 into the PVN resulted in a significant increase in cumulative 
bodyweight and bodyweight gain when compared with rAAV-eGFP treated controls. This 
change was not associated with a significant increase in cumulative food intake. Towards the 
end of the study period, there was a slight, but non-significant, increase in the cumulative 
food intake of rAAV-11βHSD1 treated animals; however, this occurred after an increase in 
weight gain had become apparent. Hence it is likely that this subtle effect on food intake was 
secondary to the large increase in weight gain i.e. the animals ate more as a result of their 
increased bodyweight. Together, these results suggest that the observed increase in 
bodyweight was likely to be the result of a reduction in energy expenditure. Therefore, GCs 
may play a physiological role in the regulation of energy expenditure via the PVN.  
 
Similarly to the experiments described in previous chapters, the coordinates chosen for rAAV 
injection into the PVN were determined from the Rat Brain Atlas (Paxinos and Watson, 
2007). Coordinates were confirmed by ink injection (appendix II) and by in situ 
hybridisation, which also served to confirm expression of the rAAV transgene cassette. 
Additionally, overexpression of rAAV-11βHSD1 in the PVN resulted in the successful 
increase of PVN corticosterone concentration when compared to controls injected with 
rAAV-eGFP. No difference in corticosterone concentration was observed in the VMH, an 
area selected as an internal control, isolated from the same animals. Together, this data 
suggests that increased 11βHSD1 activity was successfully achieved and was correctly 
targeted to the PVN.  
 
A reduction in thermogenesis in BAT depots is a possible mechanism for the proposed 
reduction in energy expenditure. BAT can contribute to energy expenditure in rodents 
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(Lowell et al., 1993), and potentially in humans (Nedergaard et al., 2007). Whilst there is no 
direct supporting evidence for a role of GCs in regulating energy expenditure via the PVN, 
the PVN plays a well-established role in the regulation of energy expenditure. Viral tracing 
studies have shown descending pathways from the PVN to the brainstem and onto BAT 
(Bamshad et al., 1999, Cano et al., 2003, Oldfield et al., 2002). Thus the PVN contains a 
large number of neurons that are responsible for regulating sympathetic outflow to BAT; 
although the mechanism by which this occurs is not fully understood. Microinjection of the 
excitatory neurotransmitter glutamate into the PVN has been shown to increase both BAT 
and core temperatures, suggesting that glutamate stimulation of neurons in the PVN activates 
thermogenesis in BAT (Amir, 1990). Furthermore, central administration of GCs suppresses 
the release of glutamate (via reduction of brain derived neurotrophic factor (BDNF)) 
(Numakawa et al., 2009). This is further substantiated by studies that show central 
administration of GCs lowers levels of CRH (Zakrzewska et al., 1999a), and infusion of GCs 
potently downregulates CRH gene expression in the PVN (Watts and Sanchez-Watts, 1995), 
a hormone that is known to stimulate thermogenesis by increasing sympathetic outflow when 
administered centrally (Arase et al., 1988). However, more recent work suggests that neurons 
in the PVN can inhibit sympathetic outflow to BAT, thereby decreasing BAT energy 
expenditure (Madden and Morrison, 2009). As such, the specific mechanism via which the 
PVN mediates sympathetic outflow to BAT remains unclear. Regardless, it is entirely 
possible that GC signalling in the PVN can alter sympathetic outflow to BAT, thus resulting 
in a reduction in energy expenditure, and that this may be responsible for the increased body 
weight seen in 11βHSD1 treated animals in this study. If this is correct, then these findings 
may not be generally translated to adult humans, as the role of BAT in adaptive 
thermogenesis in adult humans remains controversial. Indeed, although it is clear that 
functional BAT is present in adult humans (Virtanen et al., 2009, Cypess et al., 2009, van 
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Marken Lichtenbelt et al., 2009), whether is plays a role in diet-induced thermogenesis is 
debated. 
 
The PVN is intimately involved in the regulation of the HPA axis. The observed phenotype 
might therefore be explained by changes in HPA axis regulation, due to increased levels of 
GCs in the PVN as a direct result of 11βHSD1 overexpression. Certainly, a central role for 
11βHSD1 in HPA axis regulation is implied by 11βHSD1-/- mice, which display reduced GC 
feedback, consistent with decreased GC signalling in the brain, elevated nadir levels of 
plasma corticosterone, and exaggerated corticosterone response to an acute stressor (Harris et 
al., 2001). To investigate this possibility, levels of ACTH and corticosterone were measured 
in blood plasma. One difficulty of such measures is that the HPA axis is activated by stress. 
Therefore, it was necessary to ensure that blood was collected with minimal stress, and to 
achieve this, animals were killed by decapitation. Neither ACTH, nor corticosterone plasma 
levels, were altered in rAAV-11βHSD1 treated animals when compared to controls. It would 
be fair to predict a change in the circulating levels of these hormones, since the HPA axis is 
controlled by a classic negative feedback mechanism with GCs in the PVN acting to reduce 
HPA axis activity. However, this effect is mediated by CRH neurons in the parvocellular 
region of the PVN. In this experiment, stereotactic injections were targeted to a different 
region of the PVN to deliberately minimise any effects of 11βHSD1 overexpression on HPA 
axis regulation. Additionally, regulation of the HPA axis occurs at brain areas other than the 
PVN, such as the pituitary. It is therefore possible that there was a decrease in release of CRH 
from the hypothalamus but it was counteracted by reduced negative feedback on the pituitary; 
hence plasma corticosterone levels were unchanged. However, in these circumstances ACTH 
levels would be expected to increase and this was not seen. Of course, it is unfair to assume 
that measurement of plasma ACTH and corticosterone gives a full assessment of the HPA 
246 
 
axis; at best, it gives a window to assess parameters of the HPA axis, but it does not fully 
elucidate HPA axis activity. For this reason, it is entirely possible that HPA axis activity was 
modified, but it did not result in a change in circulating corticosterone or ACTH at the time of 
measurement. Hence, overexpression of 11βHSD1 in the PVN may have affected HPA axis 
activity, and this could have been partly responsible for an effect on energy expenditure and 
the observed phenotype. Alternatively, a reduction in energy expenditure could be explained 
by altered thyroid hormone levels. The hypothalamic-pituitary-thyroid (HPT) axis regulates 
release of the thyroid hormones tri-iodothyronine (T3) and thyroxine (T4), both of which are 
known to increase energy expenditure via increased thermogenesis (Silva, 2001). Previous 
studies have shown that the injection of rAAV-eGFP into the PVN results in eGFP 
expression in the median eminence (ME) (Ward et al., 2003). Therefore, it is possible that the 
injection of rAAV-11βHSD1 into the PVN altered regulation of the synthesis and release of 
CRH and TRH and subsequently altered the HPA axis and HPT axis activity respectively.  
 
GCs have a well-established interaction with hypothalamic NPY. Circulating GCs stimulate 
NPY expression (Stanley et al., 1989) and NPY neurons innervate PVN CRH neurons 
(Liposits et al., 1988) consequently increasing CRH expression, ACTH and corticosterone 
secretion (Sainsbury et al., 1997b). CRH in the PVN has inhibitory actions on food intake 
(Heinrichs and Richard, 1999) whilst injection of NPY into the PVN potently increases food 
intake (Clark et al., 1984, Stanley and Leibowitz, 1984) and decreases thermogenesis in BAT 
(Billington et al., 1991, Billington et al., 1994). If overexpression of 11βHSD1 in the PVN 
affected HPA axis activity, which reduced circulating GC levels and subsequently affected 
NPY expression, one would expect to see a change in food intake, which did not occur in this 
study. Therefore, it is possible, but unlikely the phenotype is the result of altered NPY 
release.  
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11βHSD1 mRNA and protein are endogenously expressed in both magnocellular and 
parvocellular PVN neurons (Sakai et al., 1992, Seckl, 1997) and GC receptors (GRs) are 
highly expressed in the PVN (Seckl, 1997). Therefore, it would seem likely that 11βHSD1 
plays a physiological role in the PVN, perhaps in regulating GC feedback sensitivity, 
however this has not yet been addressed in adequate detail. The PVN also has detectable 
11β-hydroxysteroid dehydrogenase 2 (11βHSD2) and mineralocorticoid receptor (MR) 
expression (Zhang et al., 2006, Swanson and Simmons, 1989). 11βHSD2 reduces GC access 
to MRs, thereby reducing sympathetic activity, thus there is a proposed role for 11βHSD2 in 
the regulation of sympathetic outflow from the PVN. Consequently, it may be that 
overexpression of 11βHSD1 in the PVN would increase MR activation and interfere with the 
physiological role of 11βHSD2 in regulating sympathetic activity. This seems unlikely 
though, because according to the proposed role of 11βHSD2 in the regulation of sympathetic 
outflow, an increase in MR activation would increase sympathetic outflow, an effect that 
would not agree with the observed phenotype. Therefore it seems unlikely that 
overexpression of 11βHSD1 would decrease sympathetic outflow by interfering with 
11βHSD2 activity in the PVN. 
 
Overexpression of 11βHSD1 in the PVN resulted in a significant increase in bodyweight 
without effecting food intake. A logical explanation for this phenotype is that increased GC 
levels in the PVN reduced sympathetic outflow, thus reducing energy expenditure. The 
results of this experiment are exciting but require further work in order to elucidate a working 
mechanism. For instance, it would be logical to firstly monitor oxygen consumption to 
provide an indirect measure of energy expenditure in these animals. Additionally, it is 
relatively straightforward to measure markers of energy expenditure such as UCP-1 mRNA 
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expression in BAT. For this reason, the data in this chapter should be considered preliminary 
work that requires further investigation. 
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6 General discussion 
There is strong evidence for a central physiological role of glucocorticoids (GCs) in 
regulating energy balance and appetite (Valsamakis et al., 2004). Pharmacological 
administration of GCs increases food intake and decreases energy expenditure (Zakrzewska 
et al., 1999a), whilst removal of endogenous GC production by adrenalectomy (ADX) results 
in decreased food intake and increased energy expenditure (Freedman et al., 1986). 
11β-hydroxysteroid dehydrogenase 1 (11βHSD1) is an enzyme that catalyses generation of 
active GC in vivo, thus acting as a modulator of intracellular GC levels. 11βHSD1 is 
endogenously expressed in a variety of tissues including liver, adipose, bone and discrete 
brain regions (Moisan, 1990, Holmes et al., 2003). Within the CNS, particularly high levels 
of expression are observed in the hypothalamus, including neurons of the arcuate nucleus 
(ARC) and the paraventricular nucleus (PVN) (Seckl, 1997, Moisan, 1990); nuclei that are 
intimately involved in the regulation of energy homeostasis. In this thesis, I utilised 
recombinant adeno-associated virus (rAAV) to overexpress the 11βHSD1 gene 
(rAAV-11βHSD1) and investigate the role of GCs in both the ARC and the PVN. 
 
Increased 11βHSD1 expression in peripheral tissues such as adipose tissue is linked with 
insulin resistance (IR) and type 2 diabetes mellitus (T2DM) (Masuzaki et al., 2001), hence 
there is currently a great deal of research focussed on understanding the link between 
11βHSD1 expression and the development of T2DM. Indeed, many pharmaceutical 
companies are pursuing the development of an effective 11βHSD1 inhibitor as a therapeutic 
agent for T2DM (Boyle and Kowalski, 2009). 11βHSD1 inhibitors have the potential to 
improve glycaemic control by lowering plasma glucose (Bolen et al., 2007). In the studies 
presented in this thesis, overexpression of 11βHSD1 in the ARC on a normal chow (NC) diet 
resulted in altered whole body glucose homeostasis. Thus the work presented here suggests 
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that centrally expressed 11βHSD1 may play a role in the regulation of glucose homeostasis. 
An oral glucose tolerance test (OGTT) 1 week post rAAV-11βHSD1 injection revealed 
impaired glucose tolerance (IGT) and provoked exaggerated glucose stimulated insulin 
secretion (GSIS). Homeostasis model assessment (HOMA) of fasting plasma glucose and 
insulin concentrations supported this finding, suggesting increased IR, decreased insulin 
sensitivity and increased β-cell function in rAAV-11βHSD1 treated animals. Additionally, an 
insulin tolerance test (ITT) 2 weeks post injection indicated reduced insulin sensitivity in 
rAAV-11βHSD1 treated animals. Thus, at the beginning of the study period, 
rAAV-11βHSD1 treated animals displayed similar effects to those that occur in the early 
stages of T2DM. This phenotype occurred without a significant increase in bodyweight 
compared to controls, suggesting that the effects were the result of altered CNS regulation of 
whole body glucose homeostasis, rather than increased IR as a result of increased bodyweight 
gain. Intriguingly, this phenotype diminished as the study progressed (weeks 6 and 7 post 
injection), and was no longer apparent by the end of the study (weeks 12 and 13 post 
injection). It is possible that rAAV-11βHSD1 was no longer effective later in the study, 
explaining the loss of phenotype. However this is highly unlikely since both WPRE and 
raised GC levels were detected in the ARC at the end of the study. Instead, it is probable that 
the effects of 11βHSD1 overexpression in the ARC were subtle, and therefore easily masked 
by age and bodyweight gain, two factors known to promote IR, as the study progressed. The 
results of this study agree with the role of the CNS in the regulation of whole body glucose 
homeostasis (Lam et al., 2009) and suggest that central 11βHSD1 and GCs may play a bigger 
role in glucose homeostasis than previously thought. Additionally, these results suggest that 
endogenous central expression of 11βHSD1, as well as endogenous peripheral expression 
(Masuzaki et al., 2001), may be implicated in the pathogenesis of T2DM. As such, the role of 
centrally expressed 11βHSD1 in the regulation of glucose homeostasis is something that 
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requires careful consideration in the development of an 11βHSD1 inhibitor for the treatment 
of T2DM.  
 
In another experiment, overexpression of 11βHSD1 in the ARC on a normal chow diet (NC 
cohort) resulted in a significant increase in food intake and subsequently, a significant 
increase in bodyweight. This finding furthers work published by Cusin et al., who 
demonstrated that intracerebroventricular (ICV) administration of GCs increases food intake 
(Cusin et al., 2001). The authors suggest that the observed hyperphagia was linked to an 
increase in ARC neuropeptide-Y (NPY) release. However, I observed no change in ARC 
NPY mRNA in my study. Nevertheless, this finding is not necessarily indicative of a lack of 
change in NPY release; hence this is something that should be investigated further in future 
studies. The results from this study support and further the existing evidence for a 
physiological role of hypothalamic GCs in the regulation of energy homeostasis. 
Interestingly, effects on food intake, and therefore on bodyweight, were ameliorated when the 
experiment was repeated with animals fed a high fat diet (HFD cohort). Feeding Wistar rats a 
HFD results in increased bodyweight and decreased food intake in comparison with rats fed a 
NC diet (Xu et al., 2008). HFD feeding increases circulating leptin levels and promotes leptin 
resistance, by a combination of reducing leptin transport across the blood brain barrier 
(BBB), upregulation of negative feedback regulators of leptin signalling and perhaps by 
decreasing hypothalamic leptin receptor expression (Xu et al., 2008). Hence it is possible that 
feeding a HFD contributed to ARC leptin resistance thus masking the phenotype. 
Additionally, HFD feeding may have promoted ghrelin resistance in ARC NPY releasing 
neurons. If the phenotype observed in the NC cohort was the result of increased NPY release, 
then ghrelin resistance may have prevented this from occurring in the HFD cohort. HFD is 
also postulated to act as a mild stressor, stimulating HPA axis activity and thus perhaps 
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altering the effects of increased ARC GC levels. This would seem unlikely though as 
circulating corticosterone levels were unchanged between the two groups, hence it is possible 
that HPA axis activity was unchanged. Short-term HFD feeding (3 weeks) of Wistar rats has 
been shown to decrease 11βHSD1 activity in both liver and adipose tissue; an effect that is 
lost in long-term feeding (20 weeks) (Drake et al., 2005). The authors suggest that this 
reduction in 11βHSD1 activity acts as a protective mechanism against the metabolic 
complications of obesity. It is possible that HFD feeding of rats in this study may have 
altered 11βHSD1 activity, thus explaining the confusing results; however, 11βHSD1 activity 
was not assessed in this study.  It seems, therefore, that effects of GCs in the hypothalamus 
on a HFD are incompletely understood and require much further investigation. 
 
Prolonged ICV infusion of dexamethasone, a synthetic GC, increases food intake and 
bodyweight, and reduces insulin sensitivity by promoting muscle insulin resistance (Cusin et 
al., 2001), potentially via activation of parasympathetic efferent fibers (Cusin et al., 2001, 
Sainsbury et al., 2001). ICV infusion of dexamethasone results in hyperinsulinemia and 
hyperleptinemia (Zakrzewska et al., 1999a). Insulin and leptin both act in the ARC to 
modulate expression of neuropeptides involved in regulating food intake. Additionally, both 
insulin and leptin resistance are associated with hyperphagia. Fasting insulin in 
rAAV-11βHSD1 treated animals was not significantly different from controls, but analysis 
by HOMA indicated increased insulin resistance (IR). Additionally, these animals displayed 
an exaggerated insulin response to a glucose load. Unfortunately, circulating leptin levels 
were not measured in these animals and this is something that would need to be assessed in 
future studies. ICV dexamethasone infusion also increases synthesis of hypothalamic NPY 
(Zakrzewska et al., 1999a). Taken together, the results of the studies discussed in this thesis 
so far, support the evidence that central GCs play a role in the regulation of food intake and 
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glucose homeostasis. Further, these results agree with the hypothesis that central GCs exert 
these effects via the ARC of the hypothalamus. 11βHSD1 is endogenously expressed in the 
ARC, hence arcuate 11βHSD1 may be responsible for regulating arcuate GCs and their 
subsequent effects. Indeed, an increase in NPY release due to increased ARC GC might 
explain the observed phenotype after rAAV-11βHSD1 intra-ARC injection on a NC diet. 
ICV infusion of NPY potently increases food intake (Clark et al., 1984), and induces 
hyperinsulinemia, hyperglycaemia and dyslipidemia (Vettor et al., 1994, Raposinho et al., 
2001) effects that are abolished on the removal of endogenous GC production (Sainsbury et 
al., 1997a). NPY neurons express GC receptors (GRs) (Harfstrand et al., 1989, la Fleur, 2006, 
Hisano et al., 1988) and GCs increase NPY expression in the ARC of organotypic cultures 
(Sato et al., 2005). Also, glucocorticoid response elements (GREs) have been identified in the 
promoter region of the rat NPY gene (Misaki et al., 1992) and ICV GC infusion increases 
NPY peptide levels (Zakrzewska et al., 1999a). Recently, it has been suggested that GCs 
increase ARC NPY mRNA expression, at least partly, by stimulation of hypothalamic 
adenosine monophosphate-activated protein kinase (AMPK) signalling and by inhibiting 
hypothalamic mammalian target of rapamycin (mTOR) signalling (Shimizu et al., 2010), two 
factors thought to regulate energy homeostasis. Insulin inhibits NPY neurons in the ARC and 
ICV NPY induces hepatic IR via sympathetic innervations independent of changes in food 
intake (van den Hoek et al., 2004, van den Hoek et al., 2008). ICV infusion of NPY reduces 
the inhibition of endogenous glucose production elicited by circulating insulin. Thus, 
overexpression of 11βHSD1 in the ARC increased NPY release and subsequently reduced the 
ability of insulin to decrease endogenous glucose production. Thus it is entirely possible that 
overexpression of 11βHSD1 in the ARC of animals fed a NC diet, altered food intake and 
glucose homeostasis by initiating a change in ARC NPY physiology. Although, it is 
intriguing that intra-ARC injection of rAAV-11βHSD1 resulted in altered glucose 
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homeostasis, without a change in bodyweight or food intake in the study in chapter 3 
(appendix III); especially since the same intra-ARC injections resulted in a significant 
increase in food intake and bodyweight in the NC experiment of chapter 4. The most likely 
explanation for this is that the animals in the study of chapter 3 were subjected to repeat 
fasting for OGTTs and ITTs throughout the entire study period. Repeated fasting has been 
shown to stunt bodyweight gain (Wheeler et al., 1990) and white adipose tissue (WAT) gain 
is reduced following repeated fasting (Kochan et al., 1997).  
 
Overexpression of 11βHSD1 in the PVN on a normal chow diet (NC) resulted in a significant 
increase in bodyweight, without increased food intake. This implies that increased 
intracellular GC in the PVN reduced energy expenditure, thus leading to an increase in 
bodyweight. This data suggests that, within the PVN, GCs have a direct effect on energy 
expenditure. BAT UCP-1 expression was measured in the ARC cohort and displayed no 
change. However, time limitations meant that UCP-1 mRNA expression was not measured in 
the PVN cohort in this thesis. ICV infusion of dexamethasone results in reduced expression 
of UCP-1 in BAT (Zakrzewska et al., 1999a). The effects of ICV infusion of dexamethasone 
were lost when the experiment was repeated in vagotomised animals, suggesting that central 
GCs exert effects, at least partially, via reduced sympathetic outflow and increased 
parasympathetic outflow. Hence, it is possible that the effects of central GCs on food intake 
and energy expenditure are spatially separated i.e. central GCs regulate food intake 
predominantly via the ARC, and energy expenditure via the PVN, however this requires 
further investigation. 
 
The studies presented here are in agreement with findings that GCs regulate both food intake 
and energy expenditure; however, the results are novel as it has not previously been possible 
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to demonstrate these effects independently. One possible explanation for this is the difficulty 
of studying hypothalamic GCs. GCs are small hydrophobic molecules which do not readily 
dissolve in non-organic solvents. Indeed, in the few studies of their effects in the CNS, they 
have been dissolved in organic solvents and then diluted in saline. Their insolubility has 
limited studies to using ICV injection. Hence it is not surprising that effects on energy intake 
have been observed to be independent of those on food intake since the entire hypothalamus 
would be exposed to compounds injected ICV. In order to demonstrate a similar effect by 
acute injection it would require specific targeting of the injection to the hypothalamic nucleus 
of interest. Unfortunately, the difficulty of dissolving GCs in aqueous solution means this is 
not technically possible. Recombinant adeno-associated virus was the ideal tool to overcome 
this problem; permitting manipulation of GC levels in discrete areas of the hypothalamus. 
Preparations of rAAV used in all studies presented here were of a sufficiently high titre to 
achieve efficient transfection of neurons (confirmed by dot blot analysis). The coordinates 
chosen for rAAV injection into both the ARC and PVN were determined from the Rat Brain 
Atlas (Paxinos and Watson, 2007) and confirmed by ink injection (appendix II) and by in situ 
hybridisation (ISH). ISH also confirmed expression of the rAAV transgene cassette by 
probing against WPRE; an integral component of the viral construct which is not 
endogenously expressed in mammalian tissues. Hence use of a probe against WPRE has 
greater specificity than use of a probe directed against 11βHSD1. Overexpression of 
11βHSD1 was further confirmed by RT-qPCR analysis of 11βHSD1 mRNA expression in 
the hypothalamus (chapter 3 only). Unfortunately RT-qPCR analysis was performed on 
mRNA extracted from the entire hypothalamus. Thus it would be advantageous to analyse 
11βHSD1 mRNA in specific nuclei in future studies. Local corticosterone concentration was 
used as a surrogate measure of 11βHSD1 activity. This revealed significantly increased levels 
of corticosterone in the ARC (chapter 3) and the PVN (chapter 5) of rAAV-11βHSD1 treated 
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animals. No difference in corticosterone concentration was observed in areas selected as 
internal controls, isolated from the same animals. Together, these experiments confirm that 
use of rAAV-11βHSD1 successfully increased GC levels and that this was achieved in the 
target nuclei.  
 
In all cohorts of animals in this study, it was important to investigate whether manipulation of 
hypothalamic GCs resulted in altered HPA axis activity. For this reason, circulating 
corticosterone, and in some cohorts ACTH, were measured on termination as a measure for 
HPA axis activity. Further to this, GC turnover was assessed in animals in the HFD cohort. 
At no point was a change observed in circulating corticosterone or ACTH levels, implying 
that HPA axis activity was unaffected. There are, however, numerous factors that can affect 
terminal corticosterone and ACTH levels (e.g. time of day and stress). For this reason, it 
would be benefitial to assess HPA axis activity at timepoints other than just on termination. 
For instance, HPA axis activity could be assessed non-invasively by measuring fecal 
corticosterone levels.   
 
The findings of the studies presented here are supported by many others examining the effect 
of GCs on food intake and energy expenditure in which it has been shown that 
pharmacological administration of GCs increases food intake and decreases energy 
expenditure (Zakrzewska et al., 1999a). Whilst removal of GCs by ADX results in decreased 
food intake and increased energy expenditure (Freedman et al., 1986). The results of the 
studies presented here suggest that the mechanisms by which local GCs centrally regulate 
food intake and energy homeostasis are nucleus specific. Further, these results suggest that 
central GCs play a role in the regulation of glucose homeostasis; hence they are clearly an 
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attractive therapeutic target for the treatment of T2DM, and perhaps in the treatment of 
obesity. 
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6.1 Future work 
It is now widely accepted that the hypothalamus plays a major role in the regulation of 
glucose homeostasis; a theory supported by the work presented in this thesis. Glucose 
homeostasis was investigated by use of OGTTs, ITTs and HOMA analysis of fasting glucose 
and insulin levels. Overexpression of 11βHSD1 in the ARC altered whole body insulin 
sensitivity and resulted in similar effects to those that occur in the early stages of T2DM. This 
is an interesting finding, but OGTTs, ITTs and HOMA analysis are only surrogate measures 
of glucose homeostasis. In future studies, it would be useful to assess effects of 
rAAV-11βHSD1 on glucose homeostasis by use of the hyperinsulinemic euglycemic clamp 
technique. This methodology is the ‘gold standard’ for monitoring glucose homeostasis and 
tests would provide reliable information on the dynamics of glucose homeostasis in 
rAAV-11βHSD1 treated animals. Additionally, it would be interesting to measure circulating 
levels of resistin, an adipokine thought to promote IR after central GC infusion (Asensio et 
al., 2004). 
 
Expression of NPY, AgRP, POMC and CART mRNA was measured by RT-qPCR analysis 
of whole hypothalamic tissue. These genes were selected as the most likely candidates to be 
involved in the mechanism for the observed phenotype after the findings from other 
laboratories. Surprisingly, no change was observed in mRNA expression of the orexigenic 
neuropeptides NPY or AgRP, in spite of the observed hyperphagic phenotype. A change in 
neuropeptide mRNA expression could have been masked by measuring the mRNA 
expression in the entire hypothalamus. Therefore, RT-qPCR analysis should be performed on 
punch biopsies of discrete hypothalamic nuclei rather than the entire hypothalamus. This 
would mean that NPY mRNA expression could be monitored specifically in the ARC. 
Therefore, the fact that NPY mRNA was not increased in these animals, does not mean that 
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NPY peptide release was unchanged. Additionally, receptor expression and sensitivity were 
not measured in this study which again could have an effect on ARC activity. In future 
studies, it would also be useful to perform RT-qPCR analysis on a wider range of genes. For 
instance, it is possible that part of the mechanism is the result of inflammation signals altering 
leptin and insulin sensitivity in the hypothalamus. There are five molecular mechanisms 
known to promote this: suppressor of cytokine signalling-3 (SOCS-3), JUN N-terminal 
kinase (JNK), IKK and PKC-theta, so these genes should also be analysed. 
 
In order to elucidate a mechanism of both the intra-PVN and intra-ARC injected animals, it 
would be useful to investigate not only hypothalamic mRNA expression, as conducted in this 
experiment, but also hypothalamic neuropeptide content. To do this, hypothalamic punch 
biopsies of specific nuclei could be taken by the same method, and then extracted in acetic 
acid. This would permit the measurement of NPY, AgRP, α-MSH, CART and CRH peptide 
levels by radioimmunoassay (RIA). An alternative proposed mechanism for the increase in 
bodyweight involved the release of thyroid hormones. For this reason, TRH could be 
measured by the same methodology.  
 
It is likely that leptin has a large role in the central mechanism of GCs, as ICV infusion of 
GCs results in hyperleptinemia. To better understand this, it would be useful to measure 
terminal circulating leptin levels by RIA. Additionally, ex vivo hypothalamic explants could 
be incubated with leptin. The release of NPY, AgRP, α-MSH and CART would then be 
measured by RIA and compared to basal levels. Additionally, leptin sensitivity could be 
investigated in vivo. To do this, rAAV-11βHSD1 treated animals could be peripherally 
injected with leptin, after which acute food intake would be monitored.  
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The results of the intra-PVN study suggest that the increased bodyweight of the 11βHSD1 
animals was not the result of increased food intake. Unfortunately, time limitations prevented 
the measurement of BAT UCP-1 content in this cohort of animals. For this reason, on 
repetition of the experiment, the animals could be observed in the comprehensive laboratory 
animal monitoring system (CLAMS). CLAMs allows for accurate and detailed observation of 
numerous parameters including food intake, activity, carbon dioxide production and oxygen 
consumption. Additionally, a pair-fed control group would eliminate variation in body weight 
from differences in food intake and post-prandial thermogenesis. Such data may be 
suggestive of metabolic alteration as a result of treatment. 
 
In contrast to the overexpression of 11βHSD1 to increase local levels of corticosterone it 
would be interesting to view the effects of a reduction in hypothalamic GCs. In previous 
experiments, this has been done globally by ADX. However, in order to locally decrease 
levels of corticosterone it would be interesting to overexpress 11βHSD2 in the PVN and 
ARC. 11βHSD2 is responsible for the conversion of the active GC corticosterone to inactive 
11-dehydrocorticosterone. This may result in a phenotype opposite to that observed here, thus 
adding validity to these results.  
 
A regular chow diet was fed to all cohorts of animals presented in this thesis, apart from those 
in the HFD cohort. A chow diet contains plant derived ingredients which are subject to 
changes in the growing season; hence these diets can vary in composition at the time of 
harvest. Thus, diet formulae may change based on the nutritional composition. Purified 
ingredients, on the other hand, are highly refined. For this reason a low-fat purified diet 
containing the same ingredients with a closely matched composition to the high fat formula 
should be fed to all cohorts in future studies if they are to be compared to a HFD cohort. 
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A further limitation of the current study was the inability to measure body fat in all cohorts of 
animals. Epididymal fat pads are not particularly sensitive to changes in body fat and as such 
are not necessarily an ideal candidate to reflect body fat content. Whole body composition 
analysis was limited to use in the HFD cohort. In future studies, it would be helpful to use 
this technique in all cohorts of animals, rather than just weighing epididymal fat pads as a 
surrogate measure of body fat content. 
 
An obvious drawback of the current study was that it only considered the local concentration 
of corticosterone as an index of 11βHSD1 enzyme activity. To rectify this, future 
experiments should include an assay on punch biopsy samples to check for the activity of 
11βHSD1. To this end, a collaboration has been organised with the department of Professor J. 
Seckl, who has experience of the required assay. In addition, brain slices should again 
undergo ISH, and should be probed for 11βHSD1 mRNA. The results of these studies would 
confirm rAAV overexpression and increased enzyme activity in the correct hypothalamic 
nuclei. 
 
  
 
263 
 
7 References 
ABBOTT, C. R., ROSSI, M., WREN, A. M., MURPHY, K. G., KENNEDY, A. R., 
STANLEY, S. A., ZOLLNER, A. N., MORGAN, D. G. A., MORGAN, I. & 
GHATEI, M. A. 2001. Evidence of an Orexigenic Role for Cocaine-and 
Amphetamine-Regulated Transcript after Administration into Discrete 
Hypothalamic Nuclei. Endocrinology, 142, 3457-3463. 
ABDALLAH, B. M., BECK-NIELSEN, H. & GASTER, M. 2005. Increased expression 
of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes. Eur 
J Clin Invest, 35, 627-34. 
AGARWAL, A. K. 2003. Cortisol metabolism and visceral obesity: role of 11beta-
hydroxysteroid dehydrogenase type I enzyme and reduced co-factor NADPH. 
Endocr Res, 29, 411-8. 
AHIMA, R. S., KELLY, J., ELMQUIST, J. K. & FLIER, J. S. 1999. Distinct physiologic 
and neuronal responses to decreased leptin and mild hyperleptinemia. 
Endocrinology, 140, 4923-31. 
AHIMA, R. S., PRABAKARAN, D. & FLIER, J. S. 1998. Postnatal leptin surge and 
regulation of circadian rhythm of leptin by feeding. Implications for energy 
homeostasis and neuroendocrine function. J Clin Invest, 101, 1020-7. 
AJA, S., SAHANDY, S., LADENHEIM, E. E., SCHWARTZ, G. J. & MORAN, T. H. 
2001. Intracerebroventricular CART peptide reduces food intake and alters 
motor behavior at a hindbrain site. Am J Physiol Regul Integr Comp Physiol, 281, 
R1862-7. 
AKACHE, B., GRIMM, D., PANDEY, K., YANT, S. R., XU, H. & KAY, M. A. 2006. 
The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus 
serotypes 8, 2, 3, and 9. J Virol, 80, 9831-6. 
AKANA, S. F., STRACK, A. M., HANSON, E. S., HORSLEY, C. J., MILLIGAN, E. D., 
BHATNAGAR, S. & DALLMAN, M. F. 1999. Interactions among chronic cold, 
corticosterone and puberty on energy intake and deposition. Stress, 3, 131-46. 
ALBERT, D. J., STORLIEN, L. H., ALBERT, J. G. & MAH, C. J. 1971. Obesity 
following disturbance of the ventromedial hypothalamus: a comparison of 
lesions, lateral cuts, and anterior cuts. Physiol Behav, 7, 135-41. 
ALONSO, G. & ASSENMACHER, I. 1981. Radioautographic studies on the 
neurohypophysial projections of the supraoptic and paraventricular nuclei in the 
rat. Cell Tissue Res, 219, 525-34. 
ALONSO, J. R., SANCHEZ, F., AREVALO, R., CARRETERO, J., VAZQUEZ, R. & 
AIJON, J. 1992. Partial coexistence of NADPH-diaphorase and somatostatin in 
the rat hypothalamic paraventricular nucleus. Neurosci Lett, 148, 101-4. 
AMIR, S. 1990. Intra-ventromedial hypothalamic injection of glutamate stimulates 
brown adipose tissue thermogenesis in the rat. Brain Res, 511, 341-4. 
264 
 
ANAND, B. K. & BROBECK, J. R. 1951. Localization of a "feeding center" in the 
hypothalamus of the rat. Proc Soc Exp Biol Med, 77, 323-4. 
ANAND, B. K., CHHINA, G. S., SHARMA, K. N., DUA, S. & SINGH, B. 1964. Activity 
of Single Neurons in the Hypothalamic Feeding Centers: Effect of Glucose. Am J 
Physiol, 207, 1146-54. 
ANDREWS, R. C., HERLIHY, O., LIVINGSTONE, D. E., ANDREW, R. & WALKER, 
B. R. 2002. Abnormal cortisol metabolism and tissue sensitivity to cortisol in 
patients with glucose intolerance. J Clin Endocrinol Metab, 87, 5587-93. 
ANDREWS, R. C., ROOYACKERS, O. & WALKER, B. R. 2003. Effects of the 11 beta-
hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in 
men with type 2 diabetes. J Clin Endocrinol Metab, 88, 285-91. 
ARASE, K., YORK, D. A., SHIMIZU, H., SHARGILL, N. & BRAY, G. A. 1988. Effects 
of corticotropin-releasing factor on food intake and brown adipose tissue 
thermogenesis in rats. Am J Physiol, 255, E255-9. 
ASENSIO, C., MUZZIN, P. & ROHNER-JEANRENAUD, F. 2004. Role of 
glucocorticoids in the physiopathology of excessive fat deposition and insulin 
resistance. Int J Obes Relat Metab Disord, 28 Suppl 4, S45-52. 
ASOKAN, A., HAMRA, J. B., GOVINDASAMY, L., AGBANDJE-MCKENNA, M. & 
SAMULSKI, R. J. 2006. Adeno-associated virus type 2 contains an integrin 
alpha5beta1 binding domain essential for viral cell entry. J Virol, 80, 8961-9. 
BAI, F. L., YAMANO, M., SHIOTANI, Y., EMSON, P. C., SMITH, A. D., POWELL, J. 
F. & TOHYAMA, M. 1985. An arcuato-paraventricular and -dorsomedial 
hypothalamic neuropeptide Y-containing system which lacks noradrenaline in 
the rat. Brain Res, 331, 172-5. 
BALE, T. L. & VALE, W. W. 2004. CRF and CRF receptors: role in stress responsivity 
and other behaviors. Annu Rev Pharmacol Toxicol, 44, 525-57. 
BALTHASAR, N., COPPARI, R., MCMINN, J., LIU, S. M., LEE, C. E., TANG, V., 
KENNY, C. D., MCGOVERN, R. A., CHUA, S. C., JR., ELMQUIST, J. K. & 
LOWELL, B. B. 2004. Leptin receptor signaling in POMC neurons is required 
for normal body weight homeostasis. Neuron, 42, 983-91. 
BAMSHAD, M., SONG, C. K. & BARTNESS, T. J. 1999. CNS origins of the 
sympathetic nervous system outflow to brown adipose tissue. Am J Physiol, 276, 
R1569-78. 
BARSH, G. S. & SCHWARTZ, M. W. 2002. Genetic approaches to studying energy 
balance: perception and integration. Nat Rev Genet, 3, 589-600. 
BARTLETT, J. S., SAMULSKI, R. J. & MCCOWN, T. J. 1998. Selective and rapid 
uptake of adeno-associated virus type 2 in brain. Hum Gene Ther, 9, 1181-6. 
BASKIN, D. G., FIGLEWICZ, D. P., WOODS, S. C., PORTE, D., JR. & DORSA, D. M. 
1987. Insulin in the brain. Annu Rev Physiol, 49, 335-47. 
265 
 
BASKIN, D. G., SCHWARTZ, M. W., SEELEY, R. J., WOODS, S. C., PORTE, D., JR., 
BREININGER, J. F., JONAK, Z., SCHAEFER, J., KROUSE, M., 
BURGHARDT, C., CAMPFIELD, L. A., BURN, P. & KOCHAN, J. P. 1999. 
Leptin receptor long-form splice-variant protein expression in neuron cell bodies 
of the brain and co-localization with neuropeptide Y mRNA in the arcuate 
nucleus. J Histochem Cytochem, 47, 353-62. 
BELLINGER, L. L. & BERNARDIS, L. L. 2002. The dorsomedial hypothalamic 
nucleus and its role in ingestive behavior and body weight regulation: lessons 
learned from lesioning studies. Physiol Behav, 76, 431-42. 
BERTHOUD, H. R. 2002. Multiple neural systems controlling food intake and body 
weight. Neurosci Biobehav Rev, 26, 393-428. 
BILLINGTON, C. J., BRIGGS, J. E., GRACE, M. & LEVINE, A. S. 1991. Effects of 
intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J 
Physiol, 260, R321-7. 
BILLINGTON, C. J., BRIGGS, J. E., HARKER, S., GRACE, M. & LEVINE, A. S. 
1994. Neuropeptide Y in hypothalamic paraventricular nucleus: a center 
coordinating energy metabolism. Am J Physiol, 266, R1765-70. 
BITTENCOURT, J. C., PRESSE, F., ARIAS, C., PETO, C., VAUGHAN, J., NAHON, 
J. L., VALE, W. & SAWCHENKO, P. E. 1992. The melanin-concentrating 
hormone system of the rat brain: an immuno- and hybridization histochemical 
characterization. J Comp Neurol, 319, 218-45. 
BJORNTORP, P. 2001. Do stress reactions cause abdominal obesity and comorbidities? 
Obes Rev, 2, 73-86. 
BLEVINS, J. E., STANLEY, B. G. & REIDELBERGER, R. D. 2000. Brain regions 
where cholecystokinin suppresses feeding in rats. Brain Res, 860, 1-10. 
BOLEN, S., FELDMAN, L., VASSY, J., WILSON, L., YEH, H. C., MARINOPOULOS, 
S., WILEY, C., SELVIN, E., WILSON, R., BASS, E. B. & BRANCATI, F. L. 
2007. Systematic review: comparative effectiveness and safety of oral 
medications for type 2 diabetes mellitus. Ann Intern Med, 147, 386-99. 
BOULLAND, J. L., QURESHI, T., SEAL, R. P., RAFIKI, A., GUNDERSEN, V., 
BERGERSEN, L. H., FREMEAU, R. T., JR., EDWARDS, R. H., STORM-
MATHISEN, J. & CHAUDHRY, F. A. 2004. Expression of the vesicular 
glutamate transporters during development indicates the widespread corelease 
of multiple neurotransmitters. J Comp Neurol, 480, 264-80. 
BOYLE, C. D. & KOWALSKI, T. J. 2009. 11beta-hydroxysteroid dehydrogenase type 1 
inhibitors: a review of recent patents. Expert Opin Ther Pat, 19, 801-25. 
BRADY, L. S., SMITH, M. A., GOLD, P. W., HERKENHAM, M. & NEUROPEPTIDE, 
Y. 1990. Altered Expression of Hypothalamic Neuropeptide mRNAs in Food-
Restricted and Food-Deprived Rats. Logo, 52. 
266 
 
BRIGGS, D. I., ENRIORI, P. J., LEMUS, M. B., COWLEY, M. A. & ANDREWS, Z. B. 
2010. Diet-induced obesity causes ghrelin resistance in arcuate NPY/AgRP 
neurons. Endocrinology, 151, 4745-55. 
BRINDLEY, D. N., COOLING, J., GLENNY, H. P., BURDITT, S. L. & MCKECHNIE, 
I. S. 1981. Effects of chronic modification of dietary fat and carbohydrate on the 
insulin, corticosterone and metabolic responses of rats fed acutely with glucose, 
fructose or ethanol. Biochem J, 200, 275-83. 
BROBERGER, C., JOHANSEN, J., JOHANSSON, C., SCHALLING, M. & 
HÖKFELT, T. 1998. The neuropeptide Y/agouti gene-related protein (AGRP) 
brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. 
Proceedings of the National Academy of Sciences of the United States of America, 
95, 15043. 
BRUNING, J. C., GAUTAM, D., BURKS, D. J., GILLETTE, J., SCHUBERT, M., 
ORBAN, P. C., KLEIN, R., KRONE, W., MULLER-WIELAND, D. & KAHN, 
C. R. 2000. Role of brain insulin receptor in control of body weight and 
reproduction. Science, 289, 2122-5. 
CACHO, J., SEVILLANO, J., DE CASTRO, J., HERRERA, E. & RAMOS, M. P. 2008. 
Validation of simple indexes to assess insulin sensitivity during pregnancy in 
Wistar and Sprague-Dawley rats. Am J Physiol Endocrinol Metab, 295, E1269-76. 
CANNON, B. & NEDERGAARD, J. 2004. Brown adipose tissue: function and 
physiological significance. Physiol Rev, 84, 277-359. 
CANO, G., PASSERIN, A. M., SCHILTZ, J. C., CARD, J. P., MORRISON, S. F. & 
SVED, A. F. 2003. Anatomical substrates for the central control of sympathetic 
outflow to interscapular adipose tissue during cold exposure. J Comp Neurol, 
460, 303-26. 
CHEN, A. S., MARSH, D. J., TRUMBAUER, M. E., FRAZIER, E. G., GUAN, X. M., 
YU, H., ROSENBLUM, C. I., VONGS, A., FENG, Y., CAO, L., METZGER, J. 
M., STRACK, A. M., CAMACHO, R. E., MELLIN, T. N., NUNES, C. N., MIN, 
W., FISHER, J., GOPAL-TRUTER, S., MACINTYRE, D. E., CHEN, H. Y. & 
VAN DER PLOEG, L. H. 2000. Inactivation of the mouse melanocortin-3 
receptor results in increased fat mass and reduced lean body mass. Nat Genet, 
26, 97-102. 
CHEN, H. Y., TRUMBAUER, M. E., CHEN, A. S., WEINGARTH, D. T., ADAMS, J. 
R., FRAZIER, E. G., SHEN, Z., MARSH, D. J., FEIGHNER, S. D., GUAN, X. 
M., YE, Z., NARGUND, R. P., SMITH, R. G., VAN DER PLOEG, L. H., 
HOWARD, A. D., MACNEIL, D. J. & QIAN, S. 2004. Orexigenic action of 
peripheral ghrelin is mediated by neuropeptide Y and agouti-related protein. 
Endocrinology, 145, 2607-12. 
CHEUNG, C. C., CLIFTON, D. K. & STEINER, R. A. 1997. Proopiomelanocortin 
neurons are direct targets for leptin in the hypothalamus. Endocrinology, 138, 
4489-92. 
267 
 
CLARK, J. T., KALRA, P. S., CROWLEY, W. R. & KALRA, S. P. 1984. Neuropeptide 
Y and human pancreatic polypeptide stimulate feeding behavior in rats. 
Endocrinology, 115, 427-9. 
COBELLI, C., TOFFOLO, G. M., DALLA MAN, C., CAMPIONI, M., DENTI, P., 
CAUMO, A., BUTLER, P. & RIZZA, R. 2007. Assessment of beta-cell function 
in humans, simultaneously with insulin sensitivity and hepatic extraction, from 
intravenous and oral glucose tests. Am J Physiol Endocrinol Metab, 293, E1-E15. 
COHN, C., SHRAGO, E. & JOSEPH, D. 1955. Effect of food administration on weight 
gains and body composition of normal and adrenalectomized rats. Am J Physiol, 
180, 503-7. 
COLL, A. P., CHALLIS, B. G., LOPEZ, M., PIPER, S., YEO, G. S. H. & O'RAHILLY, 
S. 2005. Proopiomelanocortin-Deficient Mice Are Hypersensitive to the Adverse 
Metabolic Effects of Glucocorticoids. Am Diabetes Assoc. 
CONE, R. D., COWLEY, M. A., BUTLER, A. A., FAN, W., MARKS, D. L. & LOW, M. 
J. 2001. The arcuate nucleus as a conduit for diverse signals relevant to energy 
homeostasis. International Journal of Obesity, 25, 63-67. 
CONE, R. D., LU, D., KOPPULA, S., VAGE, D. I., KLUNGLAND, H., BOSTON, B., 
CHEN, W., ORTH, D. N., POUTON, C. & KESTERSON, R. A. 1996. The 
melanocortin receptors: agonists, antagonists, and the hormonal control of 
pigmentation. Recent Prog Horm Res, 51, 287-317; discussion 318. 
CONSIDINE, R. V., SINHA, M. K., HEIMAN, M. L., KRIAUCIUNAS, A., 
STEPHENS, T. W., NYCE, M. R., OHANNESIAN, J. P., MARCO, C. C., 
MCKEE, L. J., BAUER, T. L. & ET AL. 1996. Serum immunoreactive-leptin 
concentrations in normal-weight and obese humans. N Engl J Med, 334, 292-5. 
CONWAY, B. & RENE, A. 2004. Obesity as a disease: no lightweight matter. Obes Rev, 
5, 145-51. 
COTA, D., PROULX, K. & SEELEY, R. J. 2007. The role of CNS fuel sensing in energy 
and glucose regulation. Gastroenterology, 132, 2158-68. 
COWLEY, M. A. 2003. Hypothalamic melanocortin neurons integrate signals of energy 
state. European Journal of Pharmacology, 480, 3-11. 
COWLEY, M. A., SMART, J. L., RUBINSTEIN, M., CERDAN, M. G., DIANO, S., 
HORVATH, T. L., CONE, R. D. & LOW, M. J. 2001. Leptin activates 
anorexigenic POMC neurons through a neural network in the arcuate nucleus. 
Nature, 411, 480-4. 
CREUTZFELDT, W. 1979. The incretin concept today. Diabetologia, 16, 75-85. 
CRYER, P. E. 1999. Hypoglycemia is the limiting factor in the management of diabetes. 
Diabetes Metab Res Rev, 15, 42-6. 
268 
 
CUMMINGS, D. E., OVERDUIN, J. & FOSTER-SCHUBERT, K. E. 2004. Gastric 
bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin 
Endocrinol Metab, 89, 2608-15. 
CUSHING, H. 1913. The pituitary body and its disorders. Annals of Surgery, 57, 137. 
CUSIN, I., ROHNER-JEANRENAUD, F., STRICKER-KRONGRAD, A. & 
JEANRENAUD, B. 1996. The weight-reducing effect of an 
intracerebroventricular bolus injection of leptin in genetically obese fa/fa rats. 
Reduced sensitivity compared with lean animals. Diabetes, 45, 1446-50. 
CUSIN, I., ROURU, J. & ROHNER-JEANRENAUD, F. 2001. Intracerebroventricular 
Glucocorticoid Infusion in Normal Rats: Induction of Parasympathetic-
Mediated Obesity and Insulin Resistance. NAASO. 
CYPESS, A. M., LEHMAN, S., WILLIAMS, G., TAL, I., RODMAN, D., GOLDFINE, 
A. B., KUO, F. C., PALMER, E. L., TSENG, Y. H., DORIA, A., KOLODNY, G. 
M. & KAHN, C. R. 2009. Identification and importance of brown adipose tissue 
in adult humans. N Engl J Med, 360, 1509-17. 
DAYA, S. & BERNS, K. I. 2008. Gene therapy using adeno-associated virus vectors. 
Clin Microbiol Rev, 21, 583-93. 
DE FEO, P., PERRIELLO, G., TORLONE, E., VENTURA, M. M., FANELLI, C., 
SANTEUSANIO, F., BRUNETTI, P., GERICH, J. E. & BOLLI, G. B. 1989. 
Contribution of cortisol to glucose counterregulation in humans. Am J Physiol, 
257, E35-42. 
DE KLOET, E. R., VREUGDENHIL, E., OITZL, M. S. & JOELS, M. 1998. Brain 
Corticosteroid Receptor Balance in Health and Disease 1. Endocrine Reviews, 19, 
269-301. 
DE SOUZA, C. T., ARAUJO, E. P., BORDIN, S., ASHIMINE, R., ZOLLNER, R. L., 
BOSCHERO, A. C., SAAD, M. J. & VELLOSO, L. A. 2005. Consumption of a 
fat-rich diet activates a proinflammatory response and induces insulin resistance 
in the hypothalamus. Endocrinology, 146, 4192-9. 
DEBONS, A. F. 1982. Gold thioglucose-induced hypothalamic damage, hyperphagia, 
and obesity: dependence on the adrenal gland. Endocrinology, 110, 2024-2029. 
DEBONS, A. F., ZUREK, L. D., TSE, C. S. & ABRAHAMSEN, S. 1986. Central 
nervous system control of hyperphagia in hypothalamic obesity: dependence on 
adrenal glucocorticoids. Endocrinology, 118, 1678-81. 
DENSMORE, V. S., MORTON, N. M., MULLINS, J. J. & SECKL, J. R. 2006. 11 beta-
hydroxysteroid dehydrogenase type 1 induction in the arcuate nucleus by high-
fat feeding: A novel constraint to hyperphagia? Endocrinology, 147, 4486-95. 
DICKINSON, K., NORTH, T. J., TELFORD, G., SMITH, S., BRAMMER, R., JONES, 
R. B. & HEAL, D. J. 2001. Determination of body composition in conscious adult 
female Wistar utilising total body electrical conductivity. Physiol Behav, 74, 425-
33. 
269 
 
DRAKE, A. J., LIVINGSTONE, D. E., ANDREW, R., SECKL, J. R., MORTON, N. M. 
& WALKER, B. R. 2005. Reduced adipose glucocorticoid reactivation and 
increased hepatic glucocorticoid clearance as an early adaptation to high-fat 
feeding in Wistar rats. Endocrinology, 146, 913-9. 
DRAPER, N., ECHWALD, S. M., LAVERY, G. G., WALKER, E. A., FRASER, R., 
DAVIES, E., SORENSEN, T. I., ASTRUP, A., ADAMSKI, J., HEWISON, M., 
CONNELL, J. M., PEDERSEN, O. & STEWART, P. M. 2002. Association 
studies between microsatellite markers within the gene encoding human 11beta-
hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, 
and glucocorticoid metabolism. J Clin Endocrinol Metab, 87, 4984-90. 
DRAZEN, D. L., WORTMAN, M. D., SCHWARTZ, M. W., CLEGG, D. J., VAN DIJK, 
G., WOODS, S. C. & SEELEY, R. J. 2003. Adrenalectomy Alters the Sensitivity 
of the Central Nervous System Melanocortin System. Am Diabetes Assoc. 
DROUIN, J., SUN, Y. L., CHAMBERLAND, M., GAUTHIER, Y., DE LÉAN, A., 
NEMER, M. & SCHMIDT, T. J. 1993. Novel glucocorticoid receptor complex 
with DNA element of the hormone-repressed POMC gene. The EMBO Journal, 
12, 145. 
DROUIN, J., TRIFIRO, M. A., PLANTE, R. K., NEMER, M., ERIKSSON, P. & 
WRANGE, O. 1989. Glucocorticoid receptor binding to a specific DNA sequence 
is required for hormone-dependent repression of pro-opiomelanocortin gene 
transcription. Molecular and Cellular Biology, 9, 5305-5314. 
DRUCKER, D. J. 1998. Glucagon-like peptides. Diabetes, 47, 159-69. 
DUAN, D., LI, Q., KAO, A. W., YUE, Y., PESSIN, J. E. & ENGELHARDT, J. F. 1999. 
Dynamin is required for recombinant adeno-associated virus type 2 infection. J 
Virol, 73, 10371-6. 
DUHAULT, J., BOULANGER, M., CHAMORRO, S., BOUTIN, J. A., ZUANA, O. D., 
DOUILLET, E., JEAN-LUC, F., FELETOU, M., GERMAIN, M. & HUSSON, B. 
2000. Food intake regulation in rodents: Y~ 5 or Y~ 1 NPY receptors or both? 
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 78, 173-
185. 
ELIAS, C. F., LEE, C. E., KELLY, J. F., AHIMA, R. S., KUHAR, M., SAPER, C. B. & 
ELMQUIST, J. K. 2001. Characterization of CART neurons in the rat and 
human hypothalamus. The Journal of Comparative Neurology, 432, 1-19. 
ELMQUIST, J. K., ELIAS, C. F. & SAPER, C. B. 1999. From lesions to leptin: 
hypothalamic control of food intake and body weight. Neuron, 22, 221-232. 
ELMQUIST, J. K., MARATOS-FLIER, E., SAPER, C. B. & FLIER, J. S. 1998. 
Unraveling the central nervous system pathways underlying responses to leptin. 
Nat Neurosci, 1, 445-50. 
EMESON, R. B. & EIPPER, B. A. 1986. Characterization of pro-ACTH/endorphin-
derived peptides in rat hypothalamus. J Neurosci, 6, 837-49. 
270 
 
FEINBERG, A. P. & VOGELSTEIN, B. 1983. A technique for radiolabeling DNA 
restriction endonuclease fragments to high specific activity. Anal Biochem, 132, 
6-13. 
FELDMANN, H. M., GOLOZOUBOVA, V., CANNON, B. & NEDERGAARD, J. 2009. 
UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice 
exempt from thermal stress by living at thermoneutrality. Cell Metab, 9, 203-9. 
FINK, G. 2000. Encyclopedia of stress, Academic Pr. 
FINLEY, J. C., LINDSTROM, P. & PETRUSZ, P. 1981. Immunocytochemical 
localization of beta-endorphin-containing neurons in the rat brain. 
Neuroendocrinology, 33, 28-42. 
FLIERS, E., NOPPEN, N., WIERSINGA, W. M., VISSER, T. J. & SWAAB, D. F. 1994. 
DISTRIBUTION OF THYROTROPIN-RELEASING HORMONE(TRH)-
CONTAINING CELLS AND FIBERS IN THE HUMAN HYPOTHALAMUS. 
Journal of comparative neurology(1911), 350, 311-323. 
FRASER, R., INGRAM, M. C., ANDERSON, N. H., MORRISON, C., DAVIES, E. & 
CONNELL, J. M. C. 1999. Cortisol Effects on Body Mass, Blood Pressure, and 
Cholesterol in the General Population. Am Heart Assoc. 
FREEDMAN, M. R., HORWITZ, B. A. & STERN, J. S. 1986. Effect of adrenalectomy 
and glucocorticoid replacement on development of obesity. American Journal of 
Physiology- Regulatory, Integrative and Comparative Physiology, 250, 595-607. 
GARDEMANN, A., STRULIK, H. & JUNGERMANN, K. 1986. A portal-arterial 
glucose concentration gradient as a signal for an insulin-dependent net glucose 
uptake in perfused rat liver. FEBS Lett, 202, 255-9. 
GARDINER, J. V., KONG, W. M., WARD, H., MURPHY, K. G., DHILLO, W. S. & 
BLOOM, S. R. 2005. AAV mediated expression of anti-sense neuropeptide Y 
cRNA in the arcuate nucleus of rats results in decreased weight gain and food 
intake. Biochem Biophys Res Commun, 327, 1088-93. 
GARDLIK, R., PALFFY, R., HODOSY, J., LUKACS, J., TURNA, J. & CELEC, P. 
2005. Vectors and delivery systems in gene therapy. Med Sci Monit, 11, RA110-
21. 
GEE, C. E., CHEN, C. L. C., ROBERTS, J. L., THOMPSON, R. & WATSON, S. J. 
1983. Identification of proopiomelanocortin neurones in rat hypothalamus by in 
situ cDNA-mRNA hybridization. Nature, 306, 374-376. 
GERMAN, M. S. 1993. Glucose sensing in pancreatic islet beta cells: the key role of 
glucokinase and the glycolytic intermediates. Proc Natl Acad Sci U S A, 90, 1781-
5. 
GOKE, R., LARSEN, P. J., MIKKELSEN, J. D. & SHEIKH, S. P. 1995. Distribution of 
GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain 
GLP-1 binding sites. Eur J Neurosci, 7, 2294-300. 
271 
 
GOODPASTER, B. H., KRISHNASWAMI, S., RESNICK, H., KELLEY, D. E., 
HAGGERTY, C., HARRIS, T. B., SCHWARTZ, A. V., KRITCHEVSKY, S. & 
NEWMAN, A. B. 2003. Association between regional adipose tissue distribution 
and both type 2 diabetes and impaired glucose tolerance in elderly men and 
women. Diabetes Care, 26, 372-9. 
GRAHAM, F. L. & VAN DER EB, A. J. 1973. A new technique for the assay of 
infectivity of human adenovirus 5 DNA. Virology, 52, 456-67. 
GRAMSCH, C., KLEBER, G., HOLLT, V., PASI, A., MEHRAEIN, P. & HERZ, A. 
1980. Pro-opiocortin fragments in human and rat brain: beta-endorphin and 
alpha-MSH are the predominant peptides. Brain Res, 192, 109-119. 
GREEN, P. K. 1992. Intraventricular corticosterone increases the rate of body weight 
gain in underweight adrenalectomized rats. Endocrinology, 130, 269-275. 
GRIMM, D., KERN, A., RITTNER, K. & KLEINSCHMIDT, J. A. 1998. Novel tools for 
production and purification of recombinant adenoassociated virus vectors. Hum 
Gene Ther, 9, 2745-60. 
HAGAN, M. M., RUSHING, P. A., PRITCHARD, L. M., SCHWARTZ, M. W., 
STRACK, A. M., VAN DER PLOEG, L. H. T., WOODS, S. C. & SEELEY, R. J. 
2000. Long-term orexigenic effects of AgRP-(83-132) involve mechanisms other 
than melanocortin receptor blockade. American journal of physiology.Regulatory, 
integrative and comparative physiology, 48, 47-52. 
HAHN, T. M., BREININGER, J. F., BASKIN, D. G. & SCHWARTZ, M. W. 1998. 
Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat 
Neurosci, 1, 271-2. 
HAKANSSON, M. L., HULTING, A. L. & MEISTER, B. 1996. Expression of leptin 
receptor mRNA in the hypothalamic arcuate nucleus--relationship with NPY 
neurones. Neuroreport, 7, 3087-92. 
HALAAS, J. L., BOOZER, C., BLAIR-WEST, J., FIDAHUSEIN, N., DENTON, D. A. 
& FRIEDMAN, J. M. 1997. Physiological response to long-term peripheral and 
central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A, 94, 8878-
83. 
HALAAS, J. L., GAJIWALA, K. S., MAFFEI, M., COHEN, S. L., CHAIT, B. T., 
RABINOWITZ, D., LALLONE, R. L., BURLEY, S. K. & FRIEDMAN, J. M. 
1995. Weight-reducing effects of the plasma protein encoded by the obese gene. 
Science, 269, 543-6. 
HANAHAN, D. 1983. Studies on transformation of Escherichia coli with plasmids. J 
Mol Biol, 166, 557-80. 
HANSON, E. S., LEVIN, N. & DALLMAN, M. F. 1997. Elevated Corticosterone Is Not 
Required for the Rapid Induction of Neuropeptide Y Gene Expression by an 
Overnight Fast 1. Endocrinology, 138, 1041-1047. 
272 
 
HARFSTRAND, A., CINTRA, A., FUXE, K., ARONSSON, M., WIKSTROM, A. C., 
OKRET, S., GUSTAFSSON, J. A. & AGNATI, L. F. 1989. Regional differences 
in glucocorticoid receptor immunoreactivity among neuropeptide Y 
immunoreactive neurons of the rat brain. Acta Physiol Scand, 135, 3-9. 
HARRIS, H. J., KOTELEVTSEV, Y., MULLINS, J. J., SECKL, J. R. & HOLMES, M. 
C. 2001. Intracellular regeneration of glucocorticoids by 11beta-hydroxysteroid 
dehydrogenase (11beta-HSD)-1 plays a key role in regulation of the 
hypothalamic-pituitary-adrenal axis: analysis of 11beta-HSD-1-deficient mice. 
Endocrinology, 142, 114-20. 
HASKELL-LUEVANO, C., CHEN, P., LI, C., CHANG, K., SMITH, M. S., 
CAMERON, J. L. & CONE, R. D. 1999. Characterization of the 
neuroanatomical distribution of agouti-related protein immunoreactivity in the 
rhesus monkey and the rat. Endocrinology, 140, 1408-15. 
HASKELL-LUEVANO, C. & MONCK, E. K. 2001. Agouti-related protein functions as 
an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul 
Pept, 99, 1-7. 
HEIKKINEN, S., ARGMANN, C. A., CHAMPY, M. F. & AUWERX, J. 2007. 
Evaluation of glucose homeostasis. Curr Protoc Mol Biol, Chapter 29, Unit 29B 3. 
HEINRICHS, S. C. & RICHARD, D. 1999. The role of corticotropin-releasing factor 
and urocortin in the modulation of ingestive behavior. Neuropeptides, 33, 350-9. 
HERMAN, J. P., FIGUEIREDO, H., MUELLER, N. K., ULRICH-LAI, Y., 
OSTRANDER, M. M., CHOI, D. C. & CULLINAN, W. E. 2003. Central 
mechanisms of stress integration: hierarchical circuitry controlling 
hypothalamo–pituitary–adrenocortical responsiveness. Frontiers in 
Neuroendocrinology, 24, 151-180. 
HETHERINGTON, A. W. & RANSON, S. W. 1940. Hypothalamic lesions and adiposity 
in the rat. The Anatomical Record, 78, 149-172. 
HIRSCHBERG, A. L. 1998. Hormonal regulation of appetite and food intake. Ann Med, 
30, 7-20. 
HISANO, S., KAGOTANI, Y., TSURUO, Y., DAIKOKU, S., CHIHARA, K. & 
WHITNALL, M. H. 1988. Localization of glucocorticoid receptor in 
neuropeptide Y-containing neurons in the arcuate nucleus of the rat 
hypothalamus. Neurosci Lett, 95, 13-8. 
HOLMES, M. C. & SECKL, J. R. 2006. The role of 11beta-hydroxysteroid 
dehydrogenases in the brain. Mol Cell Endocrinol, 248, 9-14. 
HOLMES, M. C., YAU, J. L., KOTELEVTSEV, Y., MULLINS, J. J. & SECKL, J. R. 
2003. 11 Beta-hydroxysteroid dehydrogenases in the brain: two enzymes two 
roles. Ann N Y Acad Sci, 1007, 357-66. 
HORVATH, T. L., DIANO, S. & VAN DEN POL, A. N. 1999. Synaptic Interaction 
between Hypocretin (Orexin) and Neuropeptide Y Cells in the Rodent and 
273 
 
Primate Hypothalamus: A Novel Circuit Implicated in Metabolic and Endocrine 
Regulations. Journal of Neuroscience, 19, 1072-1087. 
HUSZAR, D., LYNCH, C. A., FAIRCHILD-HUNTRESS, V., DUNMORE, J. H., 
FANG, Q., BERKEMEIER, L. R., GU, W., KESTERSON, R. A., BOSTON, B. 
A., CONE, R. D., SMITH, F. J., CAMPFIELD, L. A., BURN, P. & LEE, F. 1997. 
Targeted disruption of the melanocortin-4 receptor results in obesity in mice. 
Cell, 88, 131-41. 
JACOBOWITZ, D. M. & O'DONOHUE, T. L. 1978. alpha-Melanocyte stimulating 
hormone: immunohistochemical identification and mapping in neurons of rat 
brain. Proc Natl Acad Sci U S A, 75, 6300-4. 
JAMES, W. P. 2008. The fundamental drivers of the obesity epidemic. Obes Rev, 9 
Suppl 1, 6-13. 
JAUREGUI-HUERTA, F., RUVALCABA-DELGADILLO, Y., GONZALEZ-
CASTANEDA, R., GARCIA-ESTRADA, J., GONZALEZ-PEREZ, O. & 
LUQUIN, S. 2010. Responses of glial cells to stress and glucocorticoids. Curr 
Immunol Rev, 6, 195-204. 
JEANRENAUD, B. & ROHNER-JEANRENAUD, F. 2000. CNS-periphery 
relationships and body weight homeostasis: influence of the glucocorticoid 
status. International Journal of Obesity, 24, 74-76. 
JOBST, E. E., ENRIORI, P. J. & COWLEY, M. A. 2004. The electrophysiology of 
feeding circuits. Trends Endocrinol Metab, 15, 488-99. 
JOSEPH, S. A. & MICHAEL, G. J. 1988. Efferent ACTH-IR opiocortin projections 
from nucleus tractus solitarius: a hypothalamic deafferentation study. Peptides, 
9, 193-201. 
KAHN, S. E. 2001. Clinical review 135: The importance of beta-cell failure in the 
development and progression of type 2 diabetes. J Clin Endocrinol Metab, 86, 
4047-58. 
KANG, L., ROUTH, V. H., KUZHIKANDATHIL, E. V., GASPERS, L. D. & LEVIN, 
B. E. 2004. Physiological and molecular characteristics of rat hypothalamic 
ventromedial nucleus glucosensing neurons. Diabetes, 53, 549-59. 
KANNISTO, K., PIETILAINEN, K. H., EHRENBORG, E., RISSANEN, A., KAPRIO, 
J., HAMSTEN, A. & YKI-JARVINEN, H. 2004. Overexpression of 11î-
Hydroxysteroid Dehydrogenase-1 in Adipose Tissue Is Associated with Acquired 
Obesity and Features of Insulin Resistance: Studies in Young Adult Monozygotic 
Twins. Endocrine Soc. 
KASHIWAKURA, Y., TAMAYOSE, K., IWABUCHI, K., HIRAI, Y., SHIMADA, T., 
MATSUMOTO, K., NAKAMURA, T., WATANABE, M., OSHIMI, K. & 
DAIDA, H. 2005. Hepatocyte growth factor receptor is a coreceptor for adeno-
associated virus type 2 infection. J Virol, 79, 609-14. 
274 
 
KIM, M. S., ROSSI, M., ABUSNANA, S., SUNTER, D., MORGAN, D. G., SMALL, C. 
J., EDWARDS, C. M., HEATH, M. M., STANLEY, S. A. & SEAL, L. J. 2000. 
Hypothalamic localization of the feeding effect of agouti-related peptide and 
alpha-melanocyte-stimulating hormone. Diabetes, 49, 177. 
KISSEBAH, A. H. & KRAKOWER, G. R. 1994. Regional adiposity and morbidity. 
Physiol Rev, 74, 761-811. 
KLEIN, R. L., HAMBY, M. E., GONG, Y., HIRKO, A. C., WANG, S., HUGHES, J. A., 
KING, M. A. & MEYER, E. M. 2002. Dose and promoter effects of adeno-
associated viral vector for green fluorescent protein expression in the rat brain. 
Exp Neurol, 176, 66-74. 
KOCHAN, Z., KARBOWSKA, J. & SWIERCZYNSKI, J. 1997. Unususal increase of 
lipogenesis in rat white adipose tissue after multiple cycles of starvation-
refeeding. Metabolism, 46, 10-7. 
KOTELEVTSEV, Y., HOLMES, M. C., BURCHELL, A., HOUSTON, P. M., 
SCHMOLL, D., JAMIESON, P., BEST, R., BROWN, R., EDWARDS, C. R., 
SECKL, J. R. & MULLINS, J. J. 1997. 11beta-hydroxysteroid dehydrogenase 
type 1 knockout mice show attenuated glucocorticoid-inducible responses and 
resist hyperglycemia on obesity or stress. Proc Natl Acad Sci U S A, 94, 14924-9. 
KOTIN, R. M., SINISCALCO, M., SAMULSKI, R. J., ZHU, X. D., HUNTER, L., 
LAUGHLIN, C. A., MCLAUGHLIN, S., MUZYCZKA, N., ROCCHI, M. & 
BERNS, K. I. 1990. Site-specific integration by adeno-associated virus. Proc Natl 
Acad Sci U S A, 87, 2211-5. 
KOYLU, E. O., COUCEYRO, P. R., LAMBERT, P. D. & KUHAR, M. J. 1998. 
Cocaine-and Amphetamine-Regulated Transcript Peptide Immunohistochemical 
Localization in the Rat Brain. The Journal of Comparative Neurology, 391, 115-
132. 
KRISTENSEN, P., JUDGE, M. E., THIM, L., RIBEL, U., CHRISTJANSEN, K. N., 
WULFF, B. S., CLAUSEN, J. T., JENSEN, P. B., MADSEN, O. D. & VRANG, 
N. 1998. Hypothalamic CART is a new anorectic peptide regulated by leptin. 
Nature(London), 393, 72-76. 
KRUK, M. R. 1991. Ethology and pharmacology of hypothalamic aggression in the rat. 
Neurosci Biobehav Rev, 15, 527-538. 
KURINA, L. M., WEISS, L. A., GRAVES, S. W., PARRY, R., WILLIAMS, G. H., 
ABNEY, M. & OBER, C. 2005. Sex Differences in the Genetic Basis of Morning 
Serum Cortisol Levels: Genome-Wide Screen Identifies Two Novel Loci Specific 
to Women. Endocrine Soc. 
LA FLEUR, S. E. 2006. The effects of glucocorticoids on feeding behavior in rats. 
Physiology & Behavior, 89, 110-114. 
LAM, C. K., CHARI, M. & LAM, T. K. 2009. CNS regulation of glucose homeostasis. 
Physiology (Bethesda), 24, 159-70. 
275 
 
LAMBERT, P. D., COUCEYRO, P. R., MCGIRR, K. M., DALL VECHIA, S. E., 
SMITH, Y. & KUHAR, M. J. 1998. CART peptides in the central control of 
feeding and interactions with neuropeptide Y. Synapse, 29, 293-298. 
LANDRY, M., VILA-PORCILE, E., HOKFELT, T. & CALAS, A. 2003. Differential 
routing of coexisting neuropeptides in vasopressin neurons. European Journal of 
Neuroscience, 17, 579-589. 
LARSEN, P. J., JESSOP, D. S., CHOWDREY, H. S., LIGHTMAN, S. L. & 
MIKKELSEN, J. D. 1994. Chronic administration of glucocorticoids directly 
upregulates prepro-neuropeptide Y and Y1-receptor mRNA levels in the arcuate 
nucleus of the rat. J Neuroendocrinol, 6, 153-9. 
LEAHY, J. L. 2005. Pathogenesis of type 2 diabetes mellitus. Arch Med Res, 36, 197-209. 
LEHRACH, H., DIAMOND, D., WOZNEY, J. M. & BOEDTKER, H. 1977. RNA 
molecular weight determinations by gel electrophoresis under denaturing 
conditions, a critical reexamination. Biochemistry, 16, 4743-51. 
LEVIN, B. E. 2001. Glucosensing neurons do more than just sense glucose. Int J Obes 
Relat Metab Disord, 25 Suppl 5, S68-72. 
LEVIN, B. E., DUNN-MEYNELL, A. A. & ROUTH, V. H. 1999. Brain glucose sensing 
and body energy homeostasis: role in obesity and diabetes. Am J Physiol, 276, 
R1223-31. 
LIOTTA, A. S., ADVIS, J. P., KRAUSE, J. E., MCKELVY, J. F. & KRIEGER, D. T. 
1984. Demonstration of in vivo synthesis of pro-opiomelanocortin-, beta-
endorphin-, and alpha-melanotropin-like species in the adult rat brain. Journal 
of Neuroscience, 4, 956-965. 
LIPOSITS, Z., SIEVERS, L. & PAULL, W. K. 1988. Neuropeptide-Y and ACTH-
immunoreactive innervation of corticotropin releasing factor (CRF)-synthesizing 
neurons in the hypothalamus of the rat. An immunocytochemical analysis at the 
light and electron microscopic levels. Histochemistry, 88, 227-34. 
LIU, J. & DEFRANCO, D. B. 2000. Protracted Nuclear Export of Glucocorticoid 
Receptor Limits Its Turnover and Does Not Require the Exportin 1/CRM1-
Directed Nuclear Export Pathway. Molecular Endocrinology, 14, 40-51. 
LIVINGSTONE, D. E. W., JONES, G. C., SMITH, K., JAMIESON, P. M., ANDREW, 
R., KENYON, C. J. & WALKER, B. R. 2000. Understanding the Role of 
Glucocorticoids in Obesity: Tissue-Specific Alterations of Corticosterone 
Metabolism in Obese Zucker Rats 1. Endocrinology, 141, 560-563. 
LOWELL, B. B. & SPIEGELMAN, B. M. 2000. Towards a molecular understanding of 
adaptive thermogenesis. Nature, 404, 652-660. 
LOWELL, B. B., V, S. S., HAMANN, A., LAWITTS, J. A., HIMMS-HAGEN, J., 
BOYER, B. B., KOZAK, L. P. & FLIER, J. S. 1993. Development of obesity in 
transgenic mice after genetic ablation of brown adipose tissue. Nature, 366, 740-
2. 
276 
 
LYNCH, R. M., TOMPKINS, L. S., BROOKS, H. L., DUNN-MEYNELL, A. A. & 
LEVIN, B. E. 2000. Localization of glucokinase gene expression in the rat brain. 
Diabetes, 49, 693-700. 
MACKENZIE, S. M., HUDA, S. S., SATTAR, N., FRASER, R., CONNELL, J. M. C. & 
DAVIES, E. 2008. Depot-specific steroidogenic gene transcription in human 
adipose tissue. Clinical Endocrinology. 
MADDEN, C. J. & MORRISON, S. F. 2009. Neurons in the paraventricular nucleus of 
the hypothalamus inhibit sympathetic outflow to brown adipose tissue. 
Am.J.Physiol Regul.Integr.Comp Physiol. 
MADIEHE, A. M., LIN, L., WHITE, C., BRAYMER, H. D., BRAY, G. A. & YORK, D. 
A. 2001. Constitutive activation of STAT-3 and downregulation of SOCS-3 
expression induced by adrenalectomy. American Journal of Physiology- 
Regulatory, Integrative and Comparative Physiology, 281, 2048-2058. 
MAKARA, G. B. 1992. The relative importance of hypothalamic neurons containing 
corticotropin-releasing factor or vasopressin in the regulation of 
adrenocorticotropic hormone secretion. Ciba Found Symp, 168, 43-51; discussion 
51-3. 
MAKIMURA, H., MIZUNO, T. M., ROBERTS, J., SILVERSTEIN, J., BEASLEY, J. & 
MOBBS, C. V. 2000. Adrenalectomy reverses obese phenotype and restores 
hypothalamic melanocortin tone in leptin-deficient ob/ob mice. Diabetes, 49, 
1917. 
MALKOSKI, S. P. & DORIN, R. I. 1999. Composite Glucocorticoid Regulation at a 
Functionally Defined Negative Glucocorticoid Response Element of the Human 
Corticotropin-Releasing Hormone Gene. Molecular Endocrinology, 13, 1629-
1644. 
MANTHA, L. & DESHAIES, Y. 2000. Energy intake-independent modulation of 
triglyceride metabolism by glucocorticoids in the rat. Am J Physiol Regul Integr 
Comp Physiol, 278, R1424-32. 
MARGARETO, J., MARTI, A. & MARTINEZ, J. A. 2001. Changes in UCP mRNA 
expression levels in brown adipose tissue and skeletal muscle after feeding a 
high-energy diet and relationships with leptin, glucose and PPARgamma. J Nutr 
Biochem, 12, 130-137. 
MARSH, D. J., HOLLOPETER, G., KAFER, K. E. & PALMITER, R. D. 1998. Role of 
the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med, 4, 718-21. 
MARTY, N., DALLAPORTA, M. & THORENS, B. 2007. Brain glucose sensing, 
counterregulation, and energy homeostasis. Physiology (Bethesda), 22, 241-51. 
MASUZAKI, H., PATERSON, J., SHINYAMA, H., MORTON, N. M., MULLINS, J. J., 
SECKL, J. R. & FLIER, J. S. 2001. A Transgenic Model of Visceral Obesity and 
the Metabolic Syndrome. 
277 
 
MERCHENTHALER, I., HYNES, M. A., VIGH, S., SCHALLY, A. V. & PETRUSZ, P. 
1984. Corticotropin Releasing Factor (CRF): Origin and Course of Afferent 
Pathways to the Median Eminence (ME) of the Rat Hypothalamus. Logo, 39. 
MICHAILIDOU, Z., COLL, A. P., KENYON, C. J., MORTON, N. M., O'RAHILLY, 
S., SECKL, J. R. & CHAPMAN, K. E. 2007. Peripheral mechanisms 
contributing to the glucocorticoid hypersensitivity in proopiomelanocortin null 
mice treated with corticosterone. Journal of Endocrinology, 194, 161. 
MINOKOSHI, Y., ALQUIER, T., FURUKAWA, N., KIM, Y. B., LEE, A., XUE, B., 
MU, J., FOUFELLE, F., FERRE, P., BIRNBAUM, M. J., STUCK, B. J. & 
KAHN, B. B. 2004. AMP-kinase regulates food intake by responding to 
hormonal and nutrient signals in the hypothalamus. Nature, 428, 569-74. 
MISAKI, N., HIGUCHI, H., YAMAGATA, K. & MIKI, N. 1992. Identification of 
glucocorticoid responsive elements (GREs) at far upstream of rat NPY gene. 
Neurochem Int, 21, 185-189. 
MITANI, F., MUKAI, K., MIYAMOTO, H., SUEMATSU, M. & ISHIMURA, Y. 1999. 
Development of Functional Zonation in the Rat Adrenal Cortex 1. 
Endocrinology, 140, 3342-3353. 
MOISAN, M. P. 1990. 11 beta-hydroxysteroid dehydrogenase bioactivity and messenger 
RNA expression in rat forebrain: localization in hypothalamus, hippocampus, 
and cortex. Endocrinology, 127, 1450-1455. 
MONDER, C. 1991. Corticosteroids, receptors, and the organ-specific functions of 11 
beta-hydroxysteroid dehydrogenase. The FASEB Journal, 5, 3047-3054. 
MORAES, J. C., COOPE, A., MORARI, J., CINTRA, D. E., ROMAN, E. A., PAULI, J. 
R., ROMANATTO, T., CARVALHEIRA, J. B., OLIVEIRA, A. L., SAAD, M. J. 
& VELLOSO, L. A. 2009. High-fat diet induces apoptosis of hypothalamic 
neurons. PLoS One, 4, e5045. 
MORTON, G. J., CUMMINGS, D. E., BASKIN, D. G., BARSH, G. S. & SCHWARTZ, 
M. W. 2006. Central nervous system control of food intake and body weight. 
Nature(London), 443, 289-295. 
MORTON, N. M., PATERSON, J. M., MASUZAKI, H., HOLMES, M. C., STAELS, B., 
FIEVET, C., WALKER, B. R., FLIER, J. S., MULLINS, J. J. & SECKL, J. R. 
2004. Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 
11 beta-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes, 53, 931-8. 
MUNIYAPPA, R., LEE, S., CHEN, H. & QUON, M. J. 2008. Current approaches for 
assessing insulin sensitivity and resistance in vivo: advantages, limitations, and 
appropriate usage. Am J Physiol Endocrinol Metab, 294, E15-26. 
MUROYA, S., FUNAHASHI, H., URAMURA, K., SHIODA, S. & YADA, T. 2005. 
Gamma aminobutyric acid regulates glucosensitive neuropeptide Y neurons in 
arcuate nucleus via A/B receptors. Neuroreport, 16, 897-901. 
278 
 
NEDERGAARD, J., BENGTSSON, T. & CANNON, B. 2007. Unexpected evidence for 
active brown adipose tissue in adult humans. American Journal of Physiology- 
Endocrinology And Metabolism, 293, E444. 
NISHIZAWA, M., MOORE, M. C., SHIOTA, M., GUSTAVSON, S. M., SNEAD, W. L., 
NEAL, D. W. & CHERRINGTON, A. D. 2003. Effect of intraportal glucagon-
like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol Endocrinol 
Metab, 284, E1027-36. 
NUMAKAWA, T., KUMAMARU, E., ADACHI, N., YAGASAKI, Y., IZUMI, A. & 
KUNUGI, H. 2009. Glucocorticoid receptor interaction with TrkB promotes 
BDNF-triggered PLC-gamma signaling for glutamate release via a glutamate 
transporter. Proc Natl Acad Sci U S A, 106, 647-52. 
NUSSEY, S. & WHITEHEAD, S. 2001. Endocrinology: an integrated approach, Informa 
HealthCare. 
OBICI, S., FENG, Z., KARKANIAS, G., BASKIN, D. G. & ROSSETTI, L. 2002a. 
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin 
resistance in rats. Nat Neurosci, 5, 566-72. 
OBICI, S., ZHANG, B. B., KARKANIAS, G. & ROSSETTI, L. 2002b. Hypothalamic 
insulin signaling is required for inhibition of glucose production. Nat Med, 8, 
1376-82. 
OLDFIELD, B. J., GILES, M. E., WATSON, A., ANDERSON, C., COLVILL, L. M. & 
MCKINLEY, M. J. 2002. The neurochemical characterisation of hypothalamic 
pathways projecting polysynaptically to brown adipose tissue in the rat. 
Neuroscience, 110, 515-26. 
OOMURA, Y., KIMURA, K., OOYAMA, H., MAENO, T., IKI, M. & KUNIYOSHI, M. 
1964. Reciprocal Activities of the Ventromedial and Lateral Hypothalamic Areas 
of Cats. Science, 143, 484-5. 
OTULAKOWSKI, G., DUAN, W., GANDHI, S. & O'BRODOVICH, H. 2007. Steroid 
and oxygen effects on eIF4F complex, mTOR, and ENaC translation in fetal lung 
epithelia. Am J Respir Cell Mol Biol, 37, 457-66. 
PALOMEQUE, J., CHEMALY, E. R., COLOSI, P., WELLMAN, J. A., ZHOU, S., DEL 
MONTE, F. & HAJJAR, R. J. 2007. Efficiency of eight different AAV serotypes 
in transducing rat myocardium in vivo. Gene Ther, 14, 989-97. 
PAXINOS, G. & WATSON, C. 2007. The rat brain in stereotaxic coordinates, Academic 
Pr. 
POCAI, A., OBICI, S., SCHWARTZ, G. J. & ROSSETTI, L. 2005. A brain-liver circuit 
regulates glucose homeostasis. Cell Metab, 1, 53-61. 
POLONSKY, K. S., GIVEN, B. D., HIRSCH, L., SHAPIRO, E. T., TILLIL, H., 
BEEBE, C., GALLOWAY, J. A., FRANK, B. H., KARRISON, T. & VAN 
CAUTER, E. 1988. Quantitative study of insulin secretion and clearance in 
normal and obese subjects. J Clin Invest, 81, 435-41. 
279 
 
POTTEIGER, J. A., JACOBSEN, D. J. & DONNELLY, J. E. 2002. A comparison of 
methods for analyzing glucose and insulin areas under the curve following nine 
months of exercise in overweight adults. Int J Obes Relat Metab Disord, 26, 87-9. 
QING, K., MAH, C., HANSEN, J., ZHOU, S., DWARKI, V. & SRIVASTAVA, A. 1999. 
Human fibroblast growth factor receptor 1 is a co-receptor for infection by 
adeno-associated virus 2. Nat Med, 5, 71-7. 
RAMACHANDRAN, J. 1984. Corticotropin Receptors, Cyclic AMP and 
Steroidogenesis. Endocrine Research, 10, 347-363. 
RAPOSINHO, P. D., PIERROZ, D. D., BROQUA, P., WHITE, R. B., PEDRAZZINI, T. 
& AUBERT, M. L. 2001. Chronic administration of neuropeptide Y into the 
lateral ventricle of C57BL/6J male mice produces an obesity syndrome including 
hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism. Mol Cell 
Endocrinol, 185, 195-204. 
RASK, E., OLSSON, T., SODERBERG, S., ANDREW, R., LIVINGSTONE, D. E. W., 
JOHNSON, O. & WALKER, B. R. 2001. Tissue-Specific Dysregulation of 
Cortisol Metabolism in Human Obesity. Endocrine Soc. 
RISOLD, P. Y., THOMPSON, R. H. & SWANSON, L. W. 1997. The structural 
organization of connections between hypothalamus and cerebral cortex. Brain 
Research Reviews, 24, 197-254. 
RODRIGUEZ, E. M., BLAZQUEZ, J. L. & GUERRA, M. 2010. The design of barriers 
in the hypothalamus allows the median eminence and the arcuate nucleus to 
enjoy private milieus: the former opens to the portal blood and the latter to the 
cerebrospinal fluid. Peptides, 31, 757-76. 
ROSSI, M., KIM, M. S., MORGAN, D. G. A., SMALL, C. J., EDWARDS, C. M. B., 
SUNTER, D., ABUSNANA, S., GOLDSTONE, A. P., RUSSELL, S. H. & 
STANLEY, S. A. 1998. A C-Terminal Fragment of Agouti-Related Protein 
Increases Feeding and Antagonizes the Effect of Alpha-Melanocyte Stimulating 
Hormone in Vivo. Endocrinology, 139, 4428-4431. 
RUSSEK, M. 1963. Participation of hepatic glucoreceptors in the control of intake of 
food. Nature, 197, 79-80. 
RUSSEK, M. 1970. Demonstration of the influence of an hepatic glucosensitive 
mechanism on food-intake. Physiol Behav, 5, 1207-9. 
RUTLEDGE, E. A. & RUSSELL, D. W. 1997. Adeno-associated virus vector 
integration junctions. J Virol, 71, 8429-36. 
SAINSBURY, A., CUSIN, I., ROHNER-JEANRENAUD, F. & JEANRENAUD, B. 
1997a. Adrenalectomy prevents the obesity syndrome produced by chronic 
central neuropeptide Y infusion in normal rats. Diabetes(New York, NY), 46, 209-
214. 
SAINSBURY, A., ROHNER-JEANRENAUD, F., CUSIN, I., ZAKRZEWSKA, K. E., 
HALBAN, P. A., GAILLARD, R. C. & JEANRENAUD, B. 1997b. Chronic 
280 
 
central neuropeptide Y infusion in normal rats: status of the hypothalamo-
pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia, 
40, 1269-1277. 
SAINSBURY, A., WILKS, D. & COONEY, G. J. 2001. Central but not peripheral 
glucocorticoid infusion in adrenalectomized male rats increases basal and 
substrate-induced insulinemia through a parasympathetic pathway. Obes Res, 9, 
274-81. 
SAKAI, R. R., LAKSHMI, V., MONDER, C. & MCEWEN, B. S. 1992. 
Immunocytochemical localization of 11 Beta-hydroxysteroid dehydrogenase in 
hippocampus and other brain regions of the rat. J Neuroendocrinol, 4, 101-6. 
SAKURAI, T., AMEMIYA, A., ISHII, M., MATSUZAKI, I., CHEMELLI, R. M., 
TANAKA, H., WILLIAMS, S. C., RICHARDSON, J. A., KOZLOWSKI, G. P., 
WILSON, S., ARCH, J. R., BUCKINGHAM, R. E., HAYNES, A. C., CARR, S. 
A., ANNAN, R. S., MCNULTY, D. E., LIU, W. S., TERRETT, J. A., 
ELSHOURBAGY, N. A., BERGSMA, D. J. & YANAGISAWA, M. 1998. 
Orexins and orexin receptors: a family of hypothalamic neuropeptides and G 
protein-coupled receptors that regulate feeding behavior. Cell, 92, 573-85. 
SAMBROOK J, F. E. A. M. T. 1989. Molecular Cloning: A Laboratory Manual., Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, NY. 
SAMBROOK, J., FRITSCH, E., AND MANIATIS, T. 2000. Molecular Cloning  
SANDEEP, T. C., ANDREW, R., HOMER, N. Z., ANDREWS, R. C., SMITH, K. & 
WALKER, B. R. 2005. Increased in vivo regeneration of cortisol in adipose 
tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase 
type 1 inhibitor carbenoxolone. Diabetes, 54, 872-9. 
SAPOLSKY, R. M., ROMERO, L. M. & MUNCK, A. U. 2000. How do glucocorticoids 
influence stress responses? Integrating permissive, suppressive, stimulatory, and 
preparative actions. Endocr Rev, 21, 55-89. 
SATO, I., ARIMA, H., OZAKI, N., WATANABE, M., GOTO, M., HAYASHI, M., 
BANNO, R., NAGASAKI, H. & OISO, Y. 2005. Insulin inhibits neuropeptide Y 
gene expression in the arcuate nucleus through GABAergic systems. J Neurosci, 
25, 8657-64. 
SATOH, N., OGAWA, Y., KATSUURA, G., HAYASE, M., TSUJI, T., IMAGAWA, K., 
YOSHIMASA, Y., NISHI, S., HOSODA, K. & NAKAO, K. 1997. The arcuate 
nucleus as a primary site of satiety effect of leptin in rats. Neurosci Lett, 224, 149-
52. 
SAVONTAUS, E., CONWELL, I. M. & WARDLAW, S. L. 2002. Effects of 
adrenalectomy on AGRP, POMC, NPY and CART gene expression in the basal 
hypothalamus of fed and fasted rats. Brain Res, 958, 130-8. 
SAYERS, G., REDGATE, E. S. & ROYCE, P. C. 1958. Hypothalamus, 
Adenohypophysis and Adrenal Cortex. Annual Reviews in Physiology, 20, 243-
274. 
281 
 
SCHICK, R. R., SAMSAMI, S., ZIMMERMANN, J. P., EBERL, T., ENDRES, C., 
SCHUSDZIARRA, V. & CLASSEN, M. 1993. Effect of galanin on food intake in 
rats: involvement of lateral and ventromedial hypothalamic sites. Am J Physiol, 
264, R355-61. 
SCHWARTZ, M. W., SEELEY, R. J., CAMPFIELD, L. A., BURN, P. & BASKIN, D. 
G. 1996. Identification of targets of leptin action in rat hypothalamus. J Clin 
Invest, 98, 1101-6. 
SCHWARTZ, M. W., WOODS, S. C., PORTE, D., SEELEY, R. J. & BASKIN, D. G. 
2000. Central nervous system control of food intake. NATURE-LONDON-, 661-
671. 
SECKL, J. R. 1997. 11beta-Hydroxysteroid dehydrogenase in the brain: a novel 
regulator of glucocorticoid action? Front Neuroendocrinol, 18, 49-99. 
SECKL, J. R. & WALKER, B. R. 2001. Minireview: 11beta-hydroxysteroid 
dehydrogenase type 1- a tissue-specific amplifier of glucocorticoid action. 
Endocrinology, 142, 1371-6. 
SECKL, J. R. & WALKER, B. R. 2004. 11beta-hydroxysteroid dehydrogenase type 1 as 
a modulator of glucocorticoid action: from metabolism to memory. Trends 
Endocrinol Metab, 15, 418-24. 
SELYE, H. 1998. A Syndrome Produced by Diverse Nocuous Agents. Am Neuropsych 
Assoc. 
SHIMIZU, H., ARIMA, H., OZAWA, Y., WATANABE, M., BANNO, R., SUGIMURA, 
Y., OZAKI, N., NAGASAKI, H. & OISO, Y. 2010. Glucocorticoids increase NPY 
gene expression in the arcuate nucleus by inhibiting mTOR signaling in rat 
hypothalamic organotypic cultures. Peptides, 31, 145-9. 
SHIMIZU, H., ARIMA, H., WATANABE, M., GOTO, M., BANNO, R., SATO, I., 
OZAKI, N., NAGASAKI, H. & OISO, Y. 2008. Glucocorticoids increase 
neuropeptide Y and agouti-related peptide gene expression via adenosine 
monophosphate-activated protein kinase signaling in the arcuate nucleus of rats. 
Endocrinology, 149, 4544-53. 
SHIMOMURA, Y., BRAY, G. A. & LEE, M. 1987. Adrenalectomy and steroid 
treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res, 19, 295-
299. 
SILVA, J. E. 2001. The multiple contributions of thyroid hormone to heat production. J 
Clin Invest, 108, 35-7. 
SILVA, J. E. 2006. Thermogenic mechanisms and their hormonal regulation. Physiol 
Rev, 86, 435-64. 
SIPOLS, A. J., BASKIN, D. G. & SCHWARTZ, M. W. 1995. Effect of 
intracerebroventricular insulin infusion on diabetic hyperphagia and 
hypothalamic neuropeptide gene expression. Diabetes, 44, 147-51. 
282 
 
SKOFITSCH, G. & JACOBOWITZ, D. M. 1985. Immunohistochemical mapping of 
galanin-like neurons in the rat central nervous system. Peptides, 6, 509-46. 
SOUTHERN, E. M. 1975. Detection of specific sequences among DNA fragments 
separated by gel electrophoresis. J Mol Biol, 98, 503-17. 
STANLEY, B. G., CHIN, A. S. & LEIBOWITZ, S. F. 1985. Feeding and drinking 
elicited by central injection of neuropeptide Y: evidence for a hypothalamic 
site(s) of action. Brain Res Bull, 14, 521-4. 
STANLEY, B. G., KYRKOULI, S. E., LAMPERT, S. & LEIBOWITZ, S. F. 1986. 
Neuropeptide Y chronically injected into the hypothalamus: a powerful 
neurochemical inducer of hyperphagia and obesity. Peptides, 7, 1189-92. 
STANLEY, B. G., LANTHIER, D., CHIN, A. S. & LEIBOWITZ, S. F. 1989. 
Suppression of neuropeptide Y-elicited eating by adrenalectomy or 
hypophysectomy: reversal with corticosterone. Brain Res, 501, 32-6. 
STANLEY, B. G. & LEIBOWITZ, S. F. 1984. Neuropeptide Y: stimulation of feeding 
and drinking by injection into the paraventricular nucleus. Life Sci, 35, 2635-42. 
STEINBAUM, E. A. & MILLER, N. E. 1965. Obesity from Eating Elicited by Daily 
Stimulation of Hypothalamus. Am J Physiol, 208, 1-5. 
STEWART, P. M. 2003. Tissue-specific Cushing's syndrome, 11beta-hydroxysteroid 
dehydrogenases and the redefinition of corticosteroid hormone action. European 
Journal of Endocrinology, 149, 163-168. 
STEWART, P. M., BOULTON, A., KUMAR, S., CLARK, P. M. S. & SHACKLETON, 
C. H. L. 1999. Cortisol Metabolism in Human Obesity: Impaired Cortisone? 
Cortisol Conversion in Subjects with Central Adiposity 1. Endocrine Soc. 
STRACK, A. M., SEBASTIAN, R. J., SCHWARTZ, M. W. & DALLMAN, M. F. 1995. 
Glucocorticoids and insulin: reciprocal signals for energy balance. American 
Journal of Physiology- Regulatory, Integrative and Comparative Physiology, 268, 
142-149. 
STULNIG, T. M. & WALDHAUSL, W. 2004. 11beta-Hydroxysteroid dehydrogenase 
Type 1 in obesity and Type 2 diabetes. Diabetologia, 47, 1-11. 
SUMMERFORD, C. & SAMULSKI, R. J. 1998. Membrane-associated heparan sulfate 
proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol, 72, 
1438-45. 
SWANSON, L. W. & MOGENSON, G. J. 1981. Neural mechanisms for the functional 
coupling of autonomic, endocrine and somatomotor responses in adaptive 
behavior. Brain Res, 228, 1-34. 
SWANSON, L. W. & SAWCHENKO, P. E. 1983. Hypothalamic Integration: 
Organization of the Paraventricular and Supraoptic Nuclei. Annual Reviews in 
Neuroscience, 6, 269-324. 
283 
 
SWANSON, L. W. & SIMMONS, D. M. 1989. Differential steroid hormone and neural 
influences on peptide mRNA levels in CRH cells of the paraventricular nucleus: 
a hybridization histochemical study in the rat. J Comp Neurol, 285, 413-35. 
TATARANNI, P. A., LARSON, D. E., SNITKER, S., YOUNG, J. B., FLATT, J. P. & 
RAVUSSIN, E. 1996. Effects of glucocorticoids on energy metabolism and food 
intake in humans. American Journal of Physiology- Endocrinology And 
Metabolism, 271, 317-325. 
TAYLOR, R. & AGIUS, L. 1988. The biochemistry of diabetes. Biochem J, 250, 625-40. 
TENENBAUM, L., CHTARTO, A., LEHTONEN, E., VELU, T., BROTCHI, J. & 
LEVIVIER, M. 2004. Recombinant AAV-mediated gene delivery to the central 
nervous system. J Gene Med, 6 Suppl 1, S212-22. 
THIM, L., NIELSEN, P. F., JUDGE, M. E., ANDERSEN, A. S., DIERS, I., EGEL-
MITANI, M. & HASTRUP, S. 1998. Purification and characterisation of a new 
hypothalamic satiety peptide, cocaine and amphetamine regulated transcript 
(CART), produced in yeast. FEBS Letters, 428, 263-268. 
TIESJEMA, B., LA FLEUR, S. E., LUIJENDIJK, M. C. & ADAN, R. A. 2009. 
Sustained NPY overexpression in the PVN results in obesity via temporarily 
increasing food intake. Obesity (Silver Spring), 17, 1448-50. 
TOLLE, V. & LOW, M. J. 2008. In vivo evidence for inverse agonism of Agouti-related 
peptide in the central nervous system of proopiomelanocortin-deficient mice. 
Diabetes, 57, 86-94. 
TOMASZUK, A., SIMPSON, C. & WILLIAMS, G. 1996. Neuropeptide Y, the 
hypothalamus and the regulation of energy homeostasis. Horm Res, 46, 53-8. 
TONG, Y., COUET, J., SIMARD, J. & PELLETIER, G. 1990. Glucocorticoid 
regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus. Mol Cell 
Neurosci, 1, 78-83. 
TREMPE, J. P. & CARTER, B. J. 1988. Regulation of adeno-associated virus gene 
expression in 293 cells: control of mRNA abundance and translation. J Virol, 62, 
68-74. 
VAHL, T. P., ULRICH-LAI, Y. M., OSTRANDER, M. M., DOLGAS, C. M., ELFERS, 
E. E., SEELEY, R. J., D'ALESSIO, D. A. & HERMAN, J. P. 2005. Comparative 
analysis of ACTH and corticosterone sampling methods in rats. American 
Journal of Physiology- Endocrinology And Metabolism, 289, 823-828. 
VALSAMAKIS, G., ANWAR, A., TOMLINSON, J. W., SHACKLETON, C. H., 
MCTERNAN, P. G., CHETTY, R., WOOD, P. J., BANERJEE, A. K., HOLDER, 
G., BARNETT, A. H., STEWART, P. M. & KUMAR, S. 2004. 11beta-
hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 
2 diabetes mellitus. J Clin Endocrinol Metab, 89, 4755-61. 
VAN DEN HOEK, A. M., VAN HEIJNINGEN, C., SCHRODER-VAN DER ELST, J. 
P., OUWENS, D. M., HAVEKES, L. M., ROMIJN, J. A., KALSBEEK, A. & 
284 
 
PIJL, H. 2008. Intracerebroventricular administration of neuropeptide Y 
induces hepatic insulin resistance via sympathetic innervation. Diabetes, 57, 
2304-10. 
VAN DEN HOEK, A. M., VOSHOL, P. J., KARNEKAMP, B. N., BUIJS, R. M., 
ROMIJN, J. A., HAVEKES, L. M. & PIJL, H. 2004. Intracerebroventricular 
neuropeptide Y infusion precludes inhibition of glucose and VLDL production 
by insulin. Diabetes, 53, 2529-34. 
VAN MARKEN LICHTENBELT, W. D., VANHOMMERIG, J. W., SMULDERS, N. 
M., DROSSAERTS, J. M., KEMERINK, G. J., BOUVY, N. D., SCHRAUWEN, 
P. & TEULE, G. J. 2009. Cold-activated brown adipose tissue in healthy men. N 
Engl J Med, 360, 1500-8. 
VETTOR, R., ZARJEVSKI, N., CUSIN, I., ROHNER-JEANRENAUD, F. & 
JEANRENAUD, B. 1994. Induction and reversibility of an obesity syndrome by 
intracerebroventricular neuropeptide Y administration to normal rats. 
Diabetologia, 37, 1202-8. 
VIENGCHAREUN, S., ZENNARO, M. C., PASCUAL-LE TALLEC, L. & LOMBES, 
M. 2002. Brown adipocytes are novel sites of expression and regulation of 
adiponectin and resistin. FEBS Letters, 532, 345-350. 
VIRTANEN, K. A., LIDELL, M. E., ORAVA, J., HEGLIND, M., WESTERGREN, R., 
NIEMI, T., TAITTONEN, M., LAINE, J., SAVISTO, N. J., ENERBACK, S. & 
NUUTILA, P. 2009. Functional brown adipose tissue in healthy adults. N Engl J 
Med, 360, 1518-25. 
VONG, L., YE, C., YANG, Z., CHOI, B., CHUA, S., JR. & LOWELL, B. B. 2011. 
Leptin Action on GABAergic Neurons Prevents Obesity and Reduces Inhibitory 
Tone to POMC Neurons. Neuron, 71, 142-54. 
VRANG, N., LARSEN, P. J., CLAUSEN, J. T. & KRISTENSEN, P. 1999a. 
Neurochemical Characterization of Hypothalamic Cocaine-Amphetamine-
Regulated Transcript Neurons. Soc Neuroscience. 
VRANG, N., TANG-CHRISTENSEN, M., LARSEN, P. J. & KRISTENSEN, P. 1999b. 
Recombinant CART peptide induces c-Fos expression in central areas involved 
in control of feeding behaviour. Brain Research, 818, 499-509. 
W.H.O. 2006. Obesity and overweight fact sheet. [Online]. Available: 
http://www.who.int/mediacentre/factsheets/fs311/en/index.html. [Accessed]. 
WAJCHENBERG, B. L. 2000. Subcutaneous and visceral adipose tissue: their relation 
to the metabolic syndrome. Endocr Rev, 21, 697-738. 
WALKER, B. R., CONNACHER, A. A., LINDSAY, R. M., WEBB, D. J. & EDWARDS, 
C. R. 1995. Carbenoxolone increases hepatic insulin sensitivity in man: a novel 
role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. 
J Clin Endocrinol Metab, 80, 3155-9. 
285 
 
WALKER, H. C. & ROMSOS, D. R. 1992. Glucocorticoids in the CNS regulate BAT 
metabolism and plasma insulin in ob/ob mice. American Journal of Physiology- 
Endocrinology And Metabolism, 262, 110-117. 
WANG, H., KUBICA, N., ELLISEN, L. W., JEFFERSON, L. S. & KIMBALL, S. R. 
2006. Dexamethasone represses signaling through the mammalian target of 
rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem, 281, 
39128-34. 
WANG, J., OBICI, S., MORGAN, K., BARZILAI, N., FENG, Z. & ROSSETTI, L. 
2001. Overfeeding rapidly induces leptin and insulin resistance. Diabetes, 50, 
2786-91. 
WANG, R., LIU, X., HENTGES, S. T., DUNN-MEYNELL, A. A., LEVIN, B. E., 
WANG, W. & ROUTH, V. H. 2004. The regulation of glucose-excited neurons in 
the hypothalamic arcuate nucleus by glucose and feeding-relevant peptides. 
Diabetes, 53, 1959-65. 
WARD, H., GARDINER, J., KONG, W. M., MURPHY, K., BLOOM, S. & BLOOM, S. 
R. 2003. Distribution of Fluorescence following Injection of Recombinant Adeno-
Associated Virus Encoding Green Fluorescent Protein into the Paraventricular 
Nucleus. Logo, 77. 
WATSON, R. T. & PESSIN, J. E. 2006. Bridging the GAP between insulin signaling 
and GLUT4 translocation. Trends Biochem Sci, 31, 215-22. 
WATTS, A. G. & SANCHEZ-WATTS, G. 1995. Region-specific regulation of 
neuropeptide mRNAs in rat limbic forebrain neurones by aldosterone and 
corticosterone. J Physiol, 484 ( Pt 3), 721-36. 
WHEELER, J., MARTIN, R., LIN, D., YAKUBU, F. & HILL, J. O. 1990. Weight 
cycling in female rats subjected to varying meal patterns. Am J Physiol, 258, 
R124-9. 
WHITE, B. D., DEAN, R. G. & MARTIN, R. J. 1990. ADRENALECTOMY 
DECREASES NEUROPEPTIDE Y MRNA LEVELS IN THE ARCUATE 
NUCLEUS. Brain research bulletin, 25, 711-715. 
WHITNALL, M. H. 1993. Regulation of the hypothalamic corticotropin-releasing 
hormone neurosecretory system. Prog Neurobiol, 40, 573-629. 
WICKHAM, T. J., MATHIAS, P., CHERESH, D. A. & NEMEROW, G. R. 1993. 
Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization 
but not virus attachment. Cell, 73, 309-19. 
WILLESEN, M. G., KRISTENSEN, P. & ROMER, J. 1999. Co-localization of growth 
hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the 
rat. Neuroendocrinology, 70, 306-16. 
WILLIAMS, G., BING, C., CAI, X. J., HARROLD, J. A., KING, P. J. & LIU, X. H. 
2001. The hypothalamus and the control of energy homeostasis: different 
circuits, different purposes. Physiol Behav, 74, 683-701. 
286 
 
WILSON, B. D., BAGNOL, D., KAELIN, C. B., OLLMANN, M. M., GANTZ, I., 
WATSON, S. J. & BARSH, G. S. 1999. Physiological and anatomical circuitry 
between Agouti-related protein and leptin signaling. Endocrinology, 140, 2387-
97. 
WOLFF, J. A. & BUDKER, V. 2005. The mechanism of naked DNA uptake and 
expression. Adv Genet, 54, 3-20. 
WOODS, S. C., LOTTER, E. C., MCKAY, L. D. & PORTE, D., JR. 1979. Chronic 
intracerebroventricular infusion of insulin reduces food intake and body weight 
of baboons. Nature, 282, 503-5. 
WREN, A. M., SMALL, C. J., ABBOTT, C. R., DHILLO, W. S., SEAL, L. J., COHEN, 
M. A., BATTERHAM, R. L., TAHERI, S., STANLEY, S. A., GHATEI, M. A. & 
BLOOM, S. R. 2001. Ghrelin causes hyperphagia and obesity in rats. Diabetes, 
50, 2540-7. 
XIE, Q., BU, W., BHATIA, S., HARE, J., SOMASUNDARAM, T., AZZI, A. & 
CHAPMAN, M. S. 2002. The atomic structure of adeno-associated virus (AAV-
2), a vector for human gene therapy. Proc Natl Acad Sci U S A, 99, 10405-10. 
XU, R. Y., WAN, Y. P., TANG, Q. Y., WU, J. & CAI, W. 2008. The effects of high fat on 
central appetite genes in Wistar rats: a microarray analysis. Clin Chim Acta, 397, 
96-100. 
XU, Z. L., MIZUGUCHI, H., MAYUMI, T. & HAYAKAWA, T. 2003. Woodchuck 
hepatitis virus post-transcriptional regulation element enhances transgene 
expression from adenovirus vectors. Biochim Biophys Acta, 1621, 266-71. 
YASWEN, L., DIEHL, N., BRENNAN, M. B. & HOCHGESCHWENDER, U. 1999. 
Obesity in the mouse model of pro-opiomelanocortin deficiency responds to 
peripheral melanocortin. Nature Medicine, 5, 1066-1070. 
ZAKRZEWSKA, K. E., CUSIN, I., SAINSBURY, A., ROHNER-JEANRENAUD, F. & 
JEANRENAUD, B. 1997. Glucocorticoids as counterregulatory hormones of 
leptin: toward an understanding of leptin resistance. Diabetes, 46, 717-719. 
ZAKRZEWSKA, K. E., CUSIN, I., STRICKER-KRONGRAD, A., BOSS, O., 
RICQUIER, D., JEANRENAUD, B. & ROHNER-JEANRENAUD, F. 1999a. 
Induction of obesity and hyperleptinemia by central glucocorticoid infusion in 
the rat. Diabetes, 48, 365. 
ZAKRZEWSKA, K. E., SAINSBURY, A., CUSIN, I., ROURU, J., JEANRENAUD, B. 
& ROHNER-JEANRENAUD, F. 1999b. Selective Dependence of 
Intracerebroventricular Neuropeptide Y-Elicited Effects on Central 
Glucocorticoids 1. Endocrinology, 140, 3183-3187. 
ZHANG, Z. H., KANG, Y. M., YU, Y., WEI, S. G., SCHMIDT, T. J., JOHNSON, A. K. 
& FELDER, R. B. 2006. 11beta-hydroxysteroid dehydrogenase type 2 activity in 
hypothalamic paraventricular nucleus modulates sympathetic excitation. 
Hypertension, 48, 127-33. 
 
287 
 
Appendix I –List of solutions 
 
ABC buffer: 
Combine solution A, B and C in the following proportions – 100:250:150, and store at -20ºC. 
 
Solution A 
Add 1ml 125mM MgCl2and 1.25M Tris (pH 8.0) to 18µl mecaptoethanol, 5µl 
100mM dATP, 5µl 100mM dTTP and 5µl dGTP. 
 
Solution B 
2M HEPES pH 6.6 (titrated with 4M NaOH). 
 
Solution C 
Random oligonucleotides at 112µg/ml. 
 
Alkaline SDS (0.2M NaOH/1%SDS): 
Mix 2ml 10M sodium hydroxide, 5ml 20% SDS and 93ml autoclaved GDW. 
 
Amasino wash buffer: 
Mix 250ml 1M Na phosphate buffer pH 7.2, 2ml 500mM EDTA and 100ml 20% SDS with 
650ml GDW. 
 
5M ammonium acetate: 
Dissolve 385g CH3.COONH4 in 600ml autoclaved GDW and then make up to 1L. 
 
 
100mg/ml ampicillin: 
Dissolve 1g in 10ml autoclaved GDW, sterilise by passage through a 0.2μm filter and 
distribute in 1ml aliquots. 
 
10% l-arabinose: 
Dissolve 1g of L-arabinose in 10ml autoclaved GDW, sterilise by passage through a 0.2μm 
filter. 
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2.5mM ATA: 
Dissolve 0.1183g ATA in 100ml autoclaved GDW. 
 
Caesium chloride-saturated isopropanol: 
Vigorously mix 100g CsCl2, 100ml autoclaved GDW, and 100ml propan-2-ol and leave to 
settle. 
 
2M calcium chloride: 
Dissolve 5.88g of CaCl2.2H2O in 20ml GDW, sterilise by passage through a 0.2μm filter and 
store in 1ml aliquots at -20ºC. 
 
25mg/ml chloramphenicol 
Dissolve 250mg of chloramphenicol in 10ml of molecular biology grade ethanol.  
 
Denaturing solution (DNA): 
Dissolve 43.5g of NaCl in GDW, add 25ml of 10M NaOH and make up to 500ml with GDW. 
 
DENAT (denaturing solution for RNA): 
Add 300µl of 40% formaldehyde and 100µl of 20x MOPS to 1ml of formamide. 
 
Dialysis tubing: 
Cut dialysis tubing into 10cm lengths, immerse in 2% (w/v) NaHCO3/1mM EDTA and boil 
for 10 minutes. Rinse in GDW and boil for 5 minutes in 1mM C10H14H2O8Na2.2H2O. Store at 
4ºC. 
 
Denhardt's solution: 
Dissolve 10g each of ficoll, polyvinyl-pyrrolidone and BSA (fraction V) in 500ml autoclaved 
GDW. Store in aliquots at -20ºC. 
 
Dextran sulphate 
Mix 1g dextran sulphate in 1.5ml GDW. Warm at 60ºC for 2-3 hours to dissolve and vortex 
vigorously before use. 
 
289 
 
dNTP mix for PCR and reverse transcription: 
Mix 10µl each of 100mM dGTP, dCTP, dATP, and dTTP in 60µl of autoclaved GDW and 
aliquot into 20µl batches. 
 
Ethidium bromide: 
Dissolve 200mg in 20ml autoclaved GDW. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA): 
Dissolve 186.1g C10H14H2O8Na2.2H2O in 800ml autoclaved GDW and adjust pH to 8.0 with 
1M NaOH. Make up to 1L with GDW. 
 
Formamide (de-ionised): 
Add 2.7g Duolite MB 6113 (Merck) to 100ml formamide and mix until duolite turns brown 
(~1 hour). Remove Duolite by passing through Whatman GF/C filters, aliquot and store at 
-20ºC. 
 
Gel loading buffer: 
Mix 3.125ml 80% glycerol, 50µl 0.5M C10H14H2O8Na2.2H2O and 3.075ml autoclaved GDW. 
Add 10mg orange G. 
 
10% glycerol in GDW: 
Add 1ml glycerol to 9ml of GDW. 
 
GTE: 
Mix 2.5ml 1M Tris-HCl, pH 8.0, 2ml 0.5M C10H14H2O8Na2.2H2O and 5ml 18% glucose and 
make up to 100ml. Sterilise by passing through a 0.2µm filter. 
  
2x HEPES-buffered saline (HBS): 
Dissolve 1.6g NaCl, 75mg KCl, 21mg Na2HPO4, 0.22g dextrose and 1g HEPES in a total 
volume of 90 ml GDW. Adjust to pH 7.0 with 0.5M sodium hydroxide and make up to 100ml 
with GDW. Sterilise by passing through a 0.2µm filter and store in 5ml aliquots at -20ºC. 
 
290 
 
Hybridisation buffer for Northern and dot blot: 
Dissolve 0.5g milk powder and 0.5ml EDTA (500mM stock) in 48ml GDW, leave at 37ºC to 
dissolve. Allow to cool then add 25ml Na phosphate buffer (1M stock), 25ml SDS (20% 
stock), and 1ml ATA (2.5mM stock). 
 
LB culture media: 
Dissolve 5g sodium chloride, 10g tryptone and 5g yeast extract to 11ml GDW. Adjust to pH 
7.5 with 10M sodium hydroxide. Sterilise by autoclaving. 
 
LB(amp) plates: 
Add 7g agar to 500ml LB and melt by autoclaving. Supplement with 0.05mg/ml ampicillin.  
 
Lysis buffer: 
Add 8.765g NaCl, 6.055g Tris and make up to 1L with GDW. Adjust to pH 8.5. 
 
20x MOPS: 
Dissolve 83.6g 3-(N-Morpholino)propanesulphonic acid (MOPS), 8.1g sodium acetate, 7.4g 
C10H14H2O8Na2.2H2O and 2.5ml formaldehyde to 800ml GDW. Adjust to pH 7.0 with 10M 
sodium hydroxide and make up to 1L. 
 
5mg/ml MTT: 
Dissolve 50mg of MTT in 10ml of 0.01M PBS. Filter through 0.2µm Ministart filter unit 
(Sartorius). 
 
1mg/ml Napthol AS-MX phosphate: 
Dissolve 20mg of napthol in 2ml of dimethylformamide then add 18ml 0.1MTris, adjust to 
pH 8.2 and store 1ml aliquots at -20ºC.  
 
Neutralising solution: 
Dissolve 43.5g of NaCl, 60.2g of Tris base in GDW, add 35ml of HCl and make up to 500ml 
with GDW.  
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0.01M Phosphate buffered saline (PBS): 
Dissolve 8.7g NaCl, 1.41g Na2HPO4.2H2O and 0.272g KH2PO4 in 800ml of GDW. Adjust 
the pH to 7.6 with hydrochloric acid and make up to 1L with GDW. 
 
PBS/Tween: 
Add 0.25ml Tween 20 to 500ml 0.01M PBS. 
 
Phenol/chloroform/IAA: 
Mix equilibrated phenol, chloroform and iso-amyl alcohol in the ratio 25:24:1 and store under 
0.1M Tris-HCl, pH 8.0. 
 
Phosphate buffer (RIA buffer): 
Dissolve 48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g C10H14H2O8Na2.2H2O, 2.5g NaN3 in 
5l ml of GDW that had been boiled and allowed to cool. Adjust the pH to 7.6 and store at 
4ºC. 
 
Phosphate buffer with gelatin: 
The buffer was produced as above with 12.5g of gelatin dissolved in the boiling GDW then 
cooled before the addition of the other ingredients 
 
3M potassium acetate: 
Dissolve 294.4g CH3COOK in 500ml GDW, add 115ml glacial acetic acid and make up to 
1L with GDW. 
 
20mg/ml proteinase K: 
Dissolve 20mg for every 1ml autoclaved GDW and store at -20ºC. 
 
10mg/ml RNase A: 
Dissolve 100mg RNase A in 10ml 10mM Tris-HCl, pH 7.5/15mM NaCl and boil for 15 
minutes. Allow to cool and distribute in to 1ml aliquots. 
 
Sephadex G50: 
Add 8g fine grade Sephadex G-50 beads (diameter: 20-80μm) (Sigma Aldrich), 2ml 100x TE 
and 0.1ml 20% SDS to 200ml GDW and autoclave to expand beads. 
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SOB medium: 
Dissolve 20g bactotryptone, 5g yeast extract, 0.5g NaCl in 1L GDW. Adjust pH to 7.4 and 
autoclave. Before use add 20ml 1M MgSO4. 
 
2M sodium acetate, pH 5.2: 
Dissolve 164.1g CH3COONa in 800ml autoclaved GDW, adjust to pH 5.2 with glacial acetic 
acid and make up to 1L with GDW. 
 
5M sodium chloride: 
Dissolve 292.2g NaCl in 1L GDW. 
 
0.75M sodium citrate: 
Dissolve 220.5g Na3C6H5O7.2H2O in 1L autoclaved GDW and adjust to pH 7.0. 
 
20% sodium dodecyl sulphate (SDS): 
Add 200g SDS to 800ml autoclaved GDW, heat to 60ºC while stirring. Allow to cool and 
make up to 1L with GDW. 
 
10M sodium hydroxide: 
Dissolve 400g of NaOH in 500ml autoclaved GDW. Once dissolved top up to 1L with GDW. 
0.2% sodium hydroxide 1% SDS. Add 3ml 10M NaOH to 140ml GDW, mix and add 7.5ml 
20% SDS. 
 
0.5M sodium phosphate, pH 6.8: 
Dissolve 71g Na2HPO4.2H2O in 1L GDW and 41.4g NaH2PO4.H2O in 600ml GDW. 
 
50mg/ml spectinomycin: 
Dissolve 0.5g of spectinomycin in 10ml of autoclaved GDW. Sterilise by passage through a 
0.2μm filter and distribute in 1ml aliquots. 
 
20x SSC: 
Dissolve 1,753g NaCl and 882g Na3C6H5O7.2H2O in 8L GDW, adjust to pH 7.0 and make up 
to 10L. 
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20x SSPE: 
Dissolve 210.4g NaCl, 14.2g Na2HPO4 and 7.4g C10H14H2O8Na2.2H2O in 700 ml GDW, 
adjust to pH 7.7 with 10M NaOH and make up to 1L with GDW. 
 
50x TAE: 
Dissolve 242g Tris base in 843ml GDW and mix in 57ml glacial acetic acid and 100ml 0.5M 
C10H14H2O8Na2.2H2O. 
 
10x TBE: 
Dissolve 108g Tris base, 55g H3BO3 and 9.3g C10H14H2O8Na2.2H2O in 1L GDW and filter 
through Whatman GF/C microfibre filters. 
 
0.05M TBS: 
Dissolve 8.7g NaCl in 1L 0.1M Tris stock, adjust to pH 7.2 with HCL. 
 
100x TE:  
Dissolve 121.1g Trizma base and 3.7g C10H14H2O8Na2.2H2O in 800ml and adjust pH 7.5 
with hydrochloric acid. Make up to 1L. 
 
0.1M TEA Buffer: 
Dissolve 18.6g C6H15NO3.HCl (triethanolamine-hydrochloride) in 800ml of GDW, adjust to 
pH 8.0 with hydrochloric acid and make up to 1L with GDW. 
 
TES 
Mix 25ml 1M Tris-HCl pH 8.0, 5ml 5M NaCl and 5ml C10H14H2O8Na2.2H2O, and make up 
to 500ml with GDW. 
 
100mg/ml tetracyclin: 
Dissolve 50mg in 10ml ethanol and distribute in 1ml aliquots. 
 
Transformation buffer I (TFBI): 
Dissolve 589mg CH3.COOK, 2.418g RbCl, 1.979g CaCl2.2H2O and 438mg MnCl2.4H2O in 
autoclaved GDW. Add 37.5ml 80% glycerol and make up to 200ml with GDW. Sterilise by 
passing through 0.2μm filter. 
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Transformation buffer II (TFBII): 
Dissolve 418mg MOPS, 3.28g CaCl2.2H2O and 242mg RbCl in GDW. 37.5ml 80% glycerol 
are added and make up to 200ml with GDW. Sterilise by passing through a 0.2μm filter. 
0.1MTris/HCL pH 8.2: 
Dissolve 12.1g of Tris base in 1L of GDW, adjust pH to 8.2 with HCL. 
 
1M Tris Hcl pH 7.5: 
Dissolve 121.1g Trizma base in 800ml GDW. Adjust to pH to 7.5 with HCl and make up to 
500ml with GDW. 
 
Universal wash buffer: 
Mix 10ml 20% SDS and 10ml 20x SSPE with 980ml GDW. 
 
Versene: 
Dissolve 16g NaCl, 0.4g KCl, 2.88g Na2HPO4.2H2O, 1.2g C10H14H2O8Na2.2H2O and 0.4g 
KH2PO4 to 1L GDW, add 3ml phenol red (Sigma Aldrich) and make up to 2L with GDW. 
Sterilise by autoclaving. 
 
X-Gal solution: 
Add 1.5ml 0.1M K3FE(CN)6, 1.5ml 0.1M K4Fe(CN)6.3H2O, 60µl 1M MgCl2 and 240µl 
X-Gal 50mg/ml (Promega) and make up to 30ml with 0.01M PBS (Sigma Aldrich). 
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Appendix II - Ink injections into discrete hypothalamic nuclei 
 
Representative micrograph showing the location of the injection site marked with 
Indian ink in the ARC of the hypothalamus. Serial coronal 40μm sections were cut on a 
freezing sled microtome, mounted on glass slides, and stained with Cresyl violet before 
visualisation on a photo-microscope.  
Scale bar is 100µm. 
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Representative micrograph showing the location of the injection site marked with 
Indian ink in the PVN of the hypothalamus. Serial coronal 40μm sections were cut on a 
freezing sled microtome, mounted on glass slides, and stained with Cresyl violet before 
visualisation on a photo-microscope.  
Scale bar is 100µm. 
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Appendix III – Power calculation for determination of group sizes 
Experiments investigating the long term effects of altered hypothalamic 11βHSD1 activity on 
food intake require group sizes of twelve animals. The size of the groups was calculated 
using the computer programme G*Power. Power analysis was conducted for an F test 
repeated measures analysis. The power analysis was performed on the expected change on 
food intake using data from pilot studies. The study is powered to detect a 100 g difference in 
cumulative food intake (10%) with a standard deviation of 100 at the 0.05 level giving a 
required group size of twelve.  
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Appendix IV – Comparison of body-composition analysis methods 
 
Water
0
20
40
60
80
rAAV-eGFP rAAV-11βHSD1
Bo
dy
 c
om
po
si
tio
n 
(%
)
Fat
0
5
10
15
20
25
rAAV-eGFP rAAV-11βHSD1
Bo
dy
 c
om
po
si
tio
n 
(%
)
Protein
0
5
10
15
20
25
rAAV-eGFP rAAV-11βHSD1
Bo
dy
 c
om
po
si
tio
n 
(%
)
 
Effect of bilateral intra-ARC injection of rAAV-11βHSD1 on body composition in male 
Wistar rats fed a normal chow diet. Animals were injected with 1 µl of either rAAV-eGFP 
(n = 12) or rAAV-11βHSD1 (n = 10) and carcass body composition measured by foodscan 
(light bars) or chemical methods (shaded bars) following termination on day 112. Values 
shown as percentage of total carcass mean ± SEM. Non-significant by unpaired Student’s t-
test. 
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Appendix V – Validation of insulin concentration for insulin tolerance testing 
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Validation of insulin concentration for the insulin tolerance test in lean male Wistar 
rats. Animals were deprived of food for 4 hours in the early light phase. Either saline (n=2) 
or insulin 0.25 IU/kg (n=2), 0.5 IU/kg (n=2), 0.75 IU/kg (n=2) or 1.0 IU/kg (n=2) was 
administered (2 ml/kg, i.p.). Plasma glucose was measured 0, 15, 30, 60, and 120 minutes 
after insulin administration. Values shown as mean ± SEM.  
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Appendix VI - List of suppliers  
 
Ambion, Warrington, U.K. 
Amersham Pharmacia Biotech, U.K. 
Applied Biosystems, Austin, Texas, U.S.A 
ATCC, Middlesex, U.K. 
Bayer UK Ltd., Bury St. Edmunds, Suffolk, U.K. 
Beckman, Irvine, C.A. 
Boehringer, Lewes, East Sussex, U.K. 
Bright Instruments, Huntingdon, Cambridgeshire, U.K. 
Camlab, Cambridge, U.K. 
Cayman Chemicals Inc., U.S.A. 
Charles River, Margate, Kent, U.K. 
David Kopf Instruments, supplied by Clark Electromedical Inst., Reading, Berkshire, U.K.  
DJB labcare, U.K. 
Difco laboratories, MI, U.S.A. 
Eppendorf, Hamburg, Germany 
Euro Diagnostica, The Netherlands 
Fisher Scientific UK, Loughborough, Leicestershire, U.K. 
FOSS, Cheshire, U.K. 
GE Healthcare, Amersham, Buckinghamshire, U.K. 
Harvard Apparatus Ltd., Edenbridge, Kent, U.K. 
Helena Biosciences, Tyne and Wear, U.K. 
Invitrogen Life Technologies, Paisley, Renfrewshire, U.K. 
Kodak, Hemel Hempstead, Hertfordshire, UK 
LGC standards, Middlesex, U.K. 
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Life Sciences Technology, Eggenstein, Germany 
Merck Chemicals Ltd., Nottingham, Nottinghamshire, U.K. 
Millpledge, U.K. 
Molecular Dynamics, Sunnyvale, CA, U.S.A. 
MP Biomedicals, Orangeburg, NY, U.S.A. 
MSE, U.K. 
NE Technology Inc., Reading, U.K. 
New England Biolabs (UK) Ltd, Hitchin, Hertfordshire, U.K. 
Novagen, Nottingham, UK 
Orbital Biosciences, MA, U.S.A. 
Perkin Elmer, Boston, Massachussetts, U.S.A. 
Plastiques Gosslin, Hazebrouck, France 
Promega U.K. Ltd., Southampton, Hampshire, U.K. 
Research Diets, New Brunswick, New Jersey, U.S.A. 
Schering-Plough Ltd., Welwyn Garden City, Hertfordshire, U.K. 
Shandon Southern Products Ltd., Runcorn Cheshire, U.K. 
Sigma Aldrich Ltd., Poole, Dorset, U.K. 
SlideWrite, Advanced Graphics Software, Inc., U.S.A. 
Statacorp, College Station, Texas, U.S.A.  
Stratagene Ltd., Amsterdam, The Netherlands 
Techne Ltd., Burlington, New Jersey, U.S.A. 
Thermo Electron Corporation, San Jose, California, U.S.A. 
Thermo Scientific, U.K. 
Vet-Tech Solutions Ltd., U.K. 
VWR International Ltd, Poole, Dorset, U.K. 
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Wallac, Waltham, MA 
WPA, Cambridgeshire, UK 
 
 
 
 
 
 
 
 
 
